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ABSTRACT
Complex multimodal nanoparticles (NP) that target and deliver therapeutic agents to a
site of disease are a promising direction in modem medicine. As a starting point for innovation,
we designed a hybrid NP system combining the benefits of liposomes and polymeric NPs. These
particles have a polymeric surface which displays targeting ligands while avoiding macrophage
uptake. A liposome-like layer provides in vivo biocompatibility and a hydrophobic core allows
for high-capacity small molecule drug delivery.
Targeting ligands that bind injured vasculature were discovered and optimized by
screening an M13 bacteriophage library (109 independent clones) against collagen IV, the major
component of the basement membrane. Relative binding affinities using ELISA identified the
lead targeting candidate, which bound with 900-fold greater relative affinity to collagen IV when
compared with the unselected library.
The selected peptide sequence was synthesized and tested for its ability to actively target
the hybrid NP system. Paclitaxel, an anti-proliferative drug, was chosen as the delivered
pharmaceutical. Drug release was modified through a slow-eluting paclitaxel conjugate using
controlled ester hydrolysis (drug release -10-12 days in vitro). To test these targeted NPs,
injured vasculature was approximated using an aortic smooth muscle culture embedded on a
collagen IV matrix. In this setting, the hybrid NPs showed clear evidence of increased potency
using the selected ligands.
In experimental animal models of surgery-induced vascular injury, targeted NPs showed
a four-fold improved retention at angioplastied aortas over intact aortas ex vivo. Targeted NPs
were tested as intraarterially delivered therapy to angioplastied carotid arteries in vivo and
showed a two-fold better localization at injury sites versus scrambled-peptide and non-targeted
NPs. Targeted NPs were also tested using a systemic, intravenous infusion administered post-
procedure on Day I and 6 and resulted in lower neointima-to-media (N/M) scores at two weeks
compared to FDA-approved Taxol@ and injury-only groups (N/Msham= -249 + 0.046, vs.
N/MTaxol=0.837 ± 0.087, N/MNP=0.749 ± 0.136 and N/MPep-NP=0.662 ± 0.169, all P < 0.01 vs.
injury-only, mean ± SEM, n=5). These findings indicate that complex, multilayered NPs can
functionally target and treat injured vasculature, a clinical problem of primary importance.
Thesis Supervisor: Robert S. Langer, Sc.D.
Title: David H. Koch Institute Professor
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INTRODUCTION
The field of nanotechnology has crossed significant milestones from the systemic
delivery of medicines, and over the last two decades there has been a convergence in knowledge
on the biological and physicochemical properties of nanomaterials. In 2010, several liposomal
drugs and polymer-drug conjugates have already been approved by the U.S. Food and Drug
Administration (FDA) for use in many indications, but polymeric nanoparticle (NP) technology
is only now nearing clinical approval.
The commentary in Chapter 1 discusses the foundations of polymeric NP delivery using
biocompatible, biodegradable, FDA-approved controlled-release polymers. Systemically-
delivered polymeric NPs have generated immense academic and clinical interest as they are
designed to avoid immune responses and improve on drug release profiles. First generation NPs,
however, are limited by the lack of targeting to solid tumors and other sites of interest. Since
then, second generation NPs have used targeting ligands to alter the biodistribution and improve
on the efficacy of NP-delivered therapeutic agents.
Chapter 2 describes the design of hybrid lipid-polymeric NPs that combine features of
liposomes and polymeric NPs. This hybrid version has a polymeric core and a liposomal shell to
derive improved drug loading, controlled drug release, biocompatibility and efficacy. Chapter 2
also describes the development of microparticle equivalents for applications that require larger
biocompatible particles with polymeric cores.
An in depth study on the in vivo pharmacokinetic and pharmacodistribution profile of
lipid-polymeric NPs is outlined in Chapter 3. The addition of RNA aptameric ligands specific
for the prostate specific membrane antigen (PSMA) on prostate epithelial cells was found to alter
the localization of radiolabeled NPs in mouse xenograft models of prostate cancer.
Subsequently, an interest in peptide targeting ligands led to the development of peptide-
functionalized NPs against fibrin in Chapter 4. The peptide-targeted NPs were delivered to
atherosclerotic plaques in Apolipoprotein E-deficient mice and to angioplastied aortas in
balloon-injured rats. The NPs targeted thrombotic elements found in non-stenotic and stenotic
lesions and may potentially be applied towards the management of coronary artery disease.
The focus of Chapter 5 is the discovery of novel peptide ligands for targeting to injured
vasculature. Peptide ligands were characterized from a M13 bacteriophage display screen against
collagen IV and Matrigel basement membrane extracts. By comparing the candidates against an
unbiased library, a lead candidate peptide was selected for further characterization. Additionally,
a number of promising candidates were identified in sequence alignment studies for their
biological relevance to resident basement membrane structures.
Building on the foundations of peptide-targeting in Chapter 4 and given the favorable
results of the screen in Chapter 5, a spatiotemporal NP delivery system was developed to target
exposed basement membrane. In Chapter 6, targeted NPs were delivered to injured vasculature
ex vivo and in vivo. Taken together, results from these studies led to the conclusion that targeted
NPs preferentially localized to sites of injury over intact arterial vessels.
Chapter 7 puts the collective previous results and techniques into a medical context with
the targeting and treatment of injured vasculature. The lead targeted NP system was delivered
infusionally as an anti-proliferative therapy for arterial stenosis and compared against FDA-
approved Taxol@ (Cremophor-EL micelles of paclitaxel), non-targeted NPs and injury-only
sham controls. The targeted NP group reduced neointimal hyperplasia and luminal occlusion
more effectively versus Taxol and non-targeted NP groups.
As a step forward, the commentary in Chapter 8 describes the role of nanotechnology in
cardiovascular medicine and describes the potential of this NP technology as an infusional
treatment for restenosis.
Chapter 1. Background.
Nanoparticles in Medicine - Therapeutic Applications and Developments
Nanotechnology is the understanding and control of matter generally in the 1-100 nm
dimension range. The application of nanotechnology to medicine, referred to as nanomedicine,
concerns the use of precisely engineered materials at this length scale to develop novel
therapeutic and diagnostic modalities" .Nanomaterials have unique physicochemical properties
which are different from bulk material of the same composition, such as ultra small size, large
surface area to mass ratio and high reactivity. The use of materials in nanoscale may overcome
certain limitations found in traditional therapeutic and diagnostic agents, as it provides
unparalleled freedom to modify fundamental properties of solubility, diffusivity, blood
circulation half-life, drug release profile and immunogenicity. These nanoscale agents may be
more effectively and/or conveniently administered, reduce off-target toxicity and extend product
life cycle, all of which may ultimately reduce health-care costs.
The topic of this dissertation lies principally on the therapeutic applications of
systemically administered nanoparticle (NPs). Until now, the main utility of parenterally
delivered first generation NPs has been to improve on the solubility of hydrophobic drugs and
prolong drug circulation half-life in vivo. This thesis details the development of second
generation NPs with controlled release and targeting functions. Other novel functions of these
second generation nanocarriers include releasing drugs in an environmentally responsive manner
to lower the frequency of administration3 4 , and to synergistically deliver two or more drugs for
combination therapy and suppression of drug resistance.
Nanomedical research has shown immense clinical relevance, with great strides being
made towards therapeutic approval of NP drug formulations. In the past two decades, there has
been a steady increase in the number of commercially available NP-based therapeutic products,
with numerous ensuing products currently under clinical testing or entering the commercial
pipeline. More than 24 nanotechnology-based therapeutic products have been approved for
clinical use, with total sales exceeding $5.4 billion by 2006 6. Among these products, liposomal7
and polymer-drug conjugates8'9 represent the two dominant classes that account for more than
80% of the market (Table 1).
Table I ainically approved nanoparticle-based therapeutics
Composition
Uposomal platforms
Uposomal amphotericin B
Liposomal amphotericin B
Uposomal cytarabine
Uposomal daunorubicin
Uposomal doxorubicn
Liposornal IRIV vaccine
Liposomal IRIV vaccine
Liposomal morphine
Liposomal verteporfin
Uposome-PEG doxorubicin
Micellular estradiol
Polymeric platforms
-Glutamic acid, t-alanine,
L-lysine, and L-tyrosine copolymer
Methoxy-PEG-poly(Dt-lactide)
taxol
PEG-adenosine deaminase
PEG-anti-VEGF aptamer
PEG-ainterferon 2a
PEG-GCSF
PEG-MGF
PEG-L-asparaginase
Poly(allylamine hydrochloride)
Other platforms
Albumin-bound paclitaxel
Nanocrystalline aprepitant
Nanocrystalline fenofibrate
Nanocrystalline sirolimus
Trade name Company
Abelcet
AmBisome
DepoCyt
DaunoXome
Myocet
Epaxal
Inflexal V
DepoDur
Visudyne
Enzon
Gilead Sciences
SkyePharma
Gilead Sciences
Zeneus
Bema Biotech
Bema Biotech
SkyePharma, End
QLT, Novartis
Doxil/Caelyx Ortho Biotech,
Schering-Plough
Estrasorb Novavax
Copaxone TEVA Pharmaceu
Genexol-PM Samyang
Adagen
Macugen
Pegasys
Neulasta
Somavert
Oncaspar
Renagel
Abraxane
Emend
Tricor
Rapamune
Enzon
OSI Pharmaceutic
Nektar, Hoffmann
Roche
Amgen
Nektar, Pfizer
Enzon
Genzyme
Abraxis BioScienc
AstraZeneca
Elan, Merck
Elan, Abbott
Elan, Wyeth
Pharmaceuticals
Indication
Fungal infections
Fungal and protozoal infections
Malignant lymphomatous meningitis
HIV-related Kaposi's sarcoma
Combination therapy with
cyclophosphamide in metastatic
breast cancer
Hepatitis A
Influenza
o Postsurgical analgesia
Age-related macular degeneration,
pathologic myopia, ocular histoplasmosis
HIV-related Kaposi's sarcoma, metastatic
breast cancer, metastatic ovarian cancer
Menopausal therapy
ticals Multiple sclerosis
Metastatic breast cancer
Severe combined immunodeficiency
disease associated with ADA deficiency
als Age-related macular degeneration
-La Hepatitis B, hepatitis C
Neutropenia associated with cancer
chemotherapy
Acromegaly
Acute lymphoblastic leukemia
End-stage renal disease
e, Metastatic breast cancer
Antiemetic
Anti-hyperlipidemic
Immunosuppressant
ADA, adenosine deaminase; GCSF, granulocyte colony-stimulating actor HGF, hepatocyte growth factor HIV, human immunodeficiency virus; Lm., intramuscula; i.r.,
ntravltreous; RV, immunopotentlating reconstituted Influenza virosome; i.t., Intrathecal; I.v, intravenous; PEG, polyethylenegycol; s.c., subcutaneous; VEGF, vascular
endothelial growth factor.
Table 1: FDA-approved NP-based therapeutics for clinical use. This figure was originally
published in Clinical Pharmacology and Therapeutics. Zhang, L., Gu, F.X., Chan, J.M. et al.
Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther
2008; 83: 761-9. @ Nature Publishing Group.
Administration
i.v.
.v.
i.t.
i.v.
i.v.
i.m.
L.m.
Epidural
I.v.
i.m.
Topical
S.C.
iv.
i.m.
ir.
S.C.
S.C.
S.C.
iLv., l.m.
Oral
Oral
Oral
Oral
....... .............
Polymeric Nanoparticles for Drug Delivery
Besides liposomes and polymeric conjugates, the most common NP platforms today
include polymeric NPs, micelles, dendrimers, viral, albumin, polysaccharide, metallic and
ceramic-based NPs (Figure 1). These NPs have shown therapeutic potential for almost every
branch of medicine including oncology, cardiology and immunology.
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Figure 1. Schematic of therapeutic NP platforms in clinical and preclinical development.
(A) Liposome, (B) polymer-drug conjugate, (C) polymeric NP, (D) dendrimer, and (E) iron
oxide NP. Red dots represent hydrophilic drugs and blue dots represent hydrophobic drugs. This
figure was originally published in Clinical Pharmacology and Therapeutics. Zhang, L., Gu, F.X.,
Chan, J.M. et al. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin
Pharmacol Ther 2008; 83: 761-9. 0 Nature Publishing Group.
In particular, biodegradable polymeric micelles with sizes of 10-200 nm (Figure 1C)
have shown therapeutic potential as controlled-release drug delivery carriers .One example of a
polymeric NP is Genexol-PM@, a PLGA-b-methoxyPEG micellar formulation of paclitaxel that
has received regulatory approval in South Korea for clinical use, and which is currently
undergoing phase II clinical trials for a number of cancer indications in the United States
Polymeric micelles are formed by the spontaneous self-assembly of block copolymers consisting
of two or more polymer chains with different hydrophobicity into core-shell micellar structures
to minimize the system's free energy". In aqueous environments, the hydrophobic blocks form
the core to minimize exposure to aqueous surroundings, whereas the hydrophilic blocks form the
corona-like shell to stabilize the core through direct contact with water. This self-assembly
process generates a functional micellar structure that is capable of carrying pharmaceuticals,
especially poorly soluble drugs, in the hydrophobic core. The hydrophilic shell provides not only
steric protection for the micelle, thereby increasing its stability in blood, but also functional end-
groups suitable for further modification. In contrast with polymer-drug conjugates, each
polymeric micelle can carry more drugs per structure due to its relatively larger size and release
these drugs in a more regulated manner via surface or bulk erosion of the biodegradable
polymers, diffusion of the drug through the polymer matrix, or polymer swelling followed by
drug diffusion. FDA-approved poly(D,L-lactic acid) (PLA) 5 ,16, poly(D,L-lactic-co-glycolic acid)
(PLGA)"- and poly(E-caprolactone) (PCL)" polymers diblocked or multiblocked with
poly(ethylene glycol) (PEG) are the most extensively studied biodegradable polymers for
micellar-based drug delivery and controlled release.
Barriers to Efficient Nanoparticle Delivery
In the design of NPs for systemic delivery, regardless which NP platform is chosen, there are
a number of challenges to overcome in the blood circulation before therapeutic payloads can be
delivered to their target site. Major barriers to NP-based therapeutic delivery can be
characterized as follows (but not necessarily in chronological order):
1. Plasma stability and solubility
2. Dose-limiting toxicity (DLT) of NP formulation
3. Interaction with the reticulo-endothelial system (RES)
4. Opsonization and complement activation
5. Non-specific binding of serum proteins
6. Non-specific cellular uptake
7. Ease of internalization by target cells
A primary objective in the design of systemically delivered particles is RES avoidance,
given that the RES itself is not the delivery target. Experimental evidence has shown that
interaction with the RES may be modulated through key features such as NP size and surface-
biocompatibility. Particles greater than 10 pm have been shown to cause embolization in the
liver and lungs and 3-4 pm sized particles have been shown to accumulate in the open
circulation of the spleen 24. Hence, particles in the sub-micron range are preferred. A classic
strategy to increase the circulation half-life and escape RES recognition, such as by liver Kupffer
cells, consists of protecting the NP core with PEG polymer chains25-27. PEG is a highly hydrated
and flexible polymer chain that reduces plasma protein adsorption due to its surface inertness.
PEG was studied as a potential surfactant for protein delivery as early as the 1960s27 and was
first introduced into clinical use in the early 1990s. PEG was shown to dramatically increase the
circulation half-life of PLGA-PEG NPs from minutes to hours'7 and has since been used in
many systemically delivered polymeric systems. Studies have shown that PEG surface density,
PEG chain length and PEG structure (linear versus branched) all influence the effectiveness of
PEG towards NP surface-biocompatibility 28,29 . For example, the molecular weight of the PEG
segment varies typically between 2-5 kDa, the minimum lengths which are necessary for
suppressing protein opsonization and complement activation. With sufficient PEG surface
density, a mushroom-to-brush conformational transition occurs and the maximal effect of PEG
surface-grafting can be observed by a combination of steric and electrostatic repulsion of serum
albumins and complement proteins28,29. PEG clearance does not require catabolism in the liver as
the molecular weights used to confer sufficient shielding are below the cut-off size for renally
filterable molecules (< 60 kDa)30. Besides PEG, other linear polymers such as polyglutamic acid,
polysaccharide, and poly(allylamine hydrochloride) have also been used to improve on NP
surface-biocompatibility.
The size cut-off for NP localization at sites of disease has been attributed to a
phenomenon called the enhanced permeability and retention (EPR) effect ' . EPR is the effect
by which certain sizes of NPs tend to accumulate in tumors much more than in healthy tissue due
to characteristic leaky blood vessels and dysfunctional lymphatic drainage from tumor
angiogenesis 3'34 . Using the EPR strategy for extravasation into tumor tissues, maximum NP
diameters should be approximately 200 to 400 nm, smaller than the diameters of leaky
endothelial cell fenestrations that range from 200 nm to 1.2 mm 35'36 . The surface charge of NPs
must also be considered for the EPR effect. In a study of albumin surface charge, positively
charged albumin macromolecules extravasated faster in solid tumors compared to anionic or
neutral albumin 37. However, the rapid clearance of cationic molecules from the plasma suggests
38that the charge modification enhanced drug delivery to normal organs as well . Therefore,
caution should be exercised when designing NP surface properties to improve drug delivery to
solid tumors.
Once the particles have been delivered to its target site, they should be internalized by
target cells if the aim is to release therapeutic agents within the cytosol (siRNA and drugs) or in
the nucleus (gene delivery). The mode and efficiency of cellular uptake of NPs is strongly size-
dependent39-4 1. Small particles (< 500 nm) are internalized by receptor-mediated endocytosis, a
process requiring a modest rearrangement of the cell cytoskeleton; whereas larger particles (> I
pm) are internalized through a phagocytic process that requires an extensive rearrangement of
the cell cytoskeleton and the formation of protruding actin filaments42. Taken together with size
requirements for tumor delivery, the optimal NP radii should be kept under 150 nm to derive
maximal tumor and cellular uptake efficiency.
First generation polymeric NPs have been designed to overcome barriers to effective
therapeutic delivery. Although passive targeting approaches currently form the basis of clinical
therapy, they suffer from several limitations. For instance, most drugs are incapable of
distinguishing between benign and malignant cells, and consequently cause dose-limiting
toxicities (DLT) during treatment. Also, solid tumors usually contain well-perfused, rapidly
growing regions, and poorly perfused, necrotic areas43'44. Hence, drugs may not be able to diffuse
efficiently and ubiquitously throughout the tumor due to differential permeability of vessels in a
single tumor. Elevated interstitial pressures due to poor lymphatic drainage may reduce
extravasation of NPs into tumors and lead to a radial convection outward that opposes inward
diffusion. Finally, tumors upregulate a number of transporter proteins of the ATP-binding
cassette family to expel drugs from cells, causing multiple-drug resistance (MDR) and the failure
of chemotherapy treatments45.
Next Generation Nanoparticles: Targeted Nanoparticle Delivery
To overcome these limitations, second generation NPs have been designed to actively
target specific cells for drug delivery. Keeping the previously described parameters of NP
surface-biocompatibility and size constant, second generation NP systems may benefit from
active binding interactions to tissues and organs of interest. This binding may be achieved by
attaching targeting agents such as ligands - molecules that bind to specific receptors on the cell
surface - to NPs by a variety of conjugation chemistries. Through differential targeting and
uptake by a subset of cells, targeted NP systems in preclinical and clinical trials have improved
the therapeutic index of drugs by two ways: (i) increasing the upper dose limit from the reduction
of systemic toxicity, and/or (ii) reducing the dose required by enhancing local or intracellular
drug concentration46 47
Linear Shear Flow U = Sh
ligand
T -
F Ar
A 3
receptor
// ' F~~ndothelial Substrate //// '
7//X
Pa =irr exp 6(ay- + 6eq)Fs + 8 Ts a pS (mrmIK2)kBT r, rm
Figure 2. A theoretical model of NP targeting.
Modeling approach to the interaction of particles in specific contact with receptor substrates
under linear laminar flow. Pa: adhesion strength parameter. This figure was originally published
in Biomaterials by Decuzzi, P. and Ferrari, M. The adhesive strength of non-spherical particles
mediated by specific interactions. Biomaterials 2006; 27: 5307-14. © Elsevier Limited Inc.
Taken conceptually to cover all classes of affinity ligands, researchers have developed a
mathematical model'8'49 in Figure 2 predicting the adhesion probability (Pa) or the strength of
NP adhesion based on three governing parameters: geometrical (radius of the particle, a; shape
aspect ratio, y); biophysical (ligand-to-receptor surface density ratio, mI/mr; equilibrium
separation distance 6eq between the substrate and the particle; the maximum distance h, at which
ligand-receptor bonds can be formed; shear stress at the blood vessel wall, pS) and biochemical
(ligand-receptor binding affinity, Kao; and characteristic length A of the ligand-receptor bond). If
conditions of dislodging forces (hydrodynamic shear stress and torque) are balanced by specific
ligand-receptor interactions and non-specific adhesion forces at the cell-NP interface, firm
adhesion is ensured. From there, the particles can release their payload to the extracellular matrix
or be endocytosed. In short, this predictive model suggests that the targetability of NPs is defined
by a myriad of parameters, namely size, shape, ligand affinity binding constant and both ligand
and receptor densities. Thus, targeting cannot be simply defined by the ligand itself.
Along with theoretical models, NP targeting has been studied empirically for many
years47. The ligands studied range widely and are classified below as:
1. Small molecule ligands: vitamins (e.g. folic acid), carbohydrates (e.g. mannose,
galactose).
2. Protein-based ligands: peptides, small proteins (e.g. transferrin), antibodies,
antigen-binding fragments (Fab), variant fragments (F,), single-chain variant
fragments (scFv), and other types of antibody fragments.
3. Nucleic acid-based ligands: deoxynucleic acid (DNA) and ribonucleic acid
(RNA) aptamers.
Given the large number of targeting ligands available, a logical route to select one ligand
class over another may be desired. While there certainly may be reasons for a particular choice
of ligand class, there is no straightforward process to reach that particular conclusion. A myriad
of biological and physicochemical properties regarding the NP vehicle such as size, surface
hydrophilicity and surface-density of the ligand have to be optimized in parallel, which together
may impact the targeting efficacy of the surface-functionalized ligand.
Table 2 attempts to summarize the different classes of ligands based on their key
properties and review their individual benefits and shortfalls for NP functionalization and
targeting. The information presented in this table is subject to many exceptions, which is often
the case with biological ligands.
Small molecules Antibody Aptamer
Properties (e.g. vitamins, Peptide Antibody (DNA A)
carbohydrates)
Size (kDa) < 1 -1-5 Affibody (-5-8) ~150 -20-40
________________ 
cFv_(-20-40) etc.
Stability +++ +++ ++ + +
Immune compatibility +++ ++ + + +
Affinity constant, >109 108 > 10-1 ~10- >10 ~ 10-7 > 100"- 10' > 10- to 10-
propheis: Binding selectivity + + ++ +++ ++
Ease of discovery + +++ ++ + +
Ease of synthesis; ++ ++ + +
Manufacturing scale-up
considerations: Cost + + ++ +++ +++
Table 2: Various classes of targeting ligands for NP surface-functionalization.
Parameters to be considered are classified as biological, biochemical and manufacturing.
Information presented in this table gives a general guideline, and many exceptions are possible.
Symbols: low (+), medium (++) and high (+++).
Biological parameters of size, stability and immune compatibility are important
considerations when choosing a ligand class to functionalize onto NPs. Small molecules may be
preferred for their low molecular weight, structural stability and integrity. For general immune
compatibility, short peptides may evade getting processed onto major histocompatibility
complexes (MHC) that trigger adaptive immune responses. Antibody engineering improvements
have resulted in the production of smaller antibody fragments and chimeric, humanized
antibodies (antibodies with both animal and human origins) to reduce the overall size and
immunogenicity of non-human antibodies used in targeting5 0 . Larger double-stranded RNA or
DNA aptamers, however, may interact with toll-like receptors on antigen-presenting cells (e.g.
dendritic cells) and provoke an immune response. Hence, truncated versions of aptamers that
contain only minimal flanking sequences around the active site have been designed to minimize
aptamer size and reduce immune detection5 1 . The stability of DNA and RNA aptamers may be
considerably lower than small molecules and peptides as aptamers may be cleaved by
endogenous and non-specific nucleases in the blood. To reduce nuclease activity and improve
aptamer stability, aptamers have been stabilized with 2'-fluoro-modified riboses on all
pyrimidines and 3'-inverted deoxythymidine caps ("inverted T-cap")52 53.
Biochemical parameters of binding affinity constants have a significant contribution to
targeting efficacy. Binding affinity for a specific receptor, receptor isoform and even receptor
on-off state can be dramatically improved with the use of ligands that not only show sequence
51
complementarity but also three-dimensional (3D) structural conformation at the active site
Antibody-based targeting been clinically successful with 22 different mAbs approved by the
FDA by 2010, such as trastuzumab (Herceptin), an anti-HER2 mAb that binds to ErbB2 receptor
for the treatment of breast cancer, and bevacizumab (Avastin), an anti-VEGF mAb that inhibits
neoangiogenesis for the treatment of colorectal cancer54. The affinity of peptides and fragments
may be lower in comparison to antibodies and aptamers, and smaller ligands may less likely
discriminate between minute differences in receptor on-off states or isoforms. However, affinity
ligands are displayed at high densities on the surface of NPs and the collective binding from a
multivalent interaction may result in improved targeting compared to a monovalent interaction.
In one study, dendrimers conjugated to 3-15 folate molecules showed a 2,500- to 170,000-fold
enhancement in binding affinity over free folate to immobilized receptors, which was attributed
to the avidity effect from multiple folic acid groups55 . Hence, avidity can improve on, and in
some cases compensate for, binding affinity when multiple ligands are functionalized onto NP
surfaces. Furthermore, high binding affinities have been shown to decrease NP penetration into
solid tumors due to a 'binding-site barrier', where NPs bind so strongly to their targets such that
it prevents subsequent penetration into the tissue 6
To discover new targeting ligands, it is important to be able to screen and enrich for high
affinity binders in a cost-effective and efficient manner. Bacteriophage 57 and yeast 58 display
libraries allow for the selection of high affinity peptides and scFv fragments in vitro and in vivo.
For larger aptameric ligands, the SELEX (systematic evolution of ligands by exponential
enrichment) technique can be used to screen combinatorial oligonucleotide libraries against
target antigens59,60. Recently, small molecule arrays have been developed to screen small
molecule compounds against diverse targets including protein kinases, histone deacetylases,
extracellular growth factors, and transcription factors61. One caution when screening for high
affinity ligands is that the selection for sub-nanomolar binding affinities may not necessarily
improve on the selectivity for the target molecule 62. Off-target binding to related molecules could
lead to significant clinical effects.
Finally, manufacturing considerations are important if the targeted NP system is to be
translated for clinical use. Generally, the scale-up of small-molecules and peptides is much more
straightforward when compared to antibodies and aptamers. Furthermore, they are cost-effective
for large-scale production, show high batch-to-batch consistency and retain ligand stability under
various storage conditions. Not surprisingly, there are exceptions to the rule. Cyclic peptides
contain a pair of cysteines spaced apart that are oxidized to form cyclic conformations.
Concatemer formation and disulfide bond reduction may result in a loss of bioactivity, which
makes the scale-up of cyclic peptides more difficult than for linear peptides.
In conclusion, there are a host of parameters to integrate before the choice of a particular
ligand class - and the ligand itself - can be made. Hence, the selection of ligands for NP
targeting is not a zero sum game, such that the gain or loss based on one parameter can be
balanced equally by the gain of loss of another parameter. Rather, it is a delicate balance of
parameters based on the therapeutic requirements for the disease to be treated.
Moving Beyond the Targeting Paradigm
Figure 3. Targeting paradigm.
CELLS Targeted NPs have traditionally been directed
against cell-based receptors to release a
payload (hydrophobic drugs, proteins,
1*00D plasmids and siRNA).
Traditionally, NPs have been targeted against cellular-based receptors (Figure 3).
Antibodies have been directed against the upregulated Erb2 receptor 63 in breast tumors and the
upregulated PSMA antigen in prostate tumors 64. The extracellular matrices (ECM) which
surround and support cells have also been studied and applied as a source for targeting ligands
against cell surface receptors overexpressed in tumors 6. For example, hyaluronan (HA) has been
coated onto liposomes to improve circulation time and enhance targeting to HA receptor-
expressing tumors in vivo 66 . A classic example is the use of RGD (arg-gly-asp) tripeptide motifs
which are found ubiquitously throughout the ECM on matrix proteins such as fibronectin. RGD
peptides and their mimetics have been successfully used to target liposomes and polymeric NPs
67to cancer cells with upregulated integrin receptors
Figure 4. New targeting paradigm.
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More recently, investigators have explored abundant non-cellular targets in the ECM for
targeting in human disease (Figure 4). Many oncologic, cardiovascular and regenerative diseases
are associated with compromised vasculature and increased vascular permeability33. Hence,
researchers have come up with original ways to utilize this pathology for the treatment of
disease.
As a novel approach to anti-angiogenic therapy, researchers have attempted to modulate
the angiogenic process and generate locally non-permissive basement membranes by disrupting
crucial interactions within the matrix68 . For example, the use of blocking therapeutic ligands
against MMP2-processed collagen IV inhibited angiogenesis in vivo 69. The breach of the
endothelial layer may also be exploited as a high-capacity surface for targeting the underlying
28
70 71,72basement membrane. Various conjugates and NPs have been targeted to fibrin , laminin7,
collagen I73 and collagen IIk1 74 for both therapeutic drug delivery and imaging. Targeting of the
ECM provides a number of benefits over cell receptor-based targeting as it may overcome intra-
and inter-patient heterogeneity of cell-surface receptor expression found in tumors75. Advances
in molecular profiling of tumors have revealed substantial heterogeneity in both histological and
expression phenotypes of cancerous cells 76. Targeting efforts against the HER2/neu epidermal
growth factor receptor may be hampered by intratumoral heterogeneity associated with subclonal
diversity of Her2 amplified tumor cells found in 5-30% of tumors77'78. Besides the upregulated
avp3 integrin receptors on cancer cells, RGD peptides have also been shown to bind to ax5pl and
a4p1 integrins which are not specific to cancer cells 79. Hence, the heterogeneity observed in
tumors may make it difficult to discriminate cancer cells from healthy cells through the targeting
of cellular receptors. Potentially, targeting the underlying ECM exposed in disease may
overcome these issues.
Outlook
More complex multimodal NP systems that are concurrently capable of targeting,
imaging and therapy are the subject of intense research in nanotechnology. Researchers have
improved on the functionality of NPs with the addition of targeting ligands and controlled release
capacity to achieve the spatiotemporal control that is essential to many medical applications. A
myriad of functionalities can be assembled into one system, but NPs must be precisely
engineered with an optimal mix of physicochemical and biological properties to achieve an
effective design.
Indeed, this has been the bottleneck for the translation of targeted NPs into clinical
practice. Hence, even though the earliest targeted liposome was described in 198080, only a
handful of systems have ever made it to clinical trials and none have been clinically approved.
We expect the role of targeted nanotechnology as a diagnostic and therapeutic tool in the clinic
to become more prominent as more effective multifunctional systems are designed, as
formulations become more economically viable and as their long-term safety can be guaranteed.
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Chapter 2. Design and Engineering of Hybrid
Lipid-Polymeric Core-Shell Nanoparticles.
Abstract
Current approaches to encapsulate and deliver therapeutic compounds have focused on
developing liposomal and biodegradable polymeric nanoparticles (NPs), resulting in clinically
approved therapeutics such as Doxil/Caelyx and Genexol-PM, respectively. Given the clinical
success of liposomes and polymeric NPs, we hypothesized that the development of a hybrid may
combine their individual strengths. We report the design and engineering of lipid-polymer hybrid
NPs as a robust drug delivery platform. These core-shell NPs consist of three distinct functional
components: (i) a hydrophobic polymeric core, (ii) a hydrophilic polymeric shell and (iii) a
soybean lecithin monolayer at the core-shell interface. The NPs were synthesized by a single-
step nanoprecipitation method combined with self-assembly in a reproducible and predictable
manner, making it potentially suitable for scale-up. Herein we report the formulation parameters
that alter their physicochemical characteristics, plasma stability, drug release rates and
cytotoxicity values. Our data suggests that the lipid-polymeric core-shell NPs may be a useful
new controlled release drug delivery system.
The content of this chapter has been published in whole or in part in the following
journal articles:
Zhang, L., Chan, J.M., Gu, F.X., Rhee, J.W., Wang, A.Z., Radovic-Moreno, A.F.,
Alexis, F., Langer, R. Farokhzad, O.C. Self-assembled lipid-polymer hybrid
nanoparticles: a robust drug delivery platform. ACS Nano (2008). 2, 1696-1702.
Reproduced with permission from ACS Nano. American Chemical Society @
2008.
Chan, J.M., Zhang, L., Yuet, K.P., Liao, G., Rhee, J.W., Langer, R., Farokhzad,
O.C. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.
Biomaterials (2009). 30, 1627-1634. Reproduced with permission from
Biomaterials. Elsevier Limited Inc. @ 2009.
Introduction
The clinical use of liposomes as drug delivery vehicles began in 1995 when
Doxil@/Caelyx@, the first liposomal drug formulation encapsulating doxorubicin, was FDA-
1,2approved for the treatment of AIDS-related Kaposi's sarcoma . Subsequently, more liposomal
formulations were approved and Doxil was also permitted for use in oncologic indications such
as ovarian cancer and multiple myeloma. Liposomes are spherical lipid vesicles with a bilayer
membrane of natural or synthetic amphiphilic lipid molecules. They show favorable safety
profiles and systemic circulation half-lives that can reach days after being surface modified with
hydrophilic polymers such as poly(ethylene glycol) (PEG)3 4 . However, due to their hydrophilic
interiors, the loading of poorly water-soluble drugs into liposomes is limited.
Polymeric NPs, especially those which are formulated with biocompatible and
biodegradable polymers, are being increasingly applied in both academic and clinical medicine.
Polymeric NPs are advantageous for their ability to load hydrophobic drugs with high capacity
and to control drug release based on the polymer chosen. One such example is Genexol-PM@, a
PLGA-fp-methoxyPEG paclitaxel-encapsulated micelle approved for metastatic breast cancer
therapy in South Korea6 8
Not surprisingly, previous hybrids of lipid and polymer materials have been designed to
take advantage of their individual strengths. In these studies, polymeric NPs were mixed with
liposomes to form lipid-polymer complexes (lipopolyplexes) where the lipid bilayer or lipid
multilayer was fused onto the surface of polymeric NPs 9 11. In one such formulation,
doxorubicin-polymer conjugates were encapsulated in PEGylated lipid shells and delivered to
the neovasculature of tumors in vivo . All of these complexes were made by a two-step
formulation process: (i) synthesis of polymeric NP cores, and (ii) encapsulation of polymeric
NPs within liposomes that were rehydrated and extruded from lipid membranes. The two-step
synthesis of polymer cores followed by liposome extrusion gives poor control over the final NP
structure and this may ultimately hinder clinical translation. It is desirable to develop lipid-
polymer hybrid NPs that are well-defined and require a single-step formulation method to
facilitate future scale-up.
In this study, we design sub-100 nm lipid-polymer hybrid NPs through a combination of
nanoprecipitation and self-assembly. The NPs are comprised of (i) a biodegradable hydrophobic
polymeric core that can encapsulate poorly water-soluble drugs and release them at a sustained
rate, (ii) an antibiofouling hydrophilic shell to enhance NP stability, evade recognition by the
immune system and increase systemic circulation half-life, and (iii) a lipid monolayer at the
core-shell interface to prevent both drug diffusion out of the core and water penetration into the
core, thereby slowing drug release from the NPs and preventing NP degradation.
Towards the goal of finding an optimal hybrid NP formulation, we evaluate parameters
that affect the core-shell nanostructure. Subsequently, we characterize the NPs for physical
stability, controlled drug release kinetics, post-formulation purification, long-term storage and
material cytotoxicity. Various formulation parameters such as the lipid/polymer mass ratio and
lipid/lipid-PEG molar ratio control NP physical stability, size and surface zeta-potential. We
encapsulate docetaxel (Dtxl) in the NPs and show that changing the amount of lipid coverage
affects drug release kinetics, establishing the role of the lipid monolayer in the hybrid NPs. Next,
we demonstrate a potentially scalable process for the formulation, purification, and storage of
NPs. Finally, the biocompatibility of these NPs in vitro is evaluated using MTT assays on two
model human cell lines, HeLa and HepG2. This hybrid NP system may represent a new way of
combining existing lipid and polymer materials for controlled drug delivery applications.
Methods
Materials.
Poly(DL-lactide-co-glycolic acid) (PLGA) with a 50:50 monomer ratio, ester-terminated, and
viscosity of 0.72-0.92 dl/g was purchased from Durect Corporation (Pelham, AL). Soybean
lecithin consisting of 90-95% phosphatidyicholine (soybean phosphatidylcholine, sPC) was
obtained from MP Biomedicals (Solon, OH). DSPE-PEG-COOH (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-carboxy(polyethylene glycol)2000) was obtained from Avanti
(Alabaster, AL). All organic solvents, docetaxel (Dtxl) and bovine serum albumin (BSA) were
purchased from Sigma-Aldrich (St Louis, MO).
Synthesis of PLGA-lipid-PEG NPs.
NPs were synthesized from PLGA, soybean lecithin and DSPE-PEG-COOH using a modified
nanoprecipitation technique combined with self-assembly. PLGA was first dissolved in organic
solvent (acetonitrile, unless specified) with concentrations ranging from I to 25 mg/mL. Lecithin
and DSPE-PEG-COOH (7:3, molar ratio) were dissolved in a 3 mL 4% ethanol aqueous
solution at 20% of the PLGA polymer weight and heated to 65 'C to ensure all lipids were in the
liquid phase. The PLGA/acetonitrile solution was then added dropwise into the preheated lipid
aqueous solution (I mUmin) under gentle stirring followed by vigorous vortexing for 3 min. The
NPs were allowed to self-assemble for 2 h at room temperature (RT) with continuous gentle
stirring for solvent evaporation. The remaining organic solvent and free molecules were removed
by washing the NP solution three times using a 10 kDa MWCO Amicon Ultra-4 centrifugal filter
(Millipore, Billerica, MA) before resuspending the NPs in water to obtain a final desired
concentration. The NPs were used immediately, stored at 4 'C or snap frozen in liquid nitrogen
and lyophilized for long-term storage at -80 'C.
NP Size and Surface Charge Characterization.
NP size (diameter, nm), polydispersity index and surface charge (zeta potential, mV) were
determined by quasi-elastic laser light scattering using a ZetaPALS dynamic light scattering
(DLS) detector (15 mW laser, incident beam=676 nm; Brookhaven Instruments Corporation,
Holtsville, NY) at RT. Viscosity and refraction indices were set equal to those specific of water.
Particle concentration was calculated based on the PLGA polymer concentration in the NPs.
Transmission Electron Microscopy (TEM) Characterization.
TEM experiments were carried out on a JEOL JEM-200CX instrument at an acceleration voltage
of 200 kV. TEM samples were prepared by administering the NP suspension (2 mg/mL) onto
300-mesh Formvar-coated copper grids that had previously been hydrophilized under UV light
(Electron Microscopy Sciences, Hatfield, PA). Samples were blotted away after 30 min and the
grids were negatively stained for 10 min at RT with freshly prepared and sterile-filtered 3%
(w/v) uranyl acetate solution. The grids were washed twice with distilled water and air dried
prior to imaging.
Drug Loading and Release Kinetics.
To prepare drug-encapsulated NPs, Dtxl at 10 wt% of the polymer was dissolved into the
PLGA/acetonitrile solution before nanoprecipitation. To measure the drug loading yield and
release profile of Dtxl from each type of NP, 3 mL NP solutions at a concentration of 0.5 mg/mL
were split equally into 30 Slide-A-Lyzer MINI dialysis microtubes, 10 kDa MWCO (Pierce,
Rockford, IL) and dialyzed against 3 L distilled water at RT. Distilled water was changed
periodically during the dialysis process. At the indicated times, the total solution in each
microtube was recorded (n=3) and 0.1 mL of the solution per tube was mixed with an equal
volume of acetonitrile to dissolve the NPs. The Dtxl content was quantified by reverse-phase
high performance liquid chromatography (RP-HPLC) using an Agilent 1100 HPLC (Paolo Alto,
CA) equipped with a pentafluorophenyl column (Curosil-PFP, 250 x 4.6 mm, 5 pm;
Phenomenex, Torrance, CA). Dtxl absorbance was measured at 227 nm using a UV-Vis detector
with a retention time of ~12-14 min in a 1 mL/min 50/50 acetonitrile/water non-gradient mobile
phase. The Dtxl content per microtube was calculated for the actual volume from the 0.1 mL
sample measured.
NP In Vitro Stability.
NPs at a polymer concentration of 1 mg/mL were incubated with 10 vol% BSA and 10 vol%
human plasma (BioChemMed, Winchester, VA) solutions at 37 'C under gentle stirring. At each
time point, an aliquot was collected for NP size measurements. DLS measurements were
performed in triplicate at RT.
NP Cytotoxicity Assays.
NP cytotoxicity was evaluated using MTT assays. HeLa and HepG2 cells were cultured in
DMEM supplemented with 10% heat-inactivated FBS, 100 units/mL penicillin and 100 ptg/mL
streptomycin at 5% CO2, 37 'C. Cells were seeded for 24 h in a 96-well plate at densities of
10,000 cells/well. The media was replaced with 200 ptL of media-containing NPs at the required
concentrations and incubated for 24 h in triplicate. The NP/media was aspirated and 0.5 mg/mL
of MTT solution in media was incubated with the cells for another 4 h. The MTT containing
media was removed and cells were rinsed three times with PBS. 200 pL of isopropanol/DMSO
was added in a 1:1 ratio for 5 min at 37 'C to lyse the cells. MTT absorbance was measured at
570 nm against a reference wavelength of 660 nm using a SpectraMax Plus 384 microplate
spectrophotometer (Molecular Devices, Sunnyvale, CA). Higher MTT absorbance values with
background subtraction indicate higher relative cell viability. The results were plotted on a graph
and fitted using the OriginPro 8 software (OriginLab Corp, Northampton, MA).
PLGA-Lipid-PEG Microparticle Synthesis and Self-Assembly.
50 mg of PLGA in 4 mL of ethyl acetate was added to I mg DSPE-PEG2000-COOH in 8 mL of
4% EtOH solution. Alternatively, 1.7 mg DSPE-PEG3400-COOH (Laysan Bio, Arab, AL) can
be used to replace DSPE-PEG2000-COOH (molar ratio kept constant). The PLGA/DSPE-PEG
mixture was homogenized for -1 min at 9,000-10,000 rpm with a L4RTA Homogenizer and
Mixer (Silverson Inc., East Longmeadow, MA). The resulting emulsion was immediately added
to 50 mL of DI H20 and magnetically stirred overnight (-12-16 h) to evaporate the solvent and
self-assemble the microparticles (MPs). The MPs were washed three times using a 100 kDa
MWCO Amicon filter.
Scanning Electron Microscopy (SEM) Characterization.
Samples were dried on a silicon wafer chip overnight. After drying, samples were mounted on an
aluminum stub using double sided carbon tape and sputter-coated with a thin gold-palladium
film using an automated sputter coater. Samples were imaged with a JEOL JSM 6060 scanning
microscope (Peabody, MA) using a 2.5-5 kV accelerating voltage at 10-mm working distances.
Results
Self-assembly of PLGA-lipid-PEG NPs.
As shown schematically in Figure 1A, the lipid-polymer hybrid NPs are self-assembled
from PLGA, lecithin and DSPE-PEG conjugates through a single-step nanoprecipitation
method. Specifically, the PLGA polymers precipitate to form a hydrophobic core to encapsulate
poorly water-soluble drugs, while lecithin and DSPE-PEG in the appropriate molar ratio form a
lipid monolayer and PEG shell around the PLGA polymeric core. Dtxl, a model chemotherapy
drug, was used for drug encapsulation in all subsequent studies.
The lipids were heated at 65 *C before adding the Dtxl/PLGA mixture and vortexing for
3 min. The increase in thermal and mechanical energy causes the lipids to disperse and self-
assemble as a monolayer around the PLGA/organic solvent core to shield their hydrophobic fatty
acid tails. After 2 h, self-assembly and solvent evaporation was considered complete (Figure
1A). To remove the residual solvent and free lipid molecules, the NPs were purified either by
ultracentrifugation or dialysis prior to characterization.
Characterization of PLGA-lipid-PEG NP Properties.
DLS measurements were taken to characterize NP hydrodynamic size, polydispersity and
zeta potential of each preparation. The average diameter of synthesized NPs ranged between 60
and 70 nm. The zeta potential ranged between -40 mV and -60 mV in water, depending on the
size and composition of the NPs. The negative zeta potential values measured here will appear
closer to neutral in PBS buffers from charge screening. NP sizes and zeta potentials remained in
the same range with or without Dtxl loading. A schematic shows the core-shell structure of the
NPs (Figure 1B).
To characterize the structure of the NPs, samples were negatively stained by uranyl
acetate and imaged by transmission electron microscopy (TEM) (Figure IC). The TEM images
revealed that the NPs are dispersed as sub-100 nm particles with a well-defined spherical shape,
and that the incorporation of Dtxl did not appear to cause morphological changes.
PLGA-lipid-PEG NP Lipid Formulation Parameters.
The lipid/polymer weight ratio may be changed to fine-tune NP size (diameter, nm) and
surface charge (( potential, mV) for optimal NP compatibility in vivo.
Taking PLGA/acetonitrile concentration (lmg/mL of 0.82 dl/g PLGA) and lipid/lipid-
PEG molar ratio (9:1) to be constant, we first investigated the effect of total lipid (lecithin +
DSPE-PEG-COOH)/polymer mass ratio on NP size. At 0% total lipid/polymer mass ratio, the
formulation of pure PLGA NPs aggregated immediately in PBS to form -2 pm particles. An
increase in total lipid/polymer mass ratio to 10%, 15%, 20%, or 100% did not affect the -2 ptm
aggregation (Figure 2). This suggests that even good coverage of the PLGA polymeric core by a
lipid monolayer is insufficient for charge screening in PBS buffers. Next, we investigated the
effect of lipid/lipid-PEG (lecithin/DSPE-PEG-COOH) molar ratio on NP size. We expanded
our study to include lipid/lipid-PEG molar ratios of 8:2, 7.5:2.5 or 7:3, against total
lipid/polymer mass ratios of 10%, 15% or 20% (Figure 2). In contrast to the -2 pm aggregation
observed with 9:1 molar ratios, increasing the lipid-PEG representation in the lipid monolayer
gave significantly better PBS stability. As denoted by asterisks (*) in Figure 2, we chose
formulations with diameters less than 100 nm for further characterization.
The end result of investigating the lipid/polymer mass ratio and lipid-PEG/lipid molar
ratio formulation parameters was the identification of a minimum requirement for a 15%
lipid/polymer mass ratio and 7.5:2.5 lipid/lipid-PEG molar ratio to form sub-100 nm NPs
(Figure 2). Hence, an optimal NP formulation consists of (i) sufficient total lipid coverage so
that the PLGA hydrophobic core is not exposed, and also (ii) sufficient PEG surface density to
provide charge screening in PBS (Figure 3). With the addition of other types of drugs, higher
drug loadings, or functionalized PEG end-groups, it may be necessary to recalibrate the
formulation as done in Figure 2 to derive a new optimal formulation.
PLGA-lipid-PEG NP Polymer Formulation Parameters.
Another parameter we can use to control NP size is polymer inherent viscosity, which
corresponds approximately to polymer molecular weight. Using an optimal formulation of 20%
total lipid/polymer mass ratio with 7:3 lipid/lipid-PEG molar ratio denoted by an asterisk (*) in
Figure 2, we varied the PLGA polymer inherent viscosity. The NPs were stable in PBS, had
relatively similar polydispersities and showed a gentle decrease in size with increasing polymer
inherent viscosity (Figure 5C). The effect of polymer inherent viscosity on NP size is consistent
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with previous reports for PLGA-PEG polymeric NPs . A possible mechanism is that higher
molecular weight polymers precipitate to form more compact structures during nanoprecipitation
as compared to lower molecular weight polymers. 0.82 dl/g PLGA inherent viscosity was used in
all subsequent experiments to form the polymeric core.
The organic phase was studied using organic solvents of increasing dielectric constants
that exhibit increasing polarity and water miscibility. We chose four organic solvents,
tetrahydrofuran (THF), acetone, acetonitrile and dimethylforamide (DMF), all which have been
commonly used to solubilize and formulate NPs, to study the effect of the organic solvent used
to solubilize the PLGA polymer' 3. The trend towards larger NPs was observed as the solvent
used became less water miscible and the polymer concentration was raised (Figure 4A).
Interestingly, when very non-polar organic solvents such as THF was used, we obtained
extremely low polydispersities around -0.100, whereas when very polar organic solvents such as
DMF was used, polydispersities were higher at -0.300; acetonitrile and acetone gave
polydispersities around -0.200. The effect of vortexing for 3 min after nanoprecipitation should
not only disperse random lipid micelles but also disperse the solvent droplets. Presumably, the
PLGA/THF droplets showed inefficient solvent dispersion and in a more predictable fashion than
PLGA/DMF droplets, giving differences in polydispersities and sizes observed. Subsequently,
we used acetonitrile as a model organic solvent, as it is a good solvent for Dtxl. Acetone,
however, was used in Chapters 6 and 7 to precipitate smaller NPs.
It is possible to vary polymer concentrations to control the size and zeta potential of NPs.
As polymer concentrations were increased from I to 25 mg/mL in acetonitrile (with a
corresponding scale-up of lipid in the aqueous phase), we observed the trend of increasing NP
size from 65 to 160 nm along with an increase in zeta potential from -40 mV to -70 mV in water
(values are much closer to ±0 mV in buffer due to charge screening) (Figure 4A). Finally, we
tested the effect of varying solvent/water ratios on the size and zeta potential of NPs. When our
typical solvent/water ratio of 0.33 was modified from 0.1 to 1, we observed NP sizes to be
almost constant at -65 nm with a slight trend of size increase. However, when the solvent/water
ratio was increased to 5 and 10, NP sizes increased to 88.1 ± 0.4 nm and 105.3 ± 2.2 nm,
respectively (Figure 4B). The solvent/water ratio is typically kept at 1 or less to bias the system
towards drug encapsulation and NP self-assembly. At solvent/water ratios of greater than 1, the
efficiency of NP self-assembly and drug loading yield may be reduced.
In Vitro Controlled Drug Release Kinetics of PLGA-lipid-PEG NPs.
We next wanted to understand how the three functionally different layers of our PLGA-
lipid-PEG NPs controlled the release of Dtxl; namely, the total lipids present at the interface, the
length of the PLGA polymer in the core, and the PEG surface density (Figure 5A). This
experiment was performed in H20 instead of PBS buffer solution as we took into consideration
that some formulations were not optimized for stability in PBS. This experiment characterizes
fundamental properties of the NPs as opposed to simulating a physiological environment.
An inset in Figures 5A-C shows the diameters and zeta potentials of the NPs in H20.
When we changed total lipid/polymer mass ratio on three log scales from 0.1% to 100% (wt/wt),
we observed different in vitro drug release rates. Drug release rates for 0% lipid compared to
100% lipid differed as much as 20 h for 50% release (Figure 5A).
In a separate experiment, we changed the PLGA polymer length in the core. Previously,
PLGA polymeric NPs with longer PLGA chains were shown to release drugs more slowly than
NPs with shorter polymer chains'3 . Our study shows a small contribution of polymer inherent
viscosity in controlled drug release, but the dominant contribution in these core-shell NPs come
from the lipid monolayer density (Figure 5B).
Likewise, in an experiment to examine the contribution of PEG surface density to drug
release, the PEG surface density was changed from 0% to 40% (mol/mol) with the total number
of lipid and lipid-PEG molecules kept constant. Drug release was also observed to be relatively
similar (Figure 5C).
Next, we examined the drug encapsulation efficiency, loading and release profile of the
hybrid NPs in comparison with PLGA-PEG NPs and PLGA NPs. We hypothesized that the
addition of a lipid monolayer at the interface of the PLGA core and the PEG shell may serve two
distinct functions: (i) to prevent small drug molecules from freely diffusing out of the PLGA
core, thereby improving drug encapsulation efficiency and loading yield, and (ii) to reduce water
penetration rate into the PLGA core, thereby decreasing the rate of polymer hydrolysis and drug
release from the NPs. As shown in Figure 6A, when Dtxl was mixed with PLGA (5 wt%) and
dissolved in acetonitrile for the preparation of lipid-polymer hybrid NPs, 59 ± 4% (mean ± SD,
n=3) of Dtxl was encapsulated. In contrast, Dtxl encapsulation efficiencies of PLGA-PEG NPs
and PLGA NPs were approximately 19 ± 3% (mean ± SD, n=3) and 37 ± 4% (mean ± SD, n=3),
respectively. The lower encapsulation efficiencies of PLGA-PEG NPs may stem from the
possibility that some PEG blocks are buried inside the PLGA-PEG NP cores during
nanoprecipitation, giving a less hydrophobic core compared to PLGA cores of hybrid NPs and
PLGA NPs.
The encapsulated Dtxl was released from the hybrid NPs at a sustained rate over 120 h
(Figure 6B). When hybrid NPs, PLGA-PEG NPs and PLGA NPs were loaded with Dtxl at
approximately 3 wt%, it took the hybrid NPs around 20 h to release 50% of Dtxl versus 10 h and
7 h for PLGA-PEG NPs and PLGA NPs, respectively. The results indicate that the lipid core-
shell interface acts as a molecular fence that slows down drug release from the NP core. Next,
we observed that the high Dtxl encapsulation efficiency and sustained release is retained across a
range of drug loadings. For example, when the initial Dtxl input was 5, 10 and 15 wt% of the
PLGA polymer, the measured drug loading yield reached 3.0, 6.1 and 8.5 wt% respectively,
which corresponded to a nearly constant encapsulation efficiency of 60%. Dtxl encapsulation
efficiency dropped when the initial drug input was increased to 20 wt% (Figure 6C). We also
found that Dtxl was released from the hybrid NPs in a sustained manner until its loading yield
was higher than -6 wt% (Figure 6D).
In Vitro Stability of PLGA-lipid-PEG NPs.
NP stability in serum is an important criterion for utility as drug carriers in vivo. Using
the change in NP size in the presence of plasma as a surrogate for protein adsorption and
biofouling, we next studied the serum stability of lipid-polymer hybrid NPs. We incubated NPs
with 10 wt% BSA and 10 vol% human plasma solution and monitored changes in NP size over
time. PLGA-PEG NPs and PLGA NPs were tested in parallel as controls. From Figures 7A-B,
the hybrid NPs and PLGA-PEG NPs were stable in 10% BSA solutions, retaining their size of 90
+ 2 nm (polydispersity=0.223 + 0.011, mean ± SD, n=3), while a slight increase in size was
observed in 10% plasma solution. In contrast, PLGA NPs showed a dramatic size increase from
90 to 200-300 nm within 10 min of incubation in BSA or plasma. Hence, we observed that the
presence of PEG prevented protein adsorption on the NP surface, which is consistent with
14previous reports that a decrease in NP biofouling can prolong NP systemic circulation half-life .
Next, we performed assays of long-term in vitro stability and protein binding on a
formulation of 20% total lipid/PLGA mass ratio, 7:3 lipid/lipid-PEG molar ratio, and 0.82 dl/g
PLGA polymer inherent viscosity core. PBS stability assays for long-term stability were carried
out where the NPs were dialyzed in PBS over 120 h at 37 'C and withdrawn at 24 h intervals.
DLS sizing measurements demonstrate that the NPs remain stable over five days with no
significant change in size and polydispersities (Figure 7C). This result suggests that the DSPE-
PEG density on the NPs does not drop below the range of full electrostatic and steric
stabilization over the course of 120 h. It could be that the DSPE-PEG covalent bond in
PEGylated lipid molecules is very stable and the PEG group is not hydrolyzed off, or that the
lipid monolayer does not peel off over 120 h. Thus, the NPs prepared in this study should remain
stable in vitro for relatively long periods. Plasma stability assays for protein binding were
performed in which NPs were incubated in 10 vol% human plasma solution (diluted in PBS) or
100% fetal bovine serum (FBS) for 120 h at 37 'C. After an initial -20 nm increase in size, the
NPs maintained size stability throughout the 120 h study (Figure 7C), suggesting that plasma
protein binding was not a significant factor. This result suggests that the current formulation has
sufficient stability derived from steric repulsion by the PEG chain, electrostatic repulsion from
the negatively charged carboxylic end group and adequate lecithin coverage of the polymeric
core.
The mechanism of drug release from a polymeric core is typically bulk or surface
erosion, or in some cases a combination of both. These in vitro stability assays also suggest a
mechanism of drug release from the PLGA-lipid-PEG NPs. Surface erosion of particles results
in a gradual decrease in NP mean diameter over 120 h, while bulk erosion of particles results in
constant NP mean diameters over 120 h. Our data shows almost constant mean diameters with no
gradual mean diameter reduction over time (Figure 7C). We postulate that the mechanism of
drug release from PLGA-lipid-PEG NPs occurs by bulk erosion, in which Dtxl diffuses out
through channels that form within the NP core before bulk degradation, as opposed to gradual
surface erosion from the PEG shell.
Post-formulation Purification and Storage of PLGA-lipid-PEG NPs.
NPs made by nanoprecipitation contain 10-15 vol% organic solvent which fail to
evaporate during the self-assembly stage. Post-formulation purification of the NPs is necessary
to remove trace amounts of organic solvent contamination which causes NP instability and
degradation. We analyzed the diameter, polydispersity and zeta potential of our NPs after
purification by either dialysis or ultrafiltration with a commercially available centrifuge filtration
device. We found there to be no observed difference using either methods, even after multiple
washing steps using the ultrafiltration method (Figure 8A). The two purification methods can be
used together to achieve gentle organic solvent removal and to change NP concentrations or
buffer solutions. Potential pharmaceutical use of these NPs requires scalable processes for the
storage of larger batches of NPs. We encapsulated Dtxl in the NPs (5 wt%), freeze-dried the NP
solution in liquid nitrogen and lyophilized the NPs at -80 OC. The addition of cryoprotectants
such as 10% (wt/vol) sucrose allowed for recovery of 87.0 ± 0.6 nm NPs, similar to the original
64.5 ± 0.5 nm diameters. In the absence of 10% sucrose, NPs aggregated significantly to -2.1
pm (Figure 8B).
Scalability of PLGA-lipid-PEG NPs.
As a first attempt to demonstrate the potential scalability of this process, we synthesized
300 mg (polymer weight) batches of NPs. The NPs maintained the biological and
physicochemical properties as previously described. Currently, we have made reproducible -1 g
batches of sub-100 nm drug-encapsulated NPs and these are described in Chapter 7. It is vital
that the concentration and total volume of the reaction be optimized carefully because NP size
increases with polymer concentration (Figure 4A). Large volumes may suffer from inadequate
mixing and stirring during the self-assembly stage, resulting in a polydisperse batch of micron-
sized particles. More seriously, inadequate mixing results in the improper encapsulation of
hydrophobic drugs that are unprotected in aqueous environments. These drugs will subsequently
precipitate out in physiological buffers. Our -I g batches in Chapter 7 allow us to dissolve very
hydrophobic drugs to high concentrations in physiological buffers and release these drugs with
well-defined kinetics in vitro. In an academic setting, our scalability is now only limited by
equipment at our disposal (large centrifuges and magnetic stirring plates) rather than feasibility,
reproducibility and manpower. It is likely that in an industrial setting, equipment would be more
accessible, removing the current limitations of scale-up.
In Vitro Cytotoxicity of PLGA-lipid-PEG NPs.
HeLa and HepG2 cell lines were used to assess the cellular cytotoxicity of the NPs.
Cytotoxic activity was evaluated at twofold dilutions in triplicate ranging from 25 mg/mL to 0.1
mg/mL. Following 24 h exposure to the NPs, cell viability was assessed by the MTT assay. The
results were plotted onto a fitted curve and expressed as treatment over control (T/C) values for
cell survival. The NPs did not cause significant cytotoxicity against either cell line. Experimental
TC50 values of the NPs grown on HeLa cells were found to be 5.55 mg/mL for HeLa cells
(Figure 9A) and 4.58 mg/mL for HepG2 cells (Figure 9B). Representative photographs of HeLa
and HepG2 cells are shown with no NPs added (left column), incubated with NPs at TC50 values
(middle column), and incubated with NPs at TC100 values (right column) (Figure 9C).
PLGA-Lipid-PEG Microparticle Synthesis by the Homogenization Emulsion Technique.
Finally, to develop a spectrum of hybrid particles that are either relatively small (sub-100
nm) or large (1-2 pm) defined in terms of systemic delivery, we synthesized PLGA-lipid-PEG
hybrid microparticles (MPs) with similar properties to PLGA-lipid-PEG NPs. The MPs were
made by the homogenization emulsion technique using ethyl acetate, but other solvents such as
dichloromethane (DCM) and chloroform are also possible. Particle size was confirmed by DLS
to be 950 ± 23.5 nm (polydispersity=0.253 ± 0.022, n=3). Representative images of the MPs with
a field emission scanning electron microscope (SEM) showed that the use of DSPE-PEG2000-
COOH (Figure 10A, 10B) or DSPE-PEG3400-COOH (Figure 10C, 10D) resulted in
monodisperse hybrid MPs with spherical morphology. The MP batches shown in Figure 10 have
not undergone any size fractionation. In Figure 11, we analyzed the diameters of representative
MPs from Figure 10A. Generally, the sizes of the MPs are approximately 1-2 pm, and their
minimum to maximum sizes range from 0.6 to 2.6 pm.
MPs made by the emulsion technique typically require surfactants such as 0.1% to 1%
polyvinyl alcohol (PVA) in the aqueous phase to stabilize the emulsions and prevent
coalescence15 . Here, surfactants are not required aside from DSPE-PEG2000 or DSPE-
PEG3400 lipid-polymer conjugates. The elimination of PVA surfactants which may not be
completely washed away during purification steps results is the synthesis of highly
biocompatible MPs.
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Figure 1. Synthesis of PLGA-lipid-PEG core-shell NPs.
(A) The illustration shows the synthesis of PLGA-lipid-PEG NPs by a modified
nanoprecipitation method and self-assembly. (B) NPs are comprised of a hydrophobic PLGA
core, a hydrophilic PEG shell, and a lecithin monolayer at the interface of the hydrophobic core
and the hydrophilic shell. (C) A TEM image shows the core-shell structures of the NPs. NPs
were negatively stained with uranyl acetate to enhance the electron contrast between polymers
and lipids.
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Figure 2. Lipid/lipid-PEG to polymer ratios.
By varying the parameters of total lipid/polymer mass ratio and lipid/lipid-PEG molar ratio, we
can tune NP size in physiological buffers. The asterisk (*) refers to optimal NP formulations
(mean ± SD, n=3).
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Figure 3. Requirements for an optimal PLGA-lipid-PEG system.
Optimal formulations result from an adequate lipid monolayer and PEG surface density
surrounding the hydrophobic PLGA polymeric core. The NPs are stabilized by the PEG layer
which provides a steric barrier and a net repulsive force during collision events with other NPs.
The reduction in strength of the Coulomb interaction is referred to as the screening of electrical
charges on the surface of NPs and results in a sterically stabilized dispersion. Without PEG
screening, hydrophobic PLGA NPs decrease the surface area (and electrostatic interactions) in
contact with other NPs by aggregation, resulting in MP formation. Two requirements for PEG
charge screening are (i) adequate lipid monolayer coverage of the PLGA polymeric core, and (ii)
adequate lipid-PEG to lipid ratio (i.e. overall adequate lipid-PEG).
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Figure 4. The effect of formulation parameters on the size and zeta potential of PLGA-
lipid-PEG NPs.
(A) The effect of polymer concentration on NP size and zeta potential in various organic solvents
with different water miscibilities. (B) The effect of solvent/water ratio on NP size, taking
acetonitrile as the organic solvent. All results are mean + SD, n=3.
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Figure 5. Controlled and sustained drug release profiles of PLGA-lipid-PEG NPs.
(A) The effect of total lipid/polymer weight ratio on drug release from the NPs. Inset:
percentage units indicate total lipid/PLGA mass ratio. (B) The effect of PLGA inherent viscosity
on drug release. Inset: units are in dl/g. (C) The effect of lipid-PEG/lipid molar ratio on drug
release. Inset: percentage units indicate lipid-PEG/lipid molar ratio. The inset of each panel
shows the diameter and zeta potential (denoted as () of corresponding NP formulations. All
results are mean ± SD, n=3.
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Figure 6. Drug loading capacity and release profile of PLGA-lipid-PEG hybrid NPs versus
PLGA-PEG and PLGA polymeric NPs.
(A) Drug encapsulation efficiency of Dtxl in PLGA-lipid-PEG NPs versus PLGA-PEG NPs and
PLGA NPs. The initial drug input was 5 wt% of PLGA polymer weight for each type of NP. (B)
Drug release profiles from PLGA-lipid-PEG NPs, PLGA-PEG NPs and PLGA NPs. Drug
loading was -3 wt% for each type of NP. (C) Drug loading of PLGA-lipid-PEG NPs at various
initial drug inputs based on PLGA polymer weight. (D) Drug release profiles from PLGA-lipid-
PEG NPs with 3, 6 and 9 wt% drug loading. All results are mean i SD, n=3.
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Figure 7. NP temporal stability in vitro.
PLGA-lipid-PEG NPs (blue squares), PLGA-PEG NPs (black circles), and PLGA NPs (black
triangles) were incubated in a (A) 10 wt% BSA solution, and (B) 10 vol% plasma with heparin
solution at 37 *C under gentle stirring. (C) In vitro stability of PLGA-lipid-PEG NPs over
120 h. NPs were incubated with PBS, 10 vol% plasma/heparin in PBS and 100% FBS for five
days at 37 'C. At each time point, an aliquot was taken for DLS size measurements. All results
are mean ± SD, n=3.
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Figure 8. Post-formulation stability of PLGA-lipid-PEG NPs.
(A) Post-formulation stability of the NPs upon purification by ultrafiltration or dialysis. (B) Post-
formulation stability of the NPs upon liquid nitrogen freeze-drying and lyophilization with 10%
sucrose cryroprotectant. All results are mean SD, n=3.
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Figure 9. Cytotoxicity of PLGA-lipid-PEG NPs on HeLa and HepG2 cell lines.
Fitted curves show cell viability of (A) HeLa and (B) HepG2 cell lines with twofold dilutions of
NPs from 25 to 0.1 mg/mL. All results are mean ± SD, n=3. (C) Photographs of control HeLa
and HepG2 cells without NP incubation (left column); HeLa and HepG2 cells at TC50
concentrations of NPs (middle column); HeLa and HepG2 cells with the highest concentration
(25 mg/mL) of NPs (right column).
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Figure 10. SEM images of PLGA-lipid-PEG MPs.
Scanning electron microscopy (SEM) images of the MPs. The MPs shown here have not been
size-fractionated prior to imaging. (A) PLGA-lipid-PEG2000 MPs at 2,700x magnification.
Scale bar, 5 pm. (B) PLGA-lipid-PEG2000 MPs at 1,500 x magnification. Scale bar, 10 pm. (C)
PLGA-lipid-PEG3400 MPs at 2,300x magnification. Scale bar, 10 ptm. (D) PLGA-lipid-
PEG3400 MPs at 1,200x magnification. Scale bar, 10 pm.
Figure 11. Representative diameters of PLGA-lipid-PEG MPs.
Scanning electron microscopy (SEM) images of PLGA-lipid-PEG2000 MPs at 2,700x
magnification. Scale bar, 5 pm. Annotations on representative MPs show that the diameters of
MPs range from -1-2 pm with lower and upper limits at approximately 0.6 pm and 2.6 pm
respectively. The MPs shown here have not undergone size-fractionation prior to imgaging.
Discussion
In this study, we used ester-terminated poly(DL-lactic-co-glycolic acid) (PLGA) as a
model hydrophobic polymer to form the polymeric core of the NPs; polyethylene glycol (PEG)
covalently conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) as a model
hydrophilic polymer to form the 'stealth' shell of the NPs; and lecithin as a model lipid to form
the lipid monolayer at the interface of the PLGA core and PEG shell. Both PLGA and PEG
polymers have been approved by the FDA for medical applications. Lecithin is a natural lipid
extract from soybean and is Generally Regarded as Safe (GRAS). Compared with synthetic
alternatives, soybean phosphatidylcholine (sPC) can be totally biodegraded and metabolized
since it is an integral part of biological membranes. Hence, these three materials are regarded as
well tolerated for potential pharmaceutical applications. We expect the hybrid NPs to be a
biocompatible, biodegradable and safe drug carrier for potential clinical use.
The hybrid NPs show improved drug encapsulation and release profiles when compared
to PLGA-PEG and PLGA systems. We have shown in Figures 5A-C that the lipid monolayer
contributes to the consistently higher drug encapsulation efficiency and slower release observed.
Based on these experimental results, we propose a model where the lipid monolayer acts as a
molecular fence - it promotes drug retention in the hydrophobic polymeric core and restricts
water access into the core to slow down PLGA polymer erosion and drug release. Furthermore,
in the range of polymeric inherent viscosities and PEG surface densities tested, we were unable
to observe any changes in drug release when lipid monolayer coverage was kept constant
(Figure 5B and C). Therefore, the lipid monolayer may be a limiting factor for drug release and
can be manipulated to alter drug release rates. However, it is also important that the overall lipid
concentration not be increased beyond the critical micellar concentration (CMC) of lecithin (-0.4
mg/mL, data from manufacturer) or DSPE-PEG (1.1 x 10-5 M or -0.33 mg/mL) 16 which may
result in the assembly of lecithin liposomes (typical sizes are about 100-1000 nm) and -10-15
nm DSPE-PEG micelles. The coexistence of these liposomes would enhance the overall
measured size of the hybrid NPs. Conversely, when the lipid/polymer weight ratio is too low,
there is a paucity of lipids and DSPE-PEG to shield the PLGA core, resulting in a lack of
stability in physiological conditions.
For targeted delivery, the wide variety of available DSPE-PEG end-groups means that
surface functionalization of hybrid NPs with targeting molecules can be easily achieved. In this
study, we used DSPE-PEG2000-COOH which can be easily conjugated to amine-terminated
targeting ligands such as peptides, small molecules and aptamers by coupling agents such as I -
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide
(EDC/NHS) (Chapter 3). In later chapters (Chapters 4, 6 and 7), we switch to using DSPE-
PEG2000 with maleimide terminal end-groups for thiomaleimide conjugation to cysteine-
containing peptide ligands. This type of covalent conjugation can be completed within 30 min to
2 h and does not need the conjugation chemicals required by carbodiimide chemistry. The
disadvantage is that thiomaleimide chemistry is more suitable for ligands that expose only one
cysteine group for site-specific conjugation and which do not contain internal sulfydryl bonds
that are required for conformational activity, since conjugation of the wrong cysteine or
reduction of sulfydryl bonds may inadvertently denature the ligand. Finally, the commercial
availability of DSPE-PEG2000-biotin makes conjugation reactions based on the biotin-avidin
interaction also possible.
Increasingly, DSPE-PEG conjugates have been used to design micelles with hydrophobic
cores surrounded by lipid layers. Mixed micelles of egg PC/DSPE-PEGi," 7 and mAb-targeted
DSPE-PEG micelles' have been the focus of the Vladimir Torchilin group. In the lab of Darrell
Irvine, hybrid NPs and MPs with PLGA polymeric cores and lipid-PEG shells have been
designed using the sonication emulsion technique 9. DSPE-PEG has been used to encapsulate
hydrophobic CdSe quantum dots for imaging , and one study used these DSPE-PEG
21functionalized dots to observe Xenopus embryogenesis in vivo . In particular, our hybrid NP
22design has already been applied to design similar hybrid NPs . In short, other researchers have
similarly explored the use of liposome-like NPs with hydrophobic cores for parenteral delivery
of imaging agents and therapeutic payloads.
Although the focus of this project is on systemic uses of sub-100 nm NPs, we have
designed similar particles in the low micron range. Unlike typical preparations of PLGA MPs,
our MPs do not require the use of chemical surfactants such as PVA 23. The uses of these MPs
may range from intramuscular or subcutaneous depots that elute over weeks and months for the
delivery of anesthetic or contraceptive drugs. For systemic delivery, hybrid MPs may be used as
viral and cancer vaccines since their I ptm size range make them suitable candidates for
phagocytosis. The MPs may be used to present adjuvants and pathogen-associated molecular
patterns (PAMPs) such as lipopolysaccharide, double-stranded RNA and unmethylated CpG
motifs for recognition by cells of the innate immune system.
In summary, we developed a lipid-polymer hybrid NP platform consisting of a
hydrophobic polymeric core, a hydrophilic polymeric shell and a lipid monolayer at the interface
of the core and shell. The hybrid NPs have tunable size and surface charge, high drug loading
yield, sustained drug release profile and favorable stability in physiological conditions. The NPs
were well tolerated by human cell lines and prepared by a potentially scalable nanoprecipitation
process. Thus, these hybrid NPs may be suitable as a potential drug delivery system. In Chapter
3, we further characterize the in vivo pharmacokinetic and pharmacodynamic properties of these
NPs.
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Chapter 3. Pharmacokinetic-Pharmacodynamic Studies
of Hybrid Lipid-Polymeric Nanoparticles.
Abstract
This study analyzes the pharmacokinetic-pharmacodynamic (PK-PD) profile of hybrid
lipid-polymeric NPs for the systemic delivery of therapeutic drugs. To understand their PK
profile, the plasma circulation half-life of hybrid NPs was compared against PLGA-PEG NPs by
radioisotope-tracking of tritium-labeled PLGA polymers (3 H-PLGA) in the NP core.
Radiolabeled NPs delivered by intravenous injection showed circulation half-lives of
approximately 3 h and 12 h for PLGA-PEG NPs and hybrid NPs, respectively (n=6). Our
earliest targeting studies were initiated using RNA aptamers to study the PD profile of hybrid
NPs. A10 RNA aptamers recognize the extracellular domain of the prostate-specific membrane
antigen (PSMA), a well characterized membrane glycoprotein expressed on LNCaP prostate
epithelial cells. The hybrid NPs were self-assembled from DSPE-PEG-A1O RNA aptamer
triblock polymers. In vitro fluorescence microscopy studies showed greater uptake of fluorescent
dye-encapsulated aptamer-NPs by PSMA-expressing LNCaP prostate adenocarcinoma cell lines
versus non-expressing PC3 cell lines. For in vivo biodistribution studies, radiolabeled aptamer-
NPs were delivered by intravenous injection in mouse xenograft models of prostate cancer. The
addition of aptamers altered the distribution of hybrid NPs as a function of aptamer surface
density, with 5% and 10% aptamer surface coverage to PEG end-groups giving the best tumor
localization. Hence, the use of targeting ligands may improve hybrid NP localization to prostate
tumors but require extensive optimization for systemic delivery.
The content of this chapter has been published in whole or in part in the following
journal article:
Zhang, L., Chan, J.M., Gu, F.X., Rhee, J.W., Wang, A.Z., Radovic-Moreno, A.F.,
Alexis, F., Langer, R. Farokhzad, O.C. Self-assembled lipid-polymer hybrid
nanoparticles: a robust drug delivery platform. ACS Nano (2008). 2, 1696-1702.
Reproduced with permission from ACS Nano. American Chemical Society ©
2008.
Introduction
In the design of biocompatible NPs for therapeutic drug delivery, a desired feature
includes NPs which have long-circulating plasma half-lives. There are several reasons why
long-circulating or 'macrophage-evading' NPs are desired'. An important and direct reason is to
provide a reservoir in the blood compartment from which the drug can be released in a
continuous and controlled manner - above the therapeutic levels required for efficacy and below
toxic levels that cause harmful side-effects. Considering that the encapsulated drugs and
therapeutic agents themselves may have short elimination half-lives (e.g. proteins, hydrophobic
drugs, siRNA and plasmids), long-circulating NPs may help to slow down the clearance kinetics
of the system and present a pharmacologically-desired free drug profile. Furthermore, one would
expect that because of prolonged residence in the blood, long-circulating NPs with the
appropriate sub-100 nm size range also have a better chance of reaching target sites such as solid
tumors and atherosclerotic plaques, giving improved imaging diagnosis or treatment efficacy.
To study the in vivo pharmacokinetic (PK) properties of a new NP formulation, plasma
half-life can be calculated by measuring its concentration in the blood or serum of animals over
time based on a one-component model, which assumes a rapid equilibration in drug
concentrations throughout the body. The calculated half-life helps to estimate the length of time
the NPs stay in circulation and this is useful in deciding dosing frequencies for dose-response
studies. Here, we derived the circulation half-life profile of hybrid NPs and PLGA-PEG NPs
from tracking radioisotope levels in animals over time using tritium-labeled poly(lactic-co-
glycolic acid) (3H-PLGA) polymers encapsulated in the NP core. Blood samples were collected
at indicated time points and subject to scintillation counting to quantify remaining radioisotope
levels in the blood.
Next, to study the PD profile of the NPs, we functionalized the hybrid NPs with A1O 2'-
fluoropyrimidine RNA aptamer (Apt) ligands against the PSMA antigen upregulated in
metastatic prostate adenocarcinomas. We synthesized triblock lipid-PEG-Apt conjugates which
were then used to self-assemble the NPs. For in vitro cellular uptake studies, Dtxl-NP-Apts
(10% aptamer surface coverage to PEG end-groups) showed preferential uptake by PSMA-
positive LNCaP cell lines over PSMA-negative PC3 cell lines. For in vivo biodistribution
studies, we delivered radiolabeled Dtxl-NP-Apts in mouse LNCaP xenograft models of prostate
cancer and show that the addition of aptamers alter NP distribution as a function of aptamer
surface density. Inadequate aptamer surface coverage (-1%) and over-coverage (25%, 50% and
100%) resulted in poor localization to prostate xenografts compared to optimal aptamer surface
coverage at 5% and 10%. Taken together, this suggests that while in vitro cellular uptake of NPs
may be improved from aptamer functionalization, the direct relationship of aptamer
functionalization and cell uptake may not correspond in vivo. When systemically delivered, the
aptamer surface coverage on these NPs needs to be carefully optimized to achieve maximal
tumor uptake.
Hence, these PK-PD studies provide invaluable information before this hybrid NP system
can be used in medical applications. They form the rationale for the intended therapeutic dose,
dose-frequency and for the design of dose-ranging efficacy studies described in Chapter 7.
Finally, these studies allow for the formulation of hypotheses regarding the contribution of
targeting ligands to NP localization in vivo.
Methods
Materials.
BD Matrigel matrix phenol-red free was bought from BD Biosciences (San Jose, CA). 2.5%
avertin was made from 100% avertin added dropwise with constant stirring into PBS at 37 cC.
100% avertin was made from 10 g of 2,2,2- tribromoethanol (99%) mixed with 10 mL of tertiary
amyl alcohol (Sigma). Custom synthesized 3H-PLGA, Solvable tissue solubilizer and Hionic-
Fluor scintillation cocktail were purchased from Perkin-Elmer (Waltham, MA). 0.5 M EDTA,
pH 8.0 and NBD-cholesterol (22-(N-(7-nitrobenz-2-oxa- 1,3-diazol-4-yl)amino)-23,24-bisnor-5-
cholen-3p-ol) were both from Invitrogen (Carlsbad, CA). I-ethyl-3-(3 dimethylaminopropyl)
carbodiimide (EDC) and sulfo-N-hydroxysuccinimide (Sulfo-NHS) were both from Pierce
Thermo Scientific (Rockford, IL).
Animals.
Animal care and experimental procedures were performed in accordance with the regulations of
the Massachusetts Institute of Technology Division of Comparative Medicine and the Principles
of Laboratory Animal Care of the National Institutes of Health. -300-400 g male and female
Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington, MA) for
pharmacokinetic studies. Male, 8-week-old, BALB/c scid mice were purchased from Jackson
Laboratory (Bar Harbor, ME) for xenograft and pharmacodynamic studies.
In vivo Circulation Half-Life Studies.
3H-PLGA encapsulated NP samples were intravenously (i.v.) injected into Sprague-Dawley rats
(n=6) at t=0 h. -100 uL of blood was drawn from alternate saphenous leg veins at the indicated
time points. For each procedure, animals were restrained for less than 5 min using a Decapicone
restrainer (Braintree Scientific, Braintree, MA). Samples were immediately added into
previously-weighed scintillation vials containing 100 uL of 0.5 M EDTA, pH 8.0. Blood samples
were weighed. 400 pL of Solvable solubilizer was added to dissolve the sample and 200 pL of
30% H20 2 was added for I h at 60 "C to decolorize the sample. After cooling, Hionic-Fluor
scintillation cocktail was added to the maximum height of the 7-mL vial. H levels were counted
using a Packard TriCarb Scintillation Analyzer (Downers Grove, IL). Data is presented as
percent injected dose per organ or per gram of tissue.
Lipid-PEG-Aptamer Triblock Synthesis.
AlO aptamer sequence (28 kDa): 5'-NH2-spacer GGG/AGG/ACG/AUG/CGG/AUC/AGC/
CAU/GUU/UAC/GUC/ACU/CCU/UGU/CAAIUCC/UCA/UCG/GCiT-3'. Aptamers were
custom synthesized with 2' fluoropyrimidines, a 5'-amino group attached by a
hexaethyleneglycol spacer and a 3'-inverted T cap by Integrated DNA Technologies (IDT,
Leuven, Belgium). Aptamers were stored as a lyophilized powder at -80*C and resuspended in
DNase- and RNase-free water (Invitrogen). Lipid-PEG-COOH molecules were activated for 15
min with a 1/10 molar ratio to EDC/Sulfo-NHS. Aptamers were activated at 90 'C for 3 min and
snap cooled on ice. Lipid-PEG-COOH and aptamers were mixed at a 10/1 ratio and incubated
for 4 h at RT with gentle shaking. Samples were dialyzed using a 5 kDa MWCO Slide-a-Lyzer
cassette for 5 h (Pierce Thermo Scientific) with water changes to remove unconjugated lipid-
PEG-COOH molecules. Absorbance spectroscopy at 280 nm was used to quantify lipid-PEG-
aptamer triblock molecules based on the assumption that retained aptamers are conjugated to
lipid-PEG. The same procedure was used to synthesize lipid-PEG-random oligonucleotides for
in vivo biodistribution studies. NPs were filter-sterilized before i.v. injection into animals.
Cellular Uptake Studies by Fluorescence Microscopy.
To visualize the NPs, NBD-cholesterol was encapsulated in the NPs. The fluorescence emission
spectrum of NBD (ex/em=460 nm/534 nm) was detected in the green channel (490 nm/528 nm)
of a Delta Vision RT deconvolution microscope. Prostate LNCaP and PC3 cell lines were grown
in 8-well microscope chamber slides in RPMI-1640 and Ham's F-12K medium, respectively,
both supplemented with 100 units/mL aqueous penicillin G, 100 pg/mL streptomycin and 10%
FBS (fetal bovine serum). The cells were plated at concentrations that allow for 70% confluence
in 24 h (i.e., 40 000 cells/cm 2). On the day of experiments, the cells were washed with
prewarmed PBS buffer and incubated with prewarmed fresh media for 30 min before adding NPs
with a final concentration of -250 ptg/mL (n=4). After a 2 h incubation at 37 'C, the wells were
washed two times with PBS (300 ptL per well), fixed with 4% formaldehyde and mounted with
Vectashield nonfluorescent mounting medium containing DAPI (Vector Laboratory,
Burlingame, CA). The cells were then imaged using a Delta Vision RT deconvolution
microscope.
LnCaP Xenograft Mouse Model.
LNCaP cells were cultured as described in the Cellular Uptake Studies section. Cells were grown
to 90% confluency, counted and resuspended to give 15 million cells/mL in complete growth
media with 1x penicillin/streptomycin and 10% FBS for fast-growing tumors. The mice were
weighed and anesthetized intraperitoneally with 2.5% avertin (200 mg/kg body weight). The
same volume of Matrigel was added to LNCaP suspensions for a 1/1 media/Matrigel volume
ratio. 3 x 106 LNCaP cells in 200 pL media/Matrigel mixture suspensions were subcutaneously
injected into the left flank of each mouse. The LNCaP tumors were allowed to develop for -3
weeks. Tumor length and width was measured by digital calipers using the formula: (width2 X
length)/2. When the tumors were sufficiently large (-250-300 mm3), the mice were divided
randomly into groups (n=5) and NPs were prepared for administration.
In vivo Biodistribution Studies.
3H-PLGA NP formulations were resuspended in 200 pL PBS before administration. The mice
were anesthetized and dosed with NPs via retro-orbital injection. After dosing, animals were
sacrificed at 24 h. 200 pL of blood was drawn by cardiac puncture while the tumor, heart, lungs,
liver, spleen and kidneys were harvested from each animal. All samples, including blood
samples, were weighed in scintillation vials that were pre-weighed prior to sample collection.
Due to the size of the liver, it had to be homogenized and only -100 mg of tissue was analyzed.
Each organ was solubilized with 2 mL of Solvable for -12 h at 60 *C. 200 pL of 0.5 M EDTA
was added to each vial, followed by 200 pL of 30% H20 2. Blood samples were prepared as
discussed in the method for Circulation half-Life Studies. Samples were incubated for I h at 60
*C to decolorize the samples. After samples were cooled, scintillation cocktail was added to the
maximum height of the 7-mL vial. 3H levels were counted using a Packard TriCarb Scintillation
Analyzer (Downers Grove, IL). To determine the 100% dose, injected formulations were
counted as well. Data is presented as percent injected dose per organ or per gram of tissue.
Results
In Vivo Circulation Half-Life of PLGA-lipid-PEG NPs.
To measure the duration of the hybrid NPs in blood plasma, we conducted PK circulation
half-life studies comparing radioisotope-encapsulated PLGA-lipid-PEG NPs against PLGA-
PEG NPs. Samples were intravenously injected into Sprague-Dawley rats at t=O h and blood was
drawn from alternate saphenous leg veins at indicated time points. The blood samples were
processed and circulatory 3H levels were analyzed by liquid scintillation counting, with counts
adjusted for blood weight. Average reads per time point were plotted against time as a
percentage of 3H readings taken immediately after injection at t=O h. The circulation half-life of
PLGA-lipid-PEG NPs and PLGA-PEG NPs were found to be -12 h and -3 h respectively
(mean ± SD, n=6) (Figure 1).
Aptamer Targeted-NP Synthesis.
The suitability of the hybrid NPs for targeted drug delivery applications was analyzed in
vitro and in vivo using A1O aptamers as a model ligand. The AIO aptamer is a nuclease-
stabilized 2'-fluoropyrimidine RNA molecule with 57 base pairs, and it has shown high binding
affinity to the extracellular domain of the prostate specific membrane antigen (PSMA)
overexpressed by late-stage and metastatic prostate cancer2. Amine-terminated aptamers were
covalently conjugated to carboxyl-functionalized lipid-PEG conjugates using EDC/sulfo-NHS
activation chemistry, followed by dialysis to remove unconjugated lipid-PEG molecules.
The lipid-PEG-Apt conjugates were used in the nanoprecipitation and self-assembly of
NPs as illustrated in Figure 2. After self-assembly, the NPs were washed using
ultracentrifugation as described previously. To characterize and quantify aptamer surface
coverage, lipid-PEG-Apt conjugates were added at various amounts (from 0 pig to 240 Rg
aptamer weight) to the 4% ethanol aqueous phase, replacing unconjugated lipid-PEG-COOH
molecules until an excess of lipid-PEG-Apt was added. The NPs were incubated at pH 11 for 30
min to hydrolyze ester linkages in the aptamers. Samples were spun down using Pall Microsep
centrifuge devices (10 kDa MWCO) to collect the hydrolyzed nucleotides in the flow-through
(Figure 3A). RNA concentrations were measured to estimate 0-100% lipid-PEG-Apt surface
coverage of hybrid NPs. In Figure 3B, the amount of aptamers added (as lipid-PEG-Apt
conjugates) on the X-axis is shown against the amount present after self-assembly and washing
steps on the Y-axis. As the curve starts to plateau at 240 pg lipid-PEG-aptamer addition, -20 pg
lipid-PEG-Apt coverage was considered to represent 100% NP surface coverage. Subsequently,
-240 pg lipid-PEG-Apt/l mg of NP was added to give 100% surface coverage. It is not
surprising that the triblock incorporation efficiency of aptamers is approximately 8-10%, since
the large size and hydrophilic nature of aptamers affect the amphiphilic balance of the lipid-PEG
molecules. If small molecule ligands such as folate and peptides are used, the triblock
incorporation efficiency is expected to be much higher.
Cellular Uptake Studies.
The uptake of A10 aptamer-targeted NPs by different cell lines was analyzed in vitro.
LNCaP prostate adenocarcinomas which express the PSMA antigen on their plasma membrane
were chosen as the target cell line and PC3 prostate adenocarcinomas which do not express the
PSMA antigen were used as negative controls. To visualize cell uptake of the NPs using
fluorescence microscopy, a hydrophobic fluorescent probe, NBD cholesterol (ex/em=460
nm/534 nm), was encapsulated in the hybrid NPs. In Figure 4, the PSMA-targeted hybrid NPs at
10% aptamer surface coverage to PEG end-groups were taken up by LNCaP cells (PSMA
positive) (Figure 4A) but not by PC3 cells (PSMA-negative) (Figure 4C). The small amount of
NBD signal from PC3 cells may represent a portion of free NBD dye released from NPs during
incubation or alternatively may represent nonspecific uptake of particles by the PC3 cells. When
the PSMA aptamer was not used, negligible amounts of non-targeted NPs were delivered to
LNCaP (Figure 4B) and PC3 (Figure 4D) cells.
In Vivo Biodistribution of PLGA-lipid-PEG NPs.
For in vivo pharmacodynamics studies, NPs were formulated with both radioisotopes and
therapeutic payloads in the polymeric core. 3H-PLGA (100 pCi/1 mg PLGA) was added to the
PLGA/acetonitrile solution for radiolabel detection, while 100 ptg Dtxl (10 wt% initial load) was
added to form a therapeutically relevant NP formulation.
Tumor xenografts were induced by subcutaneous injections of LNCaP prostate
adenocarcinomas onto the left flanks of mice. When tumors were sufficiently large at -250-300
mm3, the mice were randomly divided into groups (n=5) and NPs were prepared for PK studies.
Sample NP groups with 0%, 1%, 5%, 10%, 25%, 50% and 100% aptamer surface coverage, as
well as 10% random oligonucleotide surface coverage, were delivered by i.v. injection into
xenografted mice. The mice were sacrificed after 24 h for blood draw by cardiac puncture and to
harvest their vital organs. After the samples were weighed, circulatory and organ 3H levels were
analyzed by liquid scintillation and adjusted for blood and organ weights. Average 3H readings
were taken as a percentage of the injected dose per organ (Figure 5). From Figure 5, most of the
NP can be found in the liver, blood and kidneys at 24 h, which is an expected profile observed
from previous studies with PLGA-PEG polymeric NPs3.
From the observation of H readings taken as a percentage of the injected dose per weight
of tumor tissue, different amounts of aptamer coverage can change the tumor distribution profile
of NPs (Figure 6). At 5% and 10% aptamer surface coverage, NPs localize more to the xenograft
compared to inadequate I% aptamer coverage. When too much of the NP surface is covered by
aptamers (25%, 50% and 100%), an increased localization effect is not observed. The NPs may
be cleared more quickly by the reticulo-endothelial system (RES) of the liver and spleen because
(i) the high levels of double-stranded RNAs on NP surfaces may act as pathogen-associated
molecular patterns (PAMPs) that are recognized by cells of the innate system; or (ii) the higher
surface density of aptamers may hinder the shielding function of the PEG layer leading to greater
clearance. Hence, for targeting ligands to improve NP localization to sites of interest such as
prostate tumors, formulations need to be carefully optimized for systemic delivery.
100
.2 90 +PLGA-lipid-PEG
05 80-
2 * *aPLGA-PEG
-3 70 **
S60*
S50
40
30
CD
10
20
0 10 20 30 40 50 60 70 80 90 100 110 120
Time (h)
Figure 1. Circulation half-life of PLGA-lipid-PEG and PLGA-b-PEG NPs.
Samples were i.v. injected into Sprague-Dawley rats at t=0 h and blood was drawn from alternate
saphenous leg veins at the indicated time points. Circulatory 3H levels were analyzed by liquid
scintillation and counts were adjusted for blood weight. Average reads per time point were
plotted against time as a percentage of 3H readings taken immediately after injection at t=0 h.
The circulation half-life of PLGA-lipid-PEG and PLGA-b-PEG NPs are -12 h and -3 h
respectively (mean ± SD, n=6, 3 male/3 female per group). *, P < 0.05; ***, P < 0.001, by one-
way ANOVA with Tukey post hoc test.
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Figure 2. Hybrid NPs with varying aptamer surface densities.
Aptamer surface density can be directly controlled by using different ratios (0%, 1%, 5%, 10%,
25%, 50% and 100%) of lipid-PEG-aptamer conjugates. The NPs were visualized by
fluorescence microscopy using NBD-cholesterol or quantified by scintillation counting using
radioisotope labeled 3H-PLGA polymers.
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Figure 3. Calibration of A1O aptamer surface coverage on hybrid NPs.
(A) Alkaline hydrolysis (pH 11) of the RNA aptamers. (B) The amount of aptamers added (as
lipid-PEG-Apt conjugates) is measured against the amount of aptamers that remain on the NPs
after self-assembly and purification. The maximum aptamer surface coverage is approximately
20 pg aptamers/mg of hybrid NPs, achieved by the addition of 240 pg of aptamers/mg of hybrid
NPs.
LNCaP
(+PSMA)
PC3
(-PSMA)
Figure 4. Cellular uptake of hybrid NPs surface-modified with the A10 RNA aptamer.
The A10 aptamer binds to the extracellular domain of the prostate specific membrane antigen
(PSMA) overexpressed in prostate epithelial cancer cell lines. For imaging, NBD-cholesterol
dyes (green) were encapsulated inside the NPs. Fluorescence microscopy images show that
aptamer-targeted NPs were delivered to (A) LNCaP cells which overexpress the PSMA protein
but not (C) PC3 cells which do not express PSMA protein. Non-targeted NPs did not
preferentially bind to either (B) LNCaP (+PSMA) cells or (D) PC3 (-PSMA) cells. Scale bar,
100 pm.
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Figure 5. Average 3H readings taken as a percentage of injected dose per organ.
3H-PLGA biodistribution at 24 h after injection. % aptamer refers to the surface-coverage of
lipid-PEG-aptamers on NPs. Results are expressed as mean ± SD, n=5 per group.
0% 1% 5% 10% 25% 50% 100% random
% aptamer 10%
Figure 6. Average 3H readings in tumors taken as a percentage of injected dose per gram of
tumor tissue.
3H-PLGA biodistribution at 24 h after injection in tumor tissue. % aptamer refers to the surface-
coverage of lipid-PEG-aptamers on NPs. Results are expressed as mean ± SD, n=5 per group.
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Discussion
A major objective underlying these in vivo PK assessments is to show that the NPs
exhibit dose-independent and time-independent PK, or that the NP clearance and volume of
distribution is constant across doses and over time. In this PK study, the in vivo circulation half-
lives of PLGA-lipid-PEG NPs and PLGA-b-PEG NPs were found to be -12 h and -3 h
respectively. Other reports also point to the same conclusion. Previous studies with PLGA-PEG
diblock NPs and Genexol-PM gave circulation half-life values of -4.5 h . On the other hand,
stealth liposomes (PEG-coated liposomes) have an average circulation half-life of -3 days (76 h)
in patients 6, similarly reported for Doxil (55 h, reports vary)7 '. Hence, this suggests that the
liposome-like shell on hybrid NPs may significantly contribute to their extended in vivo
circulation half-life.
The second objective of these studies is to extrapolate the PK data for both dose and
dosing frequency selection in dose-ranging studies. However, the dosing frequency derived from
PK data may either overestimate or underestimate the concentration needed for PD responses.
For example, if the PK data shows that there is insufficient NP in circulation after several days,
there may still be sufficient NP deposition in tissues to help with PD responses. On the other
hand, the PK data may indicate there is sufficient NP in the blood circulation, but the NPs may
be bound strongly to plasma proteins (50% of which are serum albumins) and exhibit lower
volumes of distribution. Hence, the plasma and BSA temporal stability studies described in
Chapter 2 were necessary to show that the hybrid NPs were not overwhelmingly bound by
albumin.
Even if the NPs are not albumin bound, simply enhancing NP plasma half-life may not
necessarily lead to an increase in therapeutic effect. In experimental tumors, the movement of
drugs and particulates into the extravascular compartment of tumors was shown to be limited by
high interstitial pressures, partly due to a lack of functional lymphatic drainage coupled with
lower intravascular pressure9 . Interstitial pressure tends to be higher at the center of solid tumors,
creating a mass flow movement of fluid to the periphery. Despite these potential barriers to
delivery, long-circulating NPs may have a more tolerable safety profile in terms of systemic
cytotoxicity compared to the unencapsulated drugs. They have been shown to reduce dosing
frequency, improve drug biodistribution and allow more drugs to reach the tumor site'.
As a step towards improving the PD profile of hybrid NPs, they were conjugated with
aptamers against the PSMA antigen upregulated in prostate tumors. Lipid-PEG-Apt triblock
conjugates were synthesized by carbodiimide chemistry and used to self-assemble hybrid NPs. It
is expected that the hybrid NP system may need to be functionalized with different types of
ligands. In Chapter 2, a variety of conjugation chemistries based on the different terminal end-
groups on DSPE-PEG was discussed. Here, a detailed account is given of the standard three
methods of assembling the ligand-bearing DSPE-PEG molecules into NPs. Considering that
similarities can be drawn between the surfaces of hybrid NPs and PEG-coated liposomes,
existing methods used to functionalize the end-groups of PEGylated liposomes can be
extrapolated for the hybrid NPs.
In the first method, the hybrid NPs can be preformed, washed to remove free lipid-PEG
molecules and then conjugated to the desired ligand. This method was used for studies described
in Chapter 6. While this is a straightforward method that requires lower amounts of conjugation
ligands, the conformational cloud of PEG chains may interfere with the reaction between the
reactive PEG end-group and ligand, and this strategy may lead to NPs bearing some surface
unreacted groups which may need to be quenched. Furthermore, the chemicals used for
conjugation may disrupt NP structures. Another strategy is based on the formation of lipid-PEG-
ligand conjugates and simple incubation with the preformed NPs. Here, the conjugates exchange
with other lipid-PEG molecules forming the micellar layer and is incorporated into the lipid
layer. In the third approach, lipid-PEG-ligand conjugates are preformed and used directly during
preparation (Chapter 3, 4 and 7). With the last two approaches however, the larger ligand-
bearing conjugates may not be incorporated into the micellar layer, instead favoring smaller and
more plentiful lipid-PEG molecules. Hence, it is important to quantify ligand incorporation after
purification steps regardless which of the three methods is chosen.
A previous report from our laboratory used the third approach to synthesize aptamer-
targeted NPs. Preformed PLGA-PEG-Apt triblock copolymers were mixed with PLGA-PEG
diblock copolymers in a single-step nanoprecipitation process'0 . Our study uses lipid-PEG-Apt
triblock copolymers for the nanoprecipitation and self-assembly of hybrid NPs. Likewise, Wu et
al. also formed lipid-PEG-DNA aptamer micelles using this triblock strategy". However,
problems arise when generalizing these systems for protein-based ligands such as antibodies or
affibodies because proteins cannot tolerate the harsh organic solvents and chemicals for
conjugation to PLGA-PEG polymers. The use of lipid-PEG-protein conjugates may likely
overcome the problem of solvent incompatibility. One can conjugate protein-based targeting
ligands with lipid-PEG in aqueous conditions to form lipid-PEG-ligand triblock polymers
before nanoprecipitation. The lipid-PEG-ligand conjugates may also be stored in aqueous
buffers for days to weeks, minimizing production time and NP batch-to-batch variation, allowing
for larger-scale production of targeted NPs.
In conclusion, this study showed that optimal formulations of surface-functionalized
aptamers (5% and 10%) could improve the tumor localization of hybrid NPs up to 2.5-fold over
other aptamer-targeted NP groups. Hence, it is important to balance the requirement for
improved avidity by displaying more aptamers versus maintaining an exposed PEG shield that
helps to keep the NPs in circulation.
In a shift from larger ligands (28 kDa) with fixed three-dimensional conformations, we
explored the use of small, linear peptide ligands (-1 kDa) for targeting in Chapter 4. Here,
triblock lipid-PEG-peptides are used instead of lipid-PEG-aptamers and a previously-
characterized peptide was applied to target hybrid NPs to atherosclerotic plaques.
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Chapter 4. Fibrin Targeted Nanoparticles for Delivery to Diverse
Atherosclerotic Lesion Types in Coronary Artery Disease.
Abstract
Morphologically diverse coronary lesions often co-exist in high-risk individuals, ranging from
stenotic lesions with thick fibrous caps, to the more numerous non-stenotic lesions with large
lipid cores and thin fibrous caps susceptible to rupture and thrombosis. This mixed clinical
manifestation requires multi-pronged management by both revascularization and
pharmacotherapy. Our study aims to combine the management of diverse lesion types with
peptide-targeted NP drug delivery. Fibrin is a significant component of plaque architecture and is
also deposited following basal lamina exposure during percutaneous angioplasty. -60 nm
PLGA-lipid-PEG hybrid NPs were conjugated with anti-fibrin peptide ligands and tested for
binding in animal models of early- to mid-stage lesions modeled by apolipoprotein E-knockout
mice fed an atherogenic diet. In this model of atherosclerosis, targeted-NPs localized to primary
lesions in the aortic arch and brachiocephalic artery branch points. Revascularized stenotic
lesions were modeled using balloon-angioplastied rat abdominal aortas and targeted-NPs showed
greater binding over control NP groups. These results indicate that targeted nanotechnology
against thrombotic elements may potentially be used in the management of coronary artery
disease.
Introduction
Atherothrombotic vascular disease (ATVD), the number one cause of mortality in
developed countries, is a growing problem due to the worldwide epidemic of obesity and insulin
resistance'. Although oral drugs that lower systemic risk factors have been successful 2 3, there is
a tremendous treatment gap that leaves up to 70% of the high-risk population at continued risk.
The morphology of lesions in human coronary atherosclerosis is staggering, with two extremes
from stenotic lesions (thick caps and fibrosis) to thin-cap fibroatheromas (thin caps and a large
lipid-rich pool prone to rupture and thrombosis)4 . Most lesions lie between these two extremes
and usually coexist in a given high-risk individual5 . Hence, optimum management often requires
both systemic therapy and revascularization (Figure 1A).
A sine qua non of the disrupted atherosclerotic plaque is fibrin deposition. The
coagulation cascade and fibrin formation plays a crucial role in atherogenesis6,7 and fibrin
deposition accelerates sharply with the severity of the lesion8 '9. Not only does fibrin deposition
give one of the earliest signs of plaque rupture or erosion, but along with intraplaque
hemorrhage, also forms a considerable part of the core of the growing lesion. A disrupted plaque
may be diagnosed by the detection of small deposits of fibrin in erosions or microfractures.
Fibrin deposition may also be used to characterize a 'vulnerable' lesion before a high-grade
stenosis develops that requires cardiac intervention. Likewise, vascular injury from percutaneous
transluminal angioplasty (PCTA) or stent placement in stenotic lesions may result in endothelial
denudation, extracellular matrix exposure and activation of the coagulation cascade. The end
point of this cascade is fibrin deposition in the lumen of affected vessels which may contribute to
10subsequent thrombotic events'.
The peptide ligand CREKA (cys-arg-glu-lys-ala) was identified from an in vivo phage
screen in a transgenic mouse model of breast cancer as a fibrin-binding ligand". In a separate
study, targeted micelles were shown to accumulate in Apolipoprotein-E knockout (ApoE-B-) mice
12fed a western diet for 16 weeks, a mouse model of plaques that resemble advanced lesions'
This study aims to apply the signature of fibrin deposition to manage diverse lesion types
in coronary artery disease (CAD) (Figure 1A). We designed CREKA-targeted -60 nm hybrid
NPs1'3 14 with a hydrophobic PLGA polymeric core for sustained drug release and an anti-
biofouling PEG shell covalently-conjugated with peptide targeting ligands. In the first study,
CREKA-NPs localized to mid-stage aortic lesions in ApoE-- mice models fed an atherogenic
diet for 8 weeks and not to healthy aortas of C57BL/6 mice fed a regular chow diet. In the
second study, CREKA-NPs targeted revascularized stenotic lesions in a rat model of
angioplasty, where balloon catheter injury mimics angioplasty of pre-existing stenotic lesions in
human patients. Together, these results indicate the potential use of CREKA-targeted NPs
throughout atherogenesis and following revascularization of stenotic lesions.
Methods
Materials.
Soybean lecithin was purchased from Alfa Aeser (Ward Hill, MA). 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Maleimide (PolyethyleneGlycol) 2000] (DSPE-PEG-Mal)
(ammonium salt) was purchased from Avanti Polar Lipids (Alabaster, AL). 50:50 poly(DL-lactic-
co-glycolic acid) (PLGA) polymer, carboxylate end group (inherent viscosity range: 0.15-0.25
dUg in HFIP) was purchased from Durect Corporation (Cupertino, CA). Alexa Fluor 647
hydrazide tris(triethylammonium) salt was purchased from Invitrogen (Carlsbad, CA). All
peptides were custom synthesized and purified by reverse-phase high-performance liquid
chromatography (RP-HPLC) to >98% purity by SynBioSci Corporation with mass spectral
analysis (Livermore, CA).
Animals.
Animals care and experimental procedures were performed in accordance with the regulations of
the Massachusetts Institute of Technology Division of Comparative Medicine and the Principles
of Laboratory Animal Care of the National Institutes of Health. Homozygous male ApoE^'~ mice
(B6.129P2-ApoermJunc/Crl) and male C57BL/6 mice were purchased from Jackson Laboratories
(Bar Harbor, Me). Male Sprague-Dawley rats weighing -400-500 g were obtained from Charles
River Laboratories (Wilmington, MA) and fed a normal rodent diet.
Synthesis of Lipid-PEG-Peptide Copolymers.
1 mg peptide (MW=600 Da) was dissolved in 0.1 mL PBS buffer and incubated with Bond-
BreakerTM (Tris(2-carboxyethyl)phosphine) (TCEP) (Pierce, Rockford, IL) for disulfide bond
reduction at a 10:1 TCEP:peptide molar ratio. The reaction was carried out for 30 min at RT.
Reduced peptides were mixed with 2.5 mg DSPE-PEG-Mal (5 mg/mL in PBS buffer) to achieve
a 2:1 molar ratio. The mixture was incubated at 4 'C for 24 h and then dialyzed in 3.5 kDa
MWCO Spectrapor cassettes (Spectrum Laboratories, Houston, TX) for 24 h with two water
changes.
Synthesis of Fluorescent Dye-PLGA Copolymers.
Alexa Fluor 647 (A647) dyes were covalently conjugated to PLGA (viscosity 0.19 dL/g) using
EDC/NHS chemistry in DMF. The reaction was continued overnight in the dark at RT with
gentle stirring. A647-PLGA conjugates were precipitated in 2/1 ethyl ether/methanol by
centrifugation, dried in vacuum, weighed and resuspended in acetonitrile for NP preparation.
Preparation of Peptide-NP Conjugates.
0.09 mg DSPE-PEG-peptide copolymer (1 mg/mL) was mixed with 0.06 mg lecithin (1 mg/mL)
in 3 mL of 4% ethanol aqueous solution. I mg PLGA-A647 was dissolved in acetonitrile. The
DSPE-PEG-peptide/lecithin mixture solution was heated to 65'C for 3 min under gentle stirring.
Next, the PLGA solution was added dropwise, vortexed vigorously for 3 min and gently stirred
for 2 h. The remaining organic solvent and free molecules were removed by washing the NP
solution three times using a 10 kDa MWCO Amicon Ultra-4 centrifugal filter (Millipore,
Billerica, MA). NP size (diameter, nm) and surface charge (zeta potential, mV) was evaluated
using a ZetaPALS DLS detector (15 mW laser, incident beam=676 nm; Brookhaven Instruments,
Holtsville, NY).
Induction of Early Stage Atherogenesis in ApoE Mice.
8-week old ApoE-'- mice were fed high-fat rodent diet containing 21 % pork lard supplemented
with 0.15% cholesterol for 8 weeks until they were 16-week old (diet #TD12079B, Research
Diets, New Jersey). Control C57BIJ6 mice were fed a normal chow diet for 8 weeks.
Ex Vivo ApoE Mouse Aorta Targeting Studies.
16-week old mice were sacrificed for open abdominal cavity surgery in situ. After flushing the
aorta with Hanks buffer, 0.5 mg of peptide-NP conjugates (1 mg/mL) were delivered by left-
ventricle injection and incubated in the aorta for 10 min under constant pressure using silk
threads to secure the ascending aorta, aorta branch points and abdominal aorta. After incubation,
non-adsorbed NPs were washed away using Hanks buffer. The aortic arch to abdominal aorta
was fixed in 4% paraformaldehyde, paraffin-embedded and sectioned. Adjacent H&E stained
and unstained sections were cut followed by an 80 pm interval to the next pair of sections. All
histology preparations were done by the Koch Institute Histology Core Facility. Slides were
imaged using a Delta Vision RT Deconvolution Microscope using the 20x objective (Applied
Precision Inc, Issaquah, DC).
Ex Vivo Balloon-Injured Rat Aorta Targeting Studies.
Rats were sacrificed for open abdominal cavity surgery in situ. The aorta was flushed with Hanks
buffer solution and a Fogarty@ arterial embolectomy catheter (Model: 120602F, Edwards
Lifesciences, Irvine, CA) was inserted into the aorta from the distal end. The aorta was injured
five times using the expanded balloon catheter containing 0.2 mL of air. 6 mg of peptide-NP
conjugates (6 mg/mL) were incubated in the aorta for 10 min under constant pressure, using silk
threads to secure both ends of the aorta. Non-adsorbed NPs were washed away using Hanks
buffer and the abdominal aorta was sectioned at serial intervals of 90 pm.
Results
Synthesis of Fibrin-Targeted Hybrid NPs.
To assemble the targeted-NPs, peptides were covalently conjugated via their thiol end-
groups to maleimide-terminated DSPE-PEG polymers (DSPE-PEG-Mal) (Figure 2A). The
peptide-targeted lipid-polymer NPs were self-assembled from these components through a
single-step nanoprecipitation technique (Figure 2B). The polymer/solvent was added dropwise
into a lipid solution heated above the phase transition temperature, vortexed, and allowed to
undergo self-assembly and solvent evaporation for 2 h at RT. An ultracentrifugation step
removed excess solvent and lipid molecules.
Characterization of Physicochemical Properties of Targeted-NPs.
As shown in Figure 2C, non-targeted bare NPs were 60.2 ± 0.6 nm (mean ± SD, n=3)
and the attachment of pentapeptide sequences to NP surfaces resulted in a minimal increase in
NP size to 61.8 ± 0.4 nm. In Figure 2D, the surface charge of the NPs became more negative
from -17.75 ± 0.46 mV (mean ± SD, n=3) to -56.22 ± 1.24 mV in water. Presumably, peptide
conjugation presents a carboxylic acid terminal group at the NP corona, which resulted in a more
negative surface charge. These zeta potential values will be closer to neutral in PBS buffers from
charge screening. Transmission electron microscopy (TEM) images show that spherical sub-100
nm NPs were formed by nanoprecipitation (Figure 2E).
Targeting of Thin-Cap Fibroatheroma in ApoE Mice Fed an Atherogenic Diet.
The targeting of CREKA-NPs to fibroatheromas in ApoE-/- mice was examined ex vivo.
Two negative controls were designated: D-amino acid optical isomers (D-CREKA) and
scrambled CEAKR sequences (S-CREKA). For this study, A647-PLGA encapsulated targeted-
NPs were used to visualize the NPs while excluding interference from tissue autofluorescence.
A647-PLGA encapsulated NPs were incubated in mice aortas for 10 min under constant
pressure. Subsequently, non-adsorbed NPs were washed away using Hanks buffer. The aortic
arch and left brachiocephalic artery branch points were harvested for H&E staining and
fluorescence imaging. First, a preliminary visual inspection of H&E stained sections using bright
field microscopy was done to screen for plaques (Figure 3, bottom row). The selected cross-
sections that had plaques were used as a reference to investigate NP binding in adjacent
unstained sections by fluorescence microscopy (Figure 3, top row) An overlay of A647
fluorescence and phase contrast images (Figure 3, middle row) shows fluorescent NPs bound to
plaques.
Effective binding was observed in representative cross-sections of CREKA-NPs to ApoE~
- mice aortas (Figure 3A), whereas minimal binding was observed for NPs surface-modified
with D-CREKA (Figure 3B) or S-CREKA (Figure 3C), suggesting that general non-specific
adsorption or ionic interactions were insufficient for effective targeting. Control C57BU6 mice
fed a chow diet were used as controls for healthy aorta. CREKA-NPs showed negligible binding
to these aortas (Figure 3D) which suggests that low-affinity NP adsorption may be removed by
in vivo circulatory blood flow, or from multiple washes in this study.
Targeting of Revascularized Stenotic Lesions in Balloon-Injury Rat Models.
Revascularization of stenotic lesions creates significant endothelial denudation and
basement membrane exposure, leading to a concerted action of platelets, a cascade of
coagulation factors and fibrin production on the vessel wall that forms the bulk of the clot. We
used a rat model of balloon-catheter injury to model an angioplasty procedure and confirmed that
balloon injury caused severe damage to the vascular endothelium (Figure 4). H&E and
Verhoeff-van Gieson (VvG) stained cross-sections show normal aortas with intact endothelial
cell layers. Cross-sections of balloon-injured rat aortas show an absent endothelial monolayer.
The binding of CREKA-NPs ex vivo was examined in rat models of percutaneous
angioplasty. A647-PLGA encapsulated targeted-NPs were incubated in aortas for 10 min under
constant pressure. Non-adsorbed NPs were washed away using Hanks buffer and aortas were
harvested for histological sectioning. Representative fluorescence images of aorta cross-sections
showed that CREKA-NPs bound to the balloon-injured rat aorta (Figure 5A). The overlay of
fluorescence and phase contrast images identifies the arterial wall where the NPs are bound. In
parallel experiments, NPs surface-modified with D-CREKA (Figure 5B) or S-CREKA (Figure
5C) showed negligible binding to balloon-injured rat aortas. CREKA-NPs incubated with
uninjured rat aortas also showed undetectable binding to intact arteries (Figure 5D).
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Figure 1. Fibrin-targeting for a diversity of lesions in human coronary atherosclerosis.
(A) Schematic of the progression of atherosclerosis. During atherogenesis, there is a
corresponding increase in endothelial dysfunction and fibrin deposition, which may result in
complicated, stenotic lesions that require revascularization. Arrows indicate suggested points of
intervention and treatment. (B) Enhanced vascular permeability due to endothelial inflammation
and reduced tight-junction integrity allow the NPs to extravasate into the plaque. By binding to
fibrin deposits at lesions, targeted-NPs can act as a drug depot for sustained drug release against
lipid-laden macrophage foam cells and proliferating smooth muscle cells (SMC).
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Figure 2. NP synthesis for fibrin-targeted drug delivery.
(A) Synthesis of lipid-PEG-peptide copolymers. Peptides are reduced, conjugated with DSPE-
PEG2000 and dialyzed to remove unconjugated peptides. (B) Targeted NP synthesis by modified
nanoprecipitation and self-assembly. (C) CREKA-functionalized lipid-polymer hybrid NPs have
a PLGA hydrophobic core, a hydrophilic lipid-PEG-CREKA shell and a soybean lecithin
interface (red). (D) Diameter of hybrid NPs before and after peptide conjugation, respectively
(mean ± SD, n=3). (E) Zeta potential of hybrid NPs before and after peptide conjugation,
respectively (mean ± SD, n=3). (F) Transmission electron microscopy (TEM) image of peptide-
functionalized NPs stained with 3% uranyl acetate solution. Scale bar, 100 nm.
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Figure 3. Targeting of thin-cap fibroatheroma in ApoE~' mouse aortas.
Top row: Fluorescence images of ApoE' mouse aortas incubated with NPs that were surface-
modified with (A) CREKA, (B) D-amino acid CREKA, (C) scrambled CREKA and (D)
C57BU6 mice aortas incubated with CREKA-NPs. A647-PLGA encapsulated NPs were
incubated for 10 min and non-adsorbed NPs were washed away using Hanks buffer. Arrows
indicate regions of NP deposition. Middle row: Overlay of the fluorescence and corresponding
phase contrast image. Bottom row: H&E stained cross-sections showing plaque pathology
corresponding to fluorescent images in the top row. L, lumen; M, media; A, adventitia. Scale bar,
100 pm.
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Figure 4. Uninjured and balloon-angioplastied aortas.
Representative H&E and Verhoeff-van Gieson (VvG) stained cross-sections of balloon-injured
rat aortas and uninjured rat aortas. Arrows indicate the presence or absence of an endothelial
monolayer. Scale bar, 200 pm. Inset: scale bar, 50 pm.
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Figure 5. Targeting of revascularized lesions in balloon-injured rat aortas.
Top row: Fluorescence images of balloon-injured rat aortas incubated with NPs surface-modified
with (A) CREKA, (B) D-amino acid CREKA, (C) scrambled CREKA and (D) uninjured rat
aortas incubated with CREKA-NPs. Arrows indicate regions of NP deposition. Bottom row:
Overlay of the fluorescence and phase contrast image. A647-PLGA encapsulated NPs were
incubated for 10 min and non-adsorbed NPs were washed away using Hanks buffer. L, lumen;
M, media; A, adventitia. Scale bar, 100 ptm.
Discussion
The ideal features of a vascular-targeted NP platform are: (i) long circulating half-life to
facilitate plaque accumulation, (ii) small size to enhance permeability into the endothelium, (iii)
molecular targeting to enhance retention in the plaque, and (iv) controlled release of active
agents from this extracellular depot (Figure 1B). The studies discussed here utilize
biodegradable and biocompatible hybrid NPs which have a PLGA core for sustained drug release
and a PEG shell for prolonged in vivo circulation half-life . The lipid corona at the interface of
the core and the shell allows for increased drug loading and lipid membrane-like properties'3'1 4.
The molecular targeting ligand was a small-molecule peptide, CREKA, discovered from in vivo
phage display screening in transgenic breast cancer mice 1 . In both this study and Peters, D.A. et
al. 16, the targeting ligand was applied in a cardiovascular model despite being first discovered
from a screen in a tumorigenesis model. This is possible because the general molecular
mechanisms of neoangiogenesis can be applied to both oncologic and cardiovascular indications.
These observations have led Folkman, J. et al. to describe neoangiogenesis as an 'organizing
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principle' which conceptually may be extrapolated across various diseases".
Although therapy in humans is generally designed for subjects with advanced plaques, it
is well known that these individuals also have plaques at earlier stages5 . This study shows the
targeting of early- to mid-stage lesions which may have single or multiple lipid cores and a thin
fibrotic layer. Atherothrombosis is a complex interaction between lipids, inflammation and
thrombosis, with vascular injury to the endothelium causing endothelial cells to lose their natural
thromboresistance, leading sequentially to platelet activation, deposition of platelet and fibrin
thrombi formation '1. Lipid-lowering statin therapies at doses lower than required for oral
.2delivery may be delivered to plaques to reduce foam cell formation and inflammation2
For revascularized stenotic lesions, it may be possible to inhibit smooth muscle
hyperplasia at the time of angioplasty with anti-proliferative drugs such as paclitaxel and
sirolimus9,20 . Targeted-NP treatment presents a few advantages: it is independent of the
revascularization method and stent implantation, avoids drug eluting stent (DES)-related long-
term safety issues such as late stent thrombosis , and allows for intervention at vascular branch
points 22, multiple lesions, longer lesions and smaller arteries, all of which are currently off-label
uses of DES2.
Besides the therapeutic approaches discussed here, fibrin-targeting conjugates have been
widely used as imaging agents in thromboembolic disease. Antibody fragments with high
affinity for certain cross-linked fibrin peptide domains were used for imaging with either
ultrasound or magnetic resonance imaging (MRI) contrast agents by Lanza, G. et al. in 199620.
Using these fragments, thrombi formed in situ in canine carotid arteries were detectable within
30 min by ultrasound imaging 20. Another study used gadolinium-DTPA conjugates with fibrin-
specific cyclic peptides as MRI probes for thrombosis 2. Fibrin is a useful target because it is
the major protein constituent of clots and is present at 10-100 pM in the thrombus, a
concentration range compatible for detection by gadolinium-based contrast agents.
In conclusion, CREKA-targeted NPs were able to differentially target fibrin in both a fat-
fed mouse model genetically predisposed to atherosclerosis and in a balloon-injury rat model of
angioplasty. Combined with previous studies of CREKA targeted micelles to complicated lesions
in ApoE-/ mice fed a 16-week high-fat diet' , the results reported here suggest a general
application of fibrin-targeted NPs against diverse lesion types in atherosclerotic disease.
The knowledge built in Chapter 4 from the design of peptide-targeted hybrid NPs and
working with two animal models of atherosclerosis are applied in Chapters 6 and 7. Before that,
we explore novel options for peptide-targeted NP drug delivery in Chapter 5 through the
investigation of alternative targets and discovery of novel ligands.
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Chapter 5. Screening of a Phage Display Library
for the Discovery of Novel Targeting Peptides.
Abstract
In this study, we report a screen to identify novel materials that target vascular antigens of the
endothelial basement membrane which are exposed in disease. We screened a M13
bacteriophage display library against collagen IV, the major component (50%) of the
subendothelium. Combined with fibronectin, laminin, heparan sulfate proteoglycans and minor
components, collagen IV provides a two-dimensional reticular network that supports the
endothelial layer above it. After five rounds of phage display, one phage clone was found to bind
with an IC50 value of 117 nM in competition binding assays against synthetic peptide equivalents
on a Matrigel extract rich in collagen IV and laminin. In titer count analyses, this clone bound
-900-fold and -300-fold over the original library to collagen IV and Matrigel respectively. NPs
conjugated to these targeting peptides may potentially deliver therapeutic agents directly into the
intimal and medial layers of arterial walls to improve treatment efficacy and reduce systemic
side-effects. This type of non-cellular targeting may be relevant in a myriad of human diseases
where the endothelial lining is compromised, including oncologic and cardiovascular
inflammatory disease, or in diseases where neoangiogenesis is commonly observed.
The content of this chapter has been published in whole or in part in the following
journal article:
Chan, J.M., Zhang, L., Tong, R., Ghosh, D., Gao, W., Liao, G., Yuet, K.P., Gray,
D., Rhee, J.W., Cheng, J., Golomb, G., Libby, P., Langer, R. Farokhzad, O.C.
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc
Natl Acad Sci U S A (2010) 107, 2213-2218. Reproduced in part with permission
from Proceedings of the National Academy of Sciences USA. National Academy
of Sciences @ 2010.
Introduction
Phage display describes a powerful selection technology to engineer polypeptides that
bind to a given target, such as to antibodies, enzymes and cell-surface receptors -3. It is a
technique in which the protein or peptide library is expressed on the coat of a phage virion, while
the genetic information encoding each variant resides on the inside. The physical linkage
between each variant protein sequence and the DNA encoding it enables rapid and easy
identification of individual variants based on binding affinity to a given target. High-affinity
binders can be selected from a library of displayed proteins through an in vitro process called
panning, by incubating the library on immobilized target molecules, washing away the unbound
phages and eluting the bound phages . The eluted phages are then amplified and taken through
additional panning and amplification cycles to enrich the pool in favor of binding sequences
(Figure 1). After 3-5 rounds, the sequences of individual clones can be rapidly deduced by DNA
sequencing and characterized by enzyme-linked immunosorbant assays (ELISA).
13Many phage display systems are based on M13 bacteriophage vectors'-3. M13
filamentous bacteriophages (900 x 6 nm) are viruses composed of circular single stranded DNA
(ssDNA) which is 6407 nucleotides long. The genome in a mature M13 virion is encapsulated in
-2700 copies of pVIII, the major coat protein, and capped with five copies of pIII, the minor coat
protein clustered at the rounded end4 . The pIII protein modulates phage infectivity by being the
first protein to interact with its Escherichia coli host. During bacterial infection, the pIII protein
attaches to the TolA protein receptor at the F-pilus tip. Likewise, the pIII protein is also the last
point of contact as the phage buds from the bacterial surface, during which the N-terminal leader
sequence is cleaved off. Infection with filamentous phages is not lethal and forms turbid non-
lytic plaques in E. coli, with a modest decrease in the growth rate of infected cells. Peptides have
been displayed in monovalent low-copy formats (1-5 copies) on the M13 phage through N-
terminal fusions to the minor coat protein, pIII (Figure 2). Since the displayed peptide is
sufficiently short (< 50 residues), the infectivity function of pI is not affected and all five
copies can carry displayed peptides without any measurable attenuation of phage infectivity.
Thus, monovalent phage display has been used to affinity mature many different proteins and to
discover moderate to high affinity ligands (KD of 10 gM or better).
In this study, we utilized a M13 filamentous bacteriophage library to screen for ligands
5that may be used to target across a range of diseases in a consistent and reproducible manner
Conventional molecular targeting of relevant cell-based protein epitopes can be confounded by
inter- and intra-patient heterogeneity in cell surface antigen expression. Human cancers result
from a complex series of genetic alterations that contribute to the complexity of the disease.
Intratumoral heterogeneity is observed in 5-30% of breast tumors due to subclonal diversity
within the tumor, such that less than 50% of tumor cells show HER2/neu epidermal growth
factor receptor gene amplification and upregulation . Advances in molecular profiling have also
shown heterogeneous cell phenotypes in prostate cancer from key genetic processes such as
alternative pre-mRNA splicing7. In mouse models, analysis of MMTV-Myc breast cancers reveal
substantial heterogeneity in both histological and expression phenotypes8 . Hence, human cancers
are naturally heterogeneous disease states, making the targeting of cell-surface receptors less
desirable in cases where heterogeneity is observed.
Many human diseases are associated with compromised vasculature and increased
vascular permeability9". This knowledge has enabled investigators to explore abundant non-
cellular targets such as the coagulation cascade", intra-articular cartilage' and extracellular
matrix13 . Although it is widely known that endothelial denudation can cause a serious
prothrombogenic stimulus14 , we hypothesized that the exposed basement membrane may present
a large surface area that can be targeted (Figure 3). Towards this goal, we selected for
heptapeptide ligands by biopanning a phage library (approximately 109 independent clones, 100
copies per clone) against collagen IV 15, which represents 50% of the vascular basement
16membrane . We characterized specific ligands for targeting affinity against a Matrigel extract
rich in collagen IV and laminin . A phage clone displaying the peptide sequence, KLWVLPK,
was found to bind to collagen IV with an IC50 value of 117 nm in peptide competition ELISA
assays. In subsequent titer count analyses, this clone bound -900-fold and -300-fold over the
original library to collagen IV and Matrigel respectively.
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Methods
Materials.
Human collagen IV, human collagen I and MatrigelTM growth factor reduced LDEV-free were
purchased from BD Biosciences (San Jose, CA). All peptides were custom synthesized by
GenScript (Piscataway, NJ) with C-terminal amidation and purified by RP-HPLC to >95% purity
by mass spectral analysis. LB medium, agar plates (LB/IPTG/X-gal, LB/tetracycline) and
agarose top were purchased from Teknova (Hollister, CA). PEG8000, Tween-20 and BSA were
purchased from Sigma. 96-well enzyme and radioimmunoassay (EIA/RIA) high-binding plates
(Cat #3590) were purchased from Corning Life Sciences (Lowell, MA). Gamma-irradiated
Linbro plate sealers with adhesive back (Cat #76403) were purchased from MP Biomedicals
(Solon, OH).
Screening of Library.
The screen was performed according to the manufacturer's instructions and the Molecular
Cloning laboratory manual by Sambrook, J. and Russell, D.W. 8. The Ph.D.-7 phage library was
obtained from New England Biolabs Inc. (Beverly, MA). Human collagen IV was diluted with
0.1 M NaHCO 3, pH 8.6 to -10 pg/mL. A 96-well high binding plate was coated with 100 PL of
collagen IV overnight at 4 'C, blocked (0.1 M NaHCO 3, 5 mg/mL BSA, pH 8.6) for 2 h at 4 'C
and washed with TBST (50 mM Tris, 150 mM NaCl, pH 7.5, 0.1% Tween-20). Collagen IV-
coated plates were incubated with 2 x 1011 plaque forming units (pfu) of phage virions in 100
pL 0.1 % TBST for I h at RT. Unbound phages were removed by extensive washing with TBST.
Bound phage were eluted by incubating for 5 min with 0.2 M glycine-HCI, 1 mg/mL BSA (pH
2.2) and neutralized with I M Tris-HCI (pH 9.1). The eluate was amplified (ref. Amplification
method) and titered (ref. Titering method) to calculate an input volume corresponding to 2 x 1011
pfu for the next round of panning. In successive rounds of biopanning from R2-R5, the Tween-20
concentration was raised to 0.5% in both binding and washing steps. Also, the collagen IV
enriched phage pool from RI was subtractively panned against human collagen I for I h at RT
before biopanning against collagen IV. In R5, I pg/mL collagen IV coated plates were used for
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increased stringency. 15 clones per round from R3-R5 were randomly selected for DNA
sequencing.
Phage Amplification and Precipitation.
A -20 mL ER2738 E. coli culture was grown in a 250 mL Erlenmeyer flask until OD 600 = -0.5.
The phage eluate was added to the culture and incubated for 4-5 h at 37 *C with vigorous
shaking at -220 rpm, followed by centrifugation at 10,000 rpm for 10 min at 4 'C (Thermo
Scientific Sorvall SS-34 centrifuge). -3.5 mL of 6x PEG/NaCI (200 g/L PEG8000, 146 g/L
NaCI) was added to -18 mL of the supernatant in a new tube to precipitate phage overnight at 4
*C. The next day, phages were centrifuged at 10,000 rpm for 15 min at 4 *C to precipitate phage.
Pellets were resuspended with I mL of TBS in a microcentrifuge tube. 200 gL of 6x PEG/NaCl
was added and incubated on ice for I h at 4 *C. Phages were centrifuged at 10,000 rpm for 10
min at 4 *C to precipitate phage. Pellets were resuspended in 200 gL TBS (0.02% NaN3 for long-
term storage) and stored at 4 *C. Plaque titer was counted for the next round of biopanning.
Titering and Measurement of Phage Plaque Forming Units.
PFU is a functional measurement rather than a measurement of the absolute quantity of phages
which can be estimated by absorbance spectroscopy. Phages that are defective or which fail to
infect bacteria will not produce a plaque and thus will not be counted. Power dilutions were
made (e.g. 103 dilution: I uL eluate to 1000 uL LB medium) at suggested dilution ranges for
amplified supernatants (108-10") and unamplified panning eluates (101-104). 200 gL of an E.
coli OD 60 0 = -0.5 culture was added to 10 uL of each power dilution in a new centrifuge tube,
briefly vortexed and incubated for 1-5 min at RT. The E. coli/phage solution was added to 5 mL
of melted agarose top (25 g/L LB medium, 1 g/L MgCl 2.H20 and 7 g/L agarose) in a 15 mL
polystyrene tube, briefly vortexed and poured onto pre-warmed LB/IPTG/X-gal plates. Once
solidified, plates were inverted and incubated overnight at 37 *C. Plates with -102 plaques were
counted by the formula: pfu/10 gL=blue spots x 10l**e dilutio" to derive the phage titer.
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DNA Sequencing and Peptide Sequence Analysis.
-3 mL of an OD600 = -0.5 culture was innoculated with a clone to be sequenced. Only blue
colonies were picked as white colonies represent contaminating wild-type phages. Cultures were
amplified for 4.5-5 h at 37 *C with shaking before they were centrifuged for 30 s at 10,000 rpm.
Phage DNA was lysed and extracted from the supernatant with a QlAprep Spin M13 kit (Qiagen,
Valencia, CA) and resuspended in water for storage at 4 *C. -0.5 pg of phage DNA was sent for
automated DNA sequencing at the MIT Biopolymers Laboratory using 20-mer -96 gIII
sequencing primers (New England Biolabs).
Phage ELISA Matrigel Binding Studies.
96-well plates were coated with 100 pL 1/50 dilutions of Matrigel in TBS overnight at 4'C, or
TBS buffer only. Plates were blocked with 3% BSA/TBS for 2 h at RT and washed three times.
1010 pfu of each phage clone was added in 0.5% TBST in triplicate to Matrigel and BSA-coated
wells. Bound phage particles were detected with peroxidase-conjugated mouse anti-M13
monoclonal antibodies (mAb) at 1/5000 dilution (Amersham Pharmacia Biotech, Piscataway,
NJ). After a I h incubation, the reaction was developed with 2,2'-azino-bis(3-ethylbenzthiazoline
-6-sulphonic acid) (ABTS) (Amersham). The absorbance at 405 nm was read against a reference
wavelength of 490 nm using a SpectraMax Plus 384 microplate reader (Molecular Devices,
Sunnyvale, CA).
ICs() Value Determination of Phage Clones.
Matrigel-coated and blocked 96-well plates were incubated in triplicate with 10-5-10-10 M peptide
concentrations and 109 pfu of phage in 100 pL 0.5% TBST. After I h at RT, bound phages were
labeled with anti-M13 mAbs and color was developed and detected by ABTS absorbance (405-
490 nm). Peptide inhibition curves were normalized on a percentage scale. IC50 values were
calculated using a dose-response curve fit by the formula: Y=Bottom + (Top-
Bottom)/(+10A((LogICo-X)*Hill Slope)) (Origin 8 data analysis software, Northampton, MA).
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Titer Count Analyses.
Matrigel and collagen IV-coated and blocked plates were incubated with a phage input of 1011
pfu per well in 0.5% TBST. Unbound phages were removed by extensive washing with TBST
and bound phages were eluted and neutralized. The eluate was titered to get pfu values.
Statistical Analysis.
The student's t-test was used to determine significance. All error bars represent the SD of the
mean. Differences were termed statistically significant at P < 0.05.
Results
Selection and Characterization of Basement Membrane Targeting Peptides for Vascular Wall
Targeting.
To discover a functional vascular targeting peptide, a combinatorial library of random
heptamers fused to the minor coat protein (pIII) of M13 filamentous phage was subjected to five
rounds of biopanning against human collagen IV (Figure 4).
19Excellent phage binders may be lost from previous rounds due to reduced fitness
Possible reasons include reduced infectivity rates of phages for their Escherichia coli hosts due
to low pH elution, disulfide-bond formation between cysteine containing phages resulting in the
rarity of cysteine-rich sequences, faster growth rates of certain clones, or simply a founder effect
when a fraction of amplified phages are input into the next round of biopanning. Hence, fifteen
clones per round were randomly sequenced from Round 3 to 5 (R3-R5) (Figure 5) with 100% of
the clones found to be C-8, HWGSLRA in R5. To find similarities to resident basement
membrane structures, we searched the non-redundant version of the current National Center for
Biotechnology Information (NCBI) homo sapiens sequence database using the pBLAST
algorithm against peptides from the screen . Sequences were classified into three groups. The
first group consists of peptides with similarity to resident basement membrane proteins such as
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nidogen, serum amyloid P component, gelsolin and laminin 6. The second group of peptides
were enriched in proline residues, such as Pro-Pro-Ser (PPS) and Pro-Pro-Pro (PPP) runs, which
resemble the Gly-Pro-Pro (GPP) motif in collagen triple helices15 . Finally, the third group
consists of unique peptides with no identifiable relationship with the basement membrane.
Matrigel ELISA Binding Assays of Phage Clones.
A binding experiment was performed to compare the relative affinities of the sequenced
clones for Matrigel (Figure 5). 23 unique purified phage clones were incubated in triplicate on
96-well plates against Matrigel and BSA. The bound phages were then detected with HRP-
conjugated anti-M13 mAbs. Phages were ranked according to absorbance values indicating their
binding capacity to Matrigel (mean ± SD, n=3). No reactivity was observed against BSA
compared with the original library (RO). Despite the similarity of the PP motifs with collagen IV,
Group B peptides showed less binding affinity compared to Group A and C, and showed no
detectable binding affinity above the library to Matrigel. Clones A-8, A-9, C-10 and C-I I were
the best candidates, and we noted that these four clones resembled each other.
Since the amount of target protein coated on the plate is not quantifiable and is present at
sufficiently high density to allow multivalent binding to the phage, phage ELISA will not
determine absolute affinity constants. However, this method is useful as (i) it provides a
qualitative determination of the relative binding affinities of 23 selected clones in parallel with
the RO library, and (ii) it distinguishes true target binding from binding to BSA or polystyrene
wells.
Clones A-8, A-9, C-10 and C-Il were aligned pairwise using CLUSTAL 2.0.10 and the
Jalview multiple sequence alignment editor. The consensus sequence generated was KIWVLPQ,
or more generally, KZWXLPX, where Z is a hydrophobic amino acid and X is any amino acid
(Figure 6A). The Jalview program gives the Quality, Conservation and Consensus of the
alignment. Quality is an ad-hoc measure of the likelihood of observing mutations (if any) in a
particular column of the alignment. Conservation is measured as a numerical index reflecting the
conservation of physicochemical properties in the alignment. The consensus is the percentage of
the modal residue per column (Figure 6B).
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Sequence Specific Competition Assays of Phage Clones.
For more detailed binding and inhibition studies, free peptides modeled after phage
clones A-8, A-9, C-10 and C-11 were synthesized. This allows precise control of peptide
concentration without the avidity artifacts associated with pentavalent phage display.
Additionally, without the phage attached, the peptide can be used at much higher concentrations.
During biopanning, the N-terminus of the displayed sequence was free while the C-terminus was
fused to the phage. Consequently, a free C-terminus will introduce a negatively charged group at
a position occupied by a neutral peptide bond during panning, which may completely abolish
binding. To block the negative charge, the C-terminal carboxylate of the synthetic peptide was
amidated. A Gly-Gly-Gly-Ser peptide spacer was also added to the C-terminus of the peptide to
resemble the phage-displayed format.
In a sequence-specific competition assay, we analyzed the context-dependence of the
phage towards the peptide-collagen IV binding interaction. Synthetic peptides modeled after
phage clones A-8, A-9, C- 10 and C-Il competitively inhibited their cognate phage in a dose-
dependent manner on Matrigel-coated surfaces (Figure 7). Phage C- 11 showed the best peptide
competition which suggests that the binding of C-I I may be independent of the phage context
and represent a specific peptide-collagen IV interaction. Peptide A-9 (IC50 = -551 nM) proved to
be less inhibitory than C- 11 (IC50 = -117 nM), although its cognate phage exhibited the highest
binding capacity in Figure 2A. Even though IC50 readings are dependent on conditions at which
they are measured and not an absolute indicator of binding affinity, IC50 values of half-maximal
inhibition on a dose-response curve are related to KD affinity constants and can approximate for
binding affinity.
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Titer Count Analyses of Phage Clones.
Considering that phage C-I I gave the best IC50 values, we further examined the binding
of phage C- I I in three independent titer count analyses (Figure 8). Phage C-Il and the original
library (RO) were incubated at an initial input of 101 '/mL pfu on Matrigel- and collagen IV-
coated plates. C-Il showed -300-fold Matrigel binding and -900-fold collagen IV binding over
the library (p < 0.001, mean + SD, n=3).
Epitope Mapping by Phage Display.
The A-6 phage clone (TPLPANL) showed similarity to a sequence within the H. sapiens
serum amyloid P component (SAP), TPLPANIL. A-6 had a leuAile substitution at the seventh
position of the SAP sequence, but the hydrophobic character at this amino acid position is
maintained. Furthermore, the eight position on the SAP sequence is also a leucine residue. SAP
is the precursor of amyloid P component, a universal constituent of abnormal tissue deposits in
amyloidosis. Studies have shown that SAP is a resident of vascular basement membranes2 and
more specifically, SAP was shown to bind to both collagen IV23 and laminin in vitro.
Annotations to the SAP protein structure from the RCSB Protein Data Bank showed that the
TPLPANIL sequence is found on the exposed face of each pentameric subunit (Figure 9A). In
the presence of high Ca2+ concentrations, SAP rapidly aggregates and precipitates, but in the
absence of Ca it forms a very stable decameric structure composed of two pentameric discs
interacting face-to-face 26. The TPLPANIL sequence is still exposed on the surface in SAP
decamers (Figure 9B). C-reactive protein (CRP), another member of the pentraxin family, was
shown to bind to C q via a sequence27 which aligns to the TPLPANIL sequence (Figure 9C,
9D).
Considering the homologous positions of these two sequences, it is possible that the
phage display screen may have mapped the SAP epitope for collagen IV. During the divergent
evolution of the pentraxin family, amino acid changes of this epitope could have resulted in their
divergent locations, with amyloid P as an amyloid deposit and physiological component of
basement membranes , and CRP as an acute-phase protein elevated during inflammation 28. A-6
was not chosen for functional studies as it was not the best binder in the affinity assay against
Matrigel (Figure 5). Taken together, these findings suggest that the pool of phage display
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selected peptides may contain biologically-relevant collagen IV binders supported by reports in
the literature.
Selection and Characterization of Basement Membrane Targeting Peptides against Matrigel.
In a separate phage display screen, the RO phage library was subjected to three rounds of
biopanning against Matrigel growth factor reduced, LDEV-free (Figure 10A) instead of collagen
IV. Likewise, sequenced phage clones were subject to pBLAST against the NCBI homo sapiens
sequence database (Figure 10B). A Matrigel ELISA binding assay was performed to compare
the affinities of Matrigel-selected clones against collagen IV-selected clones (Figure 10C). In
contrast to the higher affinity binders from the collagen IV selection, Matrigel-selected clones
were poorer Matrigel binders. Considering the higher complexity of the target this time, it was
most likely necessary to pan the library for a few more rounds until a consensus sequence is
reached. However, since we had a family of lead candidates from the collagen IV selection
(Figure 5), Matrigel-selected clones were not further characterized.
108
1. A phage library
panned against ar
Imunobllized targm
Is
LLA LLA ILALL
/
2. Unbound phages
are washed away.
3. Bound phages
are eluted at low pH.
L 646A j
4. Phages are amplified and
taken through additional binding
and amplification cycles.
5. Individual clones
are Isolated and
sequenced.
Figure 1. Panning with a pentavalent peptide library displayed on p1II.
From a library of displayed proteins, high-affinity binding phages can be selected in vitro by
panning on an immobilized target, washing away unbound phages and eluting bound phages.
The eluted phages are then amplified and taken through additional binding and amplification
cycles to enrich the pool in favor of binding sequences. Individual clones are picked and subject
to further characterization and DNA sequencing.
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pill leader sequence Kpn I/Acc65 I
5'-...TTA TIC GCA ATT CCT TTA GTG GTA CCT TTC TAT TCT CAC TCT
3'-...AAT AAG CGT TAA GGA AAT CAC CAT GGA AAG ATA AGA GTG AGA
... Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser His Ser
Start of mature peptide-gill fusion
EagI
Library Insert Sequence TCG GCC GAA ACT GTT GAA
See below AGC CGG CTT TGA CAA CTT
Ser Ala Glu Thr Val Glu
AGT TGT TTA GCA AAA TCC CAT ACA GAA AAT TCA ITT ACT AAC GTC TGG
TCA ACA AAT GT TTT AGG GTA TGT CTT TTA AGT AAA TGA TTG CAG ACC
Ser Cys Leu Ala Lys Ser His Thr Glu Asti Ser Phe Thr Asn Val Trp
+- 28 sequencing primer
AAA GAC GAC AAA ACT TTA GAT CGT TAC GCT AAC TAT GAG GGC...-3'
TTT CTG CTG TTT TGA AAT CIA GCA ATG CGA TTG ATA CTC CCG...-5'
Lys Asp Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly...
<- 96 sequencing primer
Library Insert Sequences
Ph.D.-7: (NNK). GGT GGA GGT
(NNM) CCA CCT CCA
Xxx, Gly Gly Gly K-GorT; M.AorC
Ph.D.-12: (NNK) GGT GGA GGT
(NNM). CCA CCT CCA
Xxx, Gly Gly Gly
Ph.D.-C7C: GCT TGT (NNK), TGC GGT GGA GGT
CGA ACA (NNM), ACG CCA CCT CCA
Ala Cys Xxx Cys Gly Gly Gly
Figure 2. Sequence of the peptide cloning site where the library is inserted into the M13KE
phage genome.
Each library is expressed with an N-terminal leader sequence that is removed upon secretion,
resulting in the randomized peptide positioned directly as a peptide library-N-terminal fusion to
the minor coat protein (pIII). The hybridization positions of the -28 and -96 sequencing primers
are indicated. The third position of each codon is limited to G or T at the randomized positions to
improve relative representations of each amino acid. This figure is reproduced from the New
England Biolabs Ph.D.-7 library manual.
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nica media unica media
T unica intima - *Tunica intima
Basal lamina Basal lamina
ndothelium Nanoparticle deposition
on colagen IV
hitact normal
endothelal layer
Endothelial denudation
during vascular injury
Figure 3. illustration of targeting to the basement membrane.
The basal lamina is not exposed when the endothelial layer is healthy and intact. During chronic
disease, the endothelial layer is breached and the underlying basal lamina is exposed. Targeting
the vasculature provides a conduit through which active molecules can be distributed to layers of
the vessel wall, such as the tunica media. During vascular injury, contractile smooth muscle cells
(SMC) migrate from the tunica media into the tunica intima (as depicted in the right diagram)
and become synthetic and proliferative.
I-- -"* Elute; Amplify; Titer -*
Incubate with collagen IV
for one hour at RT(Initial selection)
M13 phage library
(2 x 10" pfu)
Incubate with collagen I
for one hour at RT(subtraction)
Take supernatant and
Incubate with collagen IV
for one hour at RT(positive selection)
2 x 101 pfu
I
Eluts; Amplify Titer
Figure 4. Schematic of phage display selection strategy.
During the initial selection, the phage library was panned against human collagen IV. In R2 to
R5, the collagen IV enriched phage pool was subtractively panned against human collagen I. 15
clones per round were randomly picked for further biochemical analysis and DNA sequencing.
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Now,
Absorbance (405-490 nm)
R-O - . R-0 library
A-1 STFGLQD Laminin, alpha 2
A-2 IGPATRS Tenascin R
A-3 LPKELRH Leucine-rich repeats
A-4 INYHVQK Titin
A-5 GPAVLTL Agrin
A-6 TPLPANL Serum Am [old P
A-7 HRSPHTP Protocadherin LKC
A-8 KVWSLPO Titin
A-9 KIFVWPY Gelsolin
B-1 YNLPPST Tenascin XB
B-2 YHRPPPY E-cadherin
B-3 SAPPSHP -
C-1 KGEHPTV -
C-2 GANMPHP -
C-3 NHHPLPR -
C-4 SLSPNLS -
C-6 GKIWTTP -
C-6 WPLGASR -
C-7 HWLPLYG -
C-8 HWGSLRA -
C-9 HVLPLYW -
C-10 KIWKLPQ -
C-1i KLWVLPK -WMEMO___
Figure 5. Identification and characterization of peptides for targeting to the basement
membrane.
Twenty-three phage clones from Rounds 3-5 of the phage display screen. Group A: Peptide
sequences that show similarity to resident basement membrane proteins or contain collagen
binding-motifs analyzed by pBLAST against the NCBI H. sapiens nonredundant protein
sequence database. Group B: Sequences that resemble the collagen IV GPP triple helix. Group
C: Sequences with no identifiable relationship to resident basement membrane structures. The
clones were tested against the library (RO) for binding to Matrigel (lighter shaded bars) and BSA
(black bars). Bound phages were labeled with peroxidase-conjugated anti-M13 mAbs, and ABTS
absorbance was read at 405 nm against a reference wavelength of 490 nm (mean ± SD, n=3). *
P <0.01; ***, P < 0.001 all compared with RO (one-way ANOVA with Tukey post hoc test).
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0001
C-11
A-9
C-10
A-8
K? Q
s!V Q
V PK
VIP Y
Consensus K I W V L P Q
B Quamity
3 7 6
Conservation consensus
Figure 6. Alignment and consensus sequence.
Sequences were viewed and aligned by (A) CLUSTAL 2.0.10 and (B) the Jalview multiple
sequence alignment editor.
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. A-9 551
. C-10 917
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[Peptide] (M)
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Figure 7. Sequence-specific competition binding assays.
Phage clones A-8, A-9, C-10, and C-Il were competed against synthetic peptide equivalents on
Matrigel extracts and showed a dose-response relationship. IC50 values were determined and
normalized on a percentage scale by the formula: Y=Bottom + (Top-Bottom)/(I+10A((LogICso-
X)*Hill Slope)) (mean ± SD, n=3). (A) C-11; (m) A-9; (e) C-10; (V) A-8.
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1E8
0 C-11 m RO
1E7 .
-EI IES I
1E4
1E3
1E2
Matrigel CIV
Figure 8. Titer count analyses of C-11 compared to the RO phage library on Matrigel and
collagen IV.
Titers of eluted phages were averaged to give values of pfu/mL (mean ± SD, n=3). ***, P <
0.001 by a paired two-sample Student's t-test.
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Figure 9. Epitope mapping using phage display.
The A-6 phage clone (TPLPANL) shows similarity to a sequence within serum amyloid P
component, TPLPANIL. (A) The SAP protein structure (RCSB Protein Data Bank) is
displayed using the PyMol program (Schrodinger Computational Chemistry, Cambridge, MA).
The TPLPANIL sequence (white) is found on the exposed face of each pentameric subunit and
also (B) on the exposed face of the SAP decamer (white)26. (C) C-reactive protein (CRP),
another member of the pentraxin family, was shown to bind to Cl q via amino acids 175-185 that
align to the location of the TPLPANIL sequence. (D) Ball-and-stick stereo structure of CRP with
amino acids 175-185 highlighted. Figures 1OC and 1OD were originally published in the Journal
of Biological Chemistry. Bang, R. et al. Analysis of binding sites in human C-reactive protein
for FcyRI, FcyRIIA, and Clq by site-directed mutagenesis. J Biol Chem (2005) 280, 25095-102.
Reproduced in part with permission from The American Society for Biochemistry and Molecular
Biology @ 2005.
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M13 phage library
(2 x 10" pfu)
Incubate with
Matrigel (growth
factor reduced) 1- -- J
for one hour
at 37 C
Elute; Amplify; Titer
Clone
J-1
J-2
J-3
J-4
J-5
J-6
J-7
Peptide sequence
ASANSVT
SLTQYSK
HSQAHLN
FTNKYPE
MPQTWYS
TWVAGAV
GIAHAKP
J1 J2 J3 J4 J5 J6 J7 B1 A2 B3 A67 A C11
pBLAST sequenceali Igment
Fibronectin, fibrinogen
Titin, collagen XX
Glypican-5, tenascin MI
Protocadherin 4
Collagen Val
Glypican-2, leucine-rich repeat
Laminin
Figure 10. Phage display strategy against Matrigel matrices.
(A) Schematic of phage display strategy. The phage library was panned against Matrigel (GF-
reduced, LDEV-free). 15 clones from round 3 were randomly picked for DNA sequencing and
further biochemical analysis. (B) Some of the clones from this screen (green bars) were tested
against clones from the collagen IV screen (blue bars) for binding to Matrigel. Bound phages
were labeled with peroxidase-conjugated anti-M13 mAbs and ABTS absorbance was read at 405
nm against a reference wavelength of 490 nm (mean ± SD, n=3). (C) Clones chosen for analysis
were sequences that showed similarity to resident basement membrane proteins analyzed by
pBLAST against the NCBI H. sapiens nonredundant protein sequence database.
116
Discussion
The pIII-displayed M13 filamentous bacteriophage library used in this study was suitable
for the selection of small heptameric peptides present in low copy number (1-5 copies per
phage). However, other phage display formats may be more relevant for applications that require
larger peptide ligands or antibody fragments, and for cases where high-copy number display is
required.
For polyvalent high-copy display, pVIII major coat protein display may be used to select
for peptide affinity combined with an avidity effect. However, a number of issues may arise,
ranging from varying display levels based on the length and sequence of the fusion protein, to
unstable phages when fusion peptides are more than six residues in length. Newer studies have
found ways to mutate the pVIII coat protein for improved polyvalency of display29 . When the
displayed protein is large, such as scFv antibody fragments with > 50 residues, the displayed
library has to be constructed into phagemid systems. Phagemids are hybrids of M13 phages and
plasmids, and can grow both as a plasmid (origin of replication, ori, for dsDNA replication) and
phage (f I ori for ssDNA replication). Here, bacterial infection requires a 'helper' phage to
provide the wild-type pIII and pVIII in trans for single-stranded DNA replication and phagemid
DNA packaging into phage particles.
More recently, yeast display methods have been developed to enable researchers to
incorporate larger fragments into yeast genomes3 0 ,3 1 . A eukaryotic host should alleviate
expression biases present in bacterially-propagated combinatorial libraries, such as reduced
arginine levels due to arginine interference with secY-dependent secretion of pIII3 2 . Unlike
phage display, yeast display methods can be used to screen for mammalian cell-surface
receptors, secreted antibodies and cytokines which require post-translational processing by the
endothelial reticulum and quality control mechanisms of the eukaryotic secretory pathway.
However, disadvantages include smaller yeast library sizes and differential glycosylation in yeast
compared to mammalian cells.
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With a myriad of options available for screening peptides and antibody fragments, the
applications of these systems are limited only by the imagination of researchers performing the
screen. Libraries have been used to discover anti-microbial 33 and anti-viral peptides3 4' 35,
material-specific peptides3 6, cell-targeting peptides3 7, small-molecule binders such as
intracellular targets of paclitaxel38 , and even to map uncharacterized protein-protein
interactions39 . Peptides that home in on tumors and various organs in vivo have also been
discovered 40'41 . Even though in vivo phage display has been used successfully before, several
problems are encountered during in vivo panning such as: (i) phages experience significant
hydrodynamic drag and convective forces in arterial flow which causes them to marginate away
from vessel walls, (ii) the inability to block high non-specific binding, and (iii) in particular, the
unwarranted randomness in the selection due to short contact times and incomplete exposure of
phage diversity to the vasculature because nearly all of the injected phages are scavenged by the
42RES in minutes
In Chapter 4, a pentameric fibrin-binding peptide, CREKA, was used to target
platelet/fibrin clots on atherosclerotic plaques. Here, we discover a family of collagen IV-binding
peptides that we tested on Engelbreth-Holm-Swarm (EHS) mouse sarcoma basement membrane
extracts. Other screening methods were also considered in the event this strategy did not lead to
successful binders. For instance, we could pan the library against laminin or heparan sulfate
proteoglycans which constitute 30% and 10-20% of the basement membrane, respectively.
Alternatively, we could phage display angioplastied arteries ex vivo or in vivo. Finally, scFv
phagemid libraries were also considered because antibody fragments generally show greater
specificity and affinity for their targets compared to peptides. These strategies were not tested
because the selected peptides gave suitable IC50 inhibition values. When peptides are
functionalized onto NPs, the synergistic effect from having multiple peptide-receptor interactions
may improve on the overall targeting affinity.
Within this study, a number of heptameric sequences showed sequence similarity to
resident basement membrane structures such as titin, agrin, cadherin and laminin. In all cases, 5
out of 7 amino acids must show sequence identity during alignment to qualify as being similar.
Not all of these sequences may amount to functional targeting ligands on NPs, since some of
them did not perform significantly better than the original library in ELISA assays against
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Matrigel. However, the observation that some of the recovered peptides resemble basement
membrane proteins suggests a biological consequence of this screen. This is consistent with
previous reports that phage display can play a significant role in mapping epitopes of known
binders38 and in mapping uncharacterized protein-protein interactions39 . Other studies have
characterized the SAP-collagen IV interaction in vitro but a binding site was never proposed.
Although we postulate that we have identified the binding site of SAP to collagen IV, this
hypothesis remains to be experimentally verified by IC50 inhibition assays against SAP and site-
directed mutagenesis studies.
In conclusion, we discovered a family of candidate peptides that may be functionally
tested as targeting ligands on NPs. We hypothesized that we could target the endothelial
basement membrane in diseases with chronic vascular injury and inflammation. In Chapter 6,
we surface-functionalized the hybrid NPs with our candidate peptide ligands and tested the
targeted-NPs for delivery to injured vasculature ex vivo and in vivo.
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Chapter 6. Spatiotemporal Targeting
of Nanoparticles to Injured Vasculature.
Abstract
There are a number of challenges associated with designing NPs for medical applications. We
define two challenges here: (i) conventional targeting against up-regulated cell surface antigens
is limited by heterogeneity in expression, and (ii) previous studies suggest that the optimal size
of NPs designed for systemic delivery is approximately 50-150 nm, yet this size range confers a
high surface area-to-volume ratio which results in fast diffusive drug release. For spatial control,
we functionalize 60-nm hybrid NPs with novel peptides from a phage display screen against
collagen IV. For temporal control, we load the hybrid NPs with slow-eluting conjugates of
paclitaxel for controlled ester hydrolysis and drug release over 10-12 days in vitro. The targeted-
NPs inhibited human aortic smooth muscle cell proliferation in cultures embedded on collagen
IV matrices and showed greater in vivo vascular retention during percutaneous angioplasty over
non-targeted controls. This NP technology may potentially be used toward the treatment of
injured vasculature, a clinical problem of primary importance.
The content of this chapter has been published in whole or in part in the following
journal article:
Chan, J.M., Zhang, L., Tong, R., Ghosh, D., Gao, W., Liao, G., Yuet, K.P., Gray,
D., Rhee, J.W., Cheng, J., Golomb, G., Libby, P., Langer, R. Farokhzad, O.C.
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc
Natl Acad Sci U S A (2010) 107, 2213-2218. Reproduced in part with permission
from Proceedings of the National Academy of Sciences USA. National Academy
of Sciences D 2010.
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Introduction
The field of nanotechnology has crossed significant milestones from the systemic
delivery of NPs 1-5. However, the ability to overcome in vivo barriers towards tissue-specific drug
delivery at therapeutically-relevant levels remains an elusive goal. Both spatial and temporal
control of therapeutic agents may be essential to many medical applications. In this study, we
engineer a NP system that fundamentally changes the way we achieve spatiotemporal control of
drug delivery.
We designed -60-nm core-shell hybrid NPs6,7 consisting of a polymeric core, a lipid
interface and a PEG corona. For temporal control, we achieved the capacity for slow drug elution
over two weeks using poly(lactic acid) (PLA) conjugates of paclitaxel (Ptxl)8 made by a
modified drug-alkoxide ring-opening strategy9"0 . Drug burst release is a long-standing challenge
in NP formulation and conventional NPs typically demonstrate a burst release of 60-90% of their
payload within 24 h because drug release is controlled mainly by diffusion. These conjugates
allow for controlled drug release by gradual ester hydrolysis despite the large surface area and
short diffusion distances of sub-100-nm particles. Herein, we report the synthesis of Ptxl-PLA
conjugates initiated by Ptxl and catalyzed by BDIZnTMS 2, an active catalyst for chemo- and
region-selective polymerizations of lactide. The drug release profile of these conjugates is
determined not only by diffusion but also by the hydrolysis of the Ptxl-PLA linker, giving a -10-
12 day Ptxl release. These NPs were also shown to inhibit human aortic smooth muscle cell
proliferation in vitro.
For spatial control, the NPs were functionalized with ligands1 '" 12 from the phage display
screen described in Chapter 5. Here, a combinatorial library of 109 independent clones was
panned against collagen IV13 which represents 50% of the vascular basement membrane".
Eluted phage clones were characterized for their relative targeting affinities against a Matrigel
extract rich in collagen IV and laminin'. Many human diseases are associated with
compromised vasculature and increased vascular permeability'e,17 and we exploit these vascular
breaches by targeting the underlying basement membrane. Hence, targeted delivery of
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therapeutics to these vascular breaches may be a powerful means to achieve efficient delivery to
the vascular wall and improve on the efficacy of NP-based drug delivery.
Previous reports suggest that NPs show a size cut-off for retention when delivered by
angioplasty into vascular walls. 100 nm polystyrene NPs transmigrated into the medial area
whereas 500 nm NPs remained along the vascular lumen' 8 . 90 nm tyrphostin-loaded PLA NPs
also showed better drug deposition and improved anti-restenotic outcomes compared to larger
160 nm NPs19. In theoretical studies, once the sub-100 nm NPs are decorated with ligands and
delivered to diseased vasculature, unlike larger leukocytes or monocytes that roll stably over the
vessel wall, targeted NPs which are smaller by nearly two orders of magnitude are predicted to
search for the biological target in a 'bee-like mode', jumping abruptly from one adhesion site to
another. In general, sub-100 nm NPs experience smaller dislodging forces, and combined with
the binding affinities of targeting ligands, produce larger molecular bond rupture forces and
shorter times for firm adhesion
We used angioplasty-injured vasculature as a model of compromised vasculature to
21examine the utility of our NPs . We delivered the targeted NPs via both intraarterial (IA) and
i.v. administration and showed greater in vivo vascular retention at sites of injured vasculature in
the rat compared to non-targeted NPs. Inspired by the adhesive nature of burr seeds, which are
covered by "hooks" that bind onto abundant exposed surfaces, we named our system
"nanoburrs" for their adhesive quality at sites of injured vasculature. The nanoburr system may
be administered systemically for a myriad of human diseases where the endothelial lining is
6 16,17,22compromised, including oncologic' and cardiovascular inflammatory disease
125
Methods
Materials.
All peptides were custom synthesized by Genscript (Piscataway, NJ) with C-terminal amidation
and purified by RP-HPLC to >95% purity by mass spectral analysis. Peptides were synthesized
with a linker sequence (GGGC) at the C-terminus for thiomaleimide coupling. Alexa Fluor 647
hydrazide tris(triethylammonium) salt was purchased from Invitrogen (Carlsbad, CA). All
materials were bought from Sigma-Aldrich unless otherwise noted.
Paclitaxel-Polylactide Conjugation.
[(BDI)ZnN(TMS) 2] [(BDI=2-((2,6-diisopropylphenyl) amino)-4-((2,6-diisopropylphenyl)imino)
-2- pentene, TMS=trimethylsilyl] (6.2 mg, 0.01 mmol) and Ptxl (8.5 mg, 0.01 mmol) (Sigma)
were mixed in 0.5-mL anhydrous THF- D,L-lactide (36 mg, 0.25 mmol) in 2 mL anhydrous THF
was added dropwise to initiate polymerization. Lactide was completely consumed within hours
at RT and monitored by FTIR or 'H NMR spectroscopy. The polymerization solution was added
to ethyl ether (25 mL) to precipitate out the Ptxl-PLA25 conjugate (approximately 25 dL-lactide
monomer units, 19.2 wt% Ptxl).
Synthesis and Characterization of Nanoburrs.
A 3 mL DSPE-PEG/lecithin mixture in 4% ethanol containing 0.17 mg DSPE-PEG-
Maleimide/DSPE-PEG (1:4 molar ratio) and 0.08 mg lecithin was heated for 3 min above the
lipid phase transition temperature to 68 'C under gentle stirring. Next, 1 mg of Ptx1-PLA in
acetone (1 mg/mL) was added dropwise at I mI/min. The solution was vortexed vigorously for 3
min followed by self-assembly under gentle stirring for 2 h at RT. The NPs were washed three
times using a 30 kDa MWCO Amicon Ultra-4 centrifugal filter (Millipore). The NPs were
resuspended in pH 7.2 PBS buffer and 2 mM EDTA and incubated with peptides (MW= 1137.54
Da) at a 1/2 molar ratio to DSPE-PEG-Mal for 45 min at RT. The peptides were previously
reduced using Bond-breaker TCEP solution, Neutral pH (Thermo Scientific) in PBS-EDTA at a
1/1 disulfide bond/TCEP molar ratio. Free peptides were removed using a Sephadex PD-10 (G-
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25) column. For scale-up, multiple vials of NPs were made with concentrations and volumes
kept constant to maintain small NP diameters. TEM images of the nanoburrs (1 mg/mL) were
obtained by negative-staining with 3% uranyl acetate. Size (diameter, nm) and surface charge
(zeta potential, mV) were evaluated by quasi-elastic laser light scattering using a ZetaPALS
dynamic light-scattering detector (15 mW laser, incident beam=676 nm; Brookhaven
Instruments).
Release Kinetics Studies.
To assess the Ptxl-PLA bond, Ptxl and Ptxl-PLA conjugates were subject to RP-HPLC using an
Agilent 1100 HPLC equipped with a pentafluorophenyl column (Curosil-PFP, 250 x 4.6 mm, 5
pm; Phenomenex). Ptxl and Ptxl-PLA absorbance was measured with an UV-vis detector at 227
nm in a I/I acetonitrile/l % trifluoroacetic acid I mL/min nongradient mobile phase. To quantify
the Ptxl-PLA drug release profile, a 2 mg nanoburr sample was divided equally into 30 Slide-A-
Lyzer MINI dialysis microtubes, 20 kDa MWCO (Pierce). The remaining Ptxl-PLA was
quantified at various time points by RP-HPLC. Experiments were carried out in triplicate in PBS
at 37 'C.
HaSMC Cytotoxicity Studies.
96-well plates were Matrigel-coated and BSA-blocked (as described in Chapter 4) in PBS.
HaSMC were plated at 10,000 cells/well in a 37 'C, 5% CO2 incubator and grown for 24 h in
Medium 231 supplemented with 10 ptg/mL gentamycin, 0.25 ptg/mL amphotericin B and smooth
muscle growth supplement (all from Cascade Biologics, Invitrogen). Treatment groups (n=5)
included nanoburrs, scrambled-peptide NPs, non-targeted NPs, fourfold dilutions of Ptxl (in
maximum 0.1% DMSO) in media and a media-only control. Samples were incubated with cells
for 45 min. The wells were washed two times with complete media and replaced with fresh
complete media for 48 h. Medium 231 was replaced with phenol red-free RPMI medium
supplemented with 10% FBS containing [3-(4,5-dimethylthiazol-2-y)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS) and phenazine
methosulfate (PMS) and incubated for 2 h at 37 0C (CellTiter 96AQueous Non-Radioactive Cell
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Proliferation Assay; Promega). Formazan product formation was measured by absorbance at 490
nm against a reference wavelength of 650 nm.
Animals.
Sprague-Dawley rats weighing approximately 450-500 g were obtained from Charles River
Laboratories and fed a normal rodent diet. All animal procedures were conducted by a certified
contract research organization using protocols consistent with local, state, and federal regulations
as applicable and approved by the Institutional Animal Care and Use Committee.
Balloon-Angioplasty Ex Vivo Studies.
For ex vivo studies, animals were sacrificed for open abdominal cavity surgery in situ. Aortas
were flushed with saline and injured by four passages of a Fogarty arterial embolectomy 2F
balloon catheter (Model 120602F; Edwards Lifesciences) in a rotating fashion. Alexa Fluor 647
(A647) dyes were covalently conjugated to PLGA (viscosity 0.19 dL/g) using EDC/NHS
chemistry in DMF. A647-PLGA conjugates were precipitated in 2/1 ethyl ether/methanol by
centrifugation, dried in vacuum, and resuspended in acetone for NP preparation. Fluorescence
(rfu) was quantified using a GeminiXPS microplate spectrofluorometer (Molecular Devices), and
samples were diluted accordingly in PBS for comparable NP delivery into the aortas. 0.4 mL
samples (approximately 6 mg/mL) were incubated in the aorta for 5 min using metal clips to
secure both ends of the aorta. Non adsorbed samples were flushed away with saline using an
Advance Infusion Pump Series 1200 syringe pump (Roboz Surgical Instrument Co.)
programmed at 4 mL/min for 15 min.
Balloon-Angioplasty In Vivo Studies.
For in vivo IA studies, animals were anesthetized intramuscularly with ketamine (60
mg/kg)/kylzaine (10 mg/kg) and given buprenorphine as an analgesic. Left common carotids
were injured by four passages of the 2F balloon-catheter, before a 30-gauge tubing was inserted
via the external carotid into the common carotid and advanced beyond the angioplastied region
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into the aortic arch. Samples (approximately 10 mg/mL) were infused at 1 mL/min for 1 min.
The external carotids were permanently ligated. The animals were sacrificed I h after surgery,
and the carotids were harvested. For i.v. studies, animals were additionally given heparin (500
IU/kg) by i.v. injection immediately before surgery. The animals underwent left common carotid
artery surgery and samples (approximately 15 mg/mL) were given by 1 mL i.v. tail vein
injections. The animals were sacrificed after I h and the carotids were harvested.
Optical Imaging and Fluorescence Microscopy Studies.
Tissues were fixed in 4% paraformaldehyde/4% sucrose/saline overnight at 4 'C. Whole tissue
sections were imaged simultaneously using the IVIS Imaging System200 Series (Caliper Life
Sciences, Hopkinton, MA) at 640/700 (ex/em) wavelength, exposure time= 1 s, binning=medium,
F/Stop=2. Tissue sections were overlayed onto photographs taken at binning=medium, F/Stop=8.
After IVIS imaging, the same tissues were OCT-frozen and cut to give approximately 10 pM
sections for fluorescent microscopy. Representative H&E stained slides were also made from
paraffin-fixed sections. All histology sections were done by the MIT Koch Institute Histology
Facility and imaged using a DeltaVision RT deconvolution microscope using the I Ox or 20x
objective (Applied Precision Inc.).
Statistical Analysis.
One-way ANOVA with post hoc Tukey tests were used to determine significance. All error bars
represent the SD of the mean. Differences were termed statistically significant at P < 0.05.
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Results
Synthesis and Characterization of the Nanoburr Drug Delivery System.
To investigate the targeting properties of the candidate peptide against the basement
membrane, peptides were covalently conjugated onto hybrid NPs that have a hydrophobic drug-
eluting core, a hydrophilic polymeric shell, and a lipid monolayer7 . PEG' covalently conjugated
to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) was used to form the hydrophilic
polymeric shell. To complete the lipid monolayer, soybean lecithin, which is considered
Generally Regarded as Safe (GRAS), was used to form the core-shell interface. For the
hydrophobic drug-eluting core, paclitaxel-polylactide (Ptxl-PLA) conjugates were synthesized
by a drug/alkoxide-initiated ring-opening polymerization strategy'0 . Ptxl was mixed with
equimolar amounts of [(BDI)ZnN- (TMS)2] [BDI=2-((2,6-diisopropylphenyl)amino)-4-((2,6-
diisopropylphenyl) imino)-2-pentene, TMS=trimethylsilyl] 9 and the (BDI)Zn-Ptxl complex
formed in situ subsequently initiated and completed the polymerization of lactide within hours at
RT (Figure 1A). Ptxl was shown to be conjugated to the terminals of PLA by comparing the
elution profile of free Ptxl to Ptxl-PLA by RP-HPLC. Ptxl-PLA eluted at approximately 21 min
instead of eluting at the original 13-14 min Ptxl peak (Figure 1B).
In Figure 2, nanoburr synthesis is illustrated in which the core (Ptxl-PLA conjugate) and
shell (lipid and lipid-PEG) are integrated via nanoprecipitation and self-assembly. We
conjugated the KLWVLPK peptide via a C-terminal GGGC linker to DSPE-PEG-maleimide
using maleimide-thiol conjugation chemistry. The size and surface zeta potential of
nonfunctionalized NPs in water were 57.3 ± 0.4 nm (mean ± SD) (Figure 3A) and -12.83 ± 2.73
mV (mean ± SD) (Figure 3B), respectively. Peptide attachment resulted in an approximately I -
nm size increase and made the surface charge cationic (13.5 ± 5.9 mV, mean ± SD), presumably
because the peptides were N-terminally exposed to retain their original phage-displayed
orientation. TEM showed the spherical structures of nanoburrs (Figure 3C). To characterize the
nanoburrs physiochemically, we quantified their release kinetics by taking aliquots (n=3) at
scheduled time points for RP-HPLC analysis (Figure 3D). Ptxl is released by diffusion when the
Ptxl-PLA ester bond is hydrolyzed, and the amount of Ptxl released from Ptxl-LA25 was 43.4%
on day 2, and 9 1.0% and 93.8% on day 10 and day 12, respectively.
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Targeted Drug Release from Nanoburrs.
To validate the therapeutic efficacy of this treatment, a human aortic smooth muscle cell
(haSMC) cytotoxicity study was used to assess nanoburr binding affinity on Matrigel-coated
wells with haSMC (Figure 4). To test the sequence specificity of the KLWVLPK peptide (T),
two controls were designated: scrambled PWKKLLV peptide (S) and non-targeted (B) NPs. In
addition, we included a media-only control and fourfold dilutions of free Ptxl in DMSO
(maximum 0.1% DMSO in media). The maximum free Ptxl concentration used was 51 tM,
exceeding by two log scales a suitable Ptxl dose range of 50-1,000 nM for haSMC cytotoxicity.
An incubation time of 45 min was significantly shorter than typical incubation times with Ptxl
(approximately 4-24 h). The wells were rinsed twice with complete media and further incubated
with fresh media for 48 h. Unlike free Ptxl which is removed during the washing step, the
nanoburrs attached to the collagen IV matrix were retained for continued Ptxl release. Hence,
lowered formazan product formation (490 nm absorbance) reflects increased haSMC cytotoxicity
as a function of greater targeted-NP retention on Matrigel-coated plates (n=5, P < 0.001).
Binding Studies in Angioplasty Models of Injured Vasculature.
We evaluated the targeting affinity of the nanoburr system toward injured vasculature. To
create those vascular characteristics, a Fogarty 2-French balloon catheter was used to injure rat
arteries by repeatedly advancing, inflating the balloon, and withdrawing to denude the
endothelial monolayer and expose the basement membrane. This loosely mimics a percutaneous
angioplasty procedure in human patients, the difference being that in human patients the catheter
is inflated locally in a preexisting stenotic lesion. In Figure 5, a representative H&E stained
cross-section shows an injured aorta with the endothelial layer removed, and an uninjured aorta
with an intact endothelial monolayer.
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Ex Vivo Binding Studies in Angioplastied Aortas.
Our ex vivo study examined targeting of the nanoburr system to balloon-injured rat
aortas. A647-PLGA conjugates were used as a substitute for Ptxl-PLA drug conjugates to
visualize the nanoburrs by fluorescence microscopy and optical imaging. This wavelength is
beyond the autofluorescence range of typical endogenous tissue fluorophores such as collagen
and elastin, which excite and emit maximally at approximately 300-500 nm. Therefore, any
A647-PLGA fluorescence detected would be NP deposition.
A647-PLGA encapsulated nanoburrs were incubated in the abdominal aorta for 5 min
under constant pressure, followed by extensive washing using a syringe-pump to remove
nonadsorbed samples (Figure 6A). Subsequently, the abdominal aortas were harvested and
viewed by whole vessel fluorescent optical imaging (Figure 6B). In fluorescent imaging, the
detected surface intensity depends on the illumination intensity, which varies according to the
field-of-view and wavelength. To eliminate the effect of illumination intensity, images are
normalized against a reference illumination image. The resulting "normalized" fluorescent
efficiency image is unitless, and the value of each pixel represents the fractional ratio of emitted
photons per incident excitation photon. The region-of-interest (ROI) function was used to
quantify nanoburr retention (Figure 7), and measurements are displayed as average fluorescent
efficiency (relative fluorescence units, rfu). The nanoburrs bound to balloon-injured aortas at
1.43 ± 0.48 x 10~' (rfu), while scrambled-peptide and non-targeted NPs overall bound twofold
less at 48% (n=3, P < 0.05) and 47% (n=3, P < 0.05), respectively. To ensure that the nanoburrs
would not target intact endothelial layers, they were also incubated with uninjured aortas and
bound fourfold less at 3.39 ± 0.50 x 10~' (rfu) (n=3, P < 0.01) compared to injured vessels.
Frozen histological sections were photographed to show nanoburr binding along the arterial
cross-section (Figure 8).
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In Vivo Intraarterial Delivery Studies in Angioplastied Carotid Arteries.
We next examined targeting in vivo via IA infusion using a left carotid injury model
(Figure 9A). The balloon catheter is inserted into the external carotid artery branch between the
bifurcation of the common carotid artery and the site of distal ligation and retraction. Samples
were delivered at I mUmin for 1 min directly into the aortic arch and allowed to circulate for I
h.
Subsequently, the left and right common carotids attached to the aortic arch were
harvested and viewed by whole vessel fluorescent optical imaging (Figure 9B). The nanoburrs
were injected into angioplastied left carotids through a catheter positioned in the aortic arch
inserted from the external carotid artery over the course of 1 min and allowed to circulate for I h.
Fourfold more nanoburrs [8.71 ± 0.38 x 10-6 (rfu)] were found in the angioplastied left carotid
arteries compared to intact right carotids. Scrambled-peptide and non-targeted NPs were retained
in the left carotids at 40% (n=5, P=0.0818) and 53% (n=5, P=0.23716) of nanoburr retention,
respectively (Figure 10). Representative frozen histological sections show fluorescence along
the carotid arteries (Figure 11).
In Vivo Intravenous Delivery Studies in Angioplastied Carotid Arteries
The nanoburr system was studied for systemic delivery because repeat dosing may be
helpful in the treatment of chronic vascular disease. Using a left carotid injury model, the
nanoburrs were given as a I mL i.v. dose via tail-vein injection and allowed to circulate for 1 h
before animals were sacrificed (Figure 12A).
Subsequently, the left and right common carotids attached to the aortic arch were
harvested and viewed by whole vessel fluorescent optical imaging (Figure 12B). Nanoburr
retention was 5.46 ± 1.02 x 10~6 (rfu) in the angioplastied left carotids compared to scrambled-
peptide and non-targeted NPs, which were 35% (n=5, P < 0.001) and 64% (n=5, P < 0.01) of
nanoburr retention, respectively. The nanoburrs bound to the left carotids twofold over healthy
right carotids (P < 0.001) (Figure 13). Representative fluorescence images of nanoburr binding
are shown in Figure 14.
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Figure 1. Schematic of Ptxl-PLA biomaterial synthesis.
(A) Ptxl was mixed with equimolar amounts of [(BDI)ZnN(TMS) 2]; the (BDI)Zn-Ptxl complex
formed in situ initiated and completed the polymerization of lactide. Ptxl-PLA25 drug conjugates
with approximately 25 DL-lactide monomer units were synthesized for the nanoburr core. (B)
RP-HPLC analysis of Ptxl against Ptxl-PLA25 conjugates.
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Figure 2. Schematic of nanoburr synthesis by nanoprecipitation and self-assembly.
Ptxl-PLA in acetone was added dropwise to a heated lipid solution, vortexed vigorously, and
allowed to self-assemble for 2 h to form NPs. The NPs were peptide-functionalized using
maleimide-thiol chemistry. Nanoburrs have a drug-eluting polymeric core, a lipid monolayer, a
PEG antibiofouling layer and peptide ligands ('hooks') to adhere to the exposed basement
membrane during vascular injury.
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Figure 3. Nanoburr characterization.
(A) Dynamic light scattering measurements before and after peptide conjugation, respectively.
(B) Zeta potential measurements before and after peptide conjugation, respectively (mean ± SD,
n=3). (C) TEM image of nanoburrs stained with 3% uranyl acetate. Scale bar, 100 nm. (mean +
SD, n=3). (G) In vitro drug release of Ptxl from the nanoburr core. Samples at different time
points were measured for absorbance at 227 nm (mean ± SD, n=3).
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Figure 4. Targeted drug release from nanoburrs.
HaSMC cytotoxicity studies as a function of binding affinity; haSMC on Matrigel-coated plates
were incubated with nanoburrs (T), scrambled-NPs (S), non-targeted bare-NPs (B), 4-fold
dilutions of Ptxl, and a media-only control for 45 min. Samples were washed two times in
complete media and replaced with fresh media for 48 h. Formazan product formation was
measured at 490 nm against a reference wavelength of 650 nm (mean - SD, n=5). * P < 0.001
by one-way ANOVA with Tukey post hoc test.
Angioplastied vessel Normal vessel
EC removed EC intact
Figure 5. Representative H&E stained cross-sections of balloon-injured and uninjured
aortas.
Balloon-injury removes the endothelial cell (EC) monolayer as denoted by arrows in the inset.
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Figure 6. Ex vivo delivery in an abdominal aorta injury model.
(A) Schematic of balloon-injury. The yellow region denotes the angioplasty site. Samples were
delivered into the aorta segment for 5 min in situ. Nonadsorbed samples were flushed out by
saline infusion for 15 min. (B) Fluorescence images overlayed on photographs of balloon-injured
aortas incubated with nanoburrs, compared with scrambled peptide and non-targeted NPs.
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Figure 7. Quantification of nanoburr binding ex vivo to angioplastied aortas.
Aorta sections were analyzed using the region-of-interest (ROI) function of the IVIS Living
Image Software. Values are shown here as average fluorescence efficiency (rfu) (mean ± SD,
n=3). Aorta-only sections did not have NPs delivered into them. *, P < 0.05; **, P < 0.01 by one-
way ANOVA with Tukey post hoc test.
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Figure 8. Representative images of nanoburr b
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Figure 9. In vivo IA delivery in a carotid injury model.
(A) A catheter was inserted via the external carotid into the common carotid and advanced into
the aortic arch. Samples were delivered at 1 mL/min for I min and allowed to circulate for 1 h
before the animals were sacrificed. (E) Fluorescence images overlayed on photographs of carotid
arteries incubated with nanoburrs, compared with scrambled-peptide and non-targeted NPs.
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Figure 10. Quantification of nanoburr binding in vivo to angioplastied left common
carotids by IA delivery.
Both the left and right common carotid arteries were analyzed using the ROI function of the IVIS
Living Image Software. Values are shown here as average fluorescence efficiency (rfu) (mean ±
SD, n=3). Carotid only sections did not have NPs delivered into them. *, P < 0.05 by one-way
ANOVA with Tukey post hoc test.
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Figure 11. Representative images of nanoburr binding in vivo by IA delivery to
angioplastied left common carotids.
(Top) Fluorescence and phase contrast images of carotid arteries incubated with nanoburrs.
(Middle) Carotid arteries incubated with scrambled-peptide NPs. (Bottom) Carotid arteries
incubated with non-targeted NPs. Scale bar, 100 pm. Images were obtained with a DeltaVision
deconvolution microscope using the 20x objective.
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Figure 12. In vivo systemic delivery in a carotid angioplasty model.
(A) Samples were delivered by I mL i.v. tail vein injection and allowed to circulate for I h
before the animals were sacrificed. (B) Fluorescence images overlayed on photographs of carotid
arteries incubated with nanoburrs, compared with scrambled-peptide and non-targeted NPs. For
imaging, Alexa Fluor 647-PLGA dye conjugates were encapsulated in place of Ptxl-PLA drug
conjugates. Scale bar, 1 cm.
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Figure 13. Quantification of nanoburr binding in vivo to angioplastied left common
carotids by i.v. delivery.
Both the left and right common carotid arteries were analyzed using the ROI function of the IVIS
Living Image Software. Values are shown here as average fluorescence efficiency (rfu) (mean ±
SD, n=5). Carotid-only sections did not have NPs delivered into them. **, P < 0.01; ***, P <
0.001 by one-way ANOVA with Tukey post hoc test.
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Figure 14. Representative images of nanoburr binding in vivo by i.v. delivery to
angioplastied left common carotids.
(Left to Right) Fluorescence, phase contrast and overlay images of angioplastied left common
carotid arteries incubated with nanoburrs at 1Ox and 20x magnification. Scale bar, 100 pm.
Images were obtained with a DeltaVision deconvolution microscope using the 1Ox and 20x
objective.
Discussion
In the design of controlled release NPs for vascular targeting, researchers hope to (i)
reduce dosing frequency, and (ii) maintain plasma drug levels in the therapeutic window for
efficacy. To limit dosing schedules to an acceptable frequency and achieve a therapeutic dose
across a predetermined time frame, two parameters of drug loading and drug release must be
carefully considered. Increased drug loading into the NP core tends to reduce overall stability,
giving an undesired burst release effect and reduced efficacy. Larger particles tend to have
slower in vitro release profiles, but when systemically delivered may be more readily detected
and cleared from circulation, resulting in a lack of efficacy . For vascular targeting, because
small particles show improved vessel adhesion and retention' ,19,25, integrating slow-eluting
conjugates into the nanoburr design allows for (i) improved drug loading, (ii) sub-100-nm NPs
for vascular targeting, and (iii) sustained drug release over ten days.
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The use of polymers to control drug release is also a significant feature of drug eluting
stents (DES)26. Taxus Ptxl-eluting moderate release stents (25 wt% Ptxl to polymer, 171 pig Ptxl)
release an initial bolus of Ptxl in 48 h, followed by low-level release over 10 days. Taxus slow
27
release stents (8.8 wt% Ptxl to polymer, 85 pg Ptxl) release drugs over 30 days . In these stents
however, only less than -10% of the Ptxl fraction is ever released. Hence, the drug release
profile from the nanoburrs in this study may be relevant for the treatment of angioplastied
vessels. Ideally, the NPs should have an approximately one-week drug release profile at sites of
vascular injury during the initial period of proliferation and inflammation. With the nanoburrs,
drug elution rates may be further controlled by varying lactide/Ptxl ratios during ring-opening
8polymerization, resulting in different PLA chain lengths attached to the Ptxl drug .
This study utilized a peptide-targeted NP delivery system against resident proteins of the
basement membrane. The potential applications of related systems are diverse, ranging from
therapeutic to diagnostic applications in oncologic, cardiovascular and regenerative diseases.
The targeting of basement membrane proteins may be used to modulate key integrin-
matrix interactions during angiogenesis. Anti-angiogenic therapy is currently one of most active
fields in cancer research, with strategies aimed at inhibiting tumor vascularization either by
upregulation of endogenous inhibitors or downregulation of angiogenic signals from factors such
as VEGF. Integrin ligands play key roles in endothelial cell survival, migration and new vessel
differentiation and reorganization. Novel anti-angiogenic approaches include the use of
therapeutic blocking ligands to disrupt crucial integrin-matrix interactions and generate locally
nonpermissive basement membranes 28. These compounds halted tumor growth in murine models
and are now in clinical trials 2 8 . Phage display was used to find peptides that target MMP2-
processed collagen IV and these peptides subsequently blocked angiogenesis in vivo29.
Researchers have fluorescently imaged colorectal carcinomas in mice using multivalent
'trimerbodies' (scFv fragments connected to the N-terminal trimerization subdomain of the
collagen XVIII NCI domain) against the human carcinoembryonic antigen (CEA), an
angiogenesis-associated epitope of laminin30 ,3 1 . Future applications may include targeted
therapeutic delivery to functional laminin domains, as laminin is a resident basement membrane
protein with a well-studied role in tube formation.
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The targeting of matrix proteins may also be useful for the imaging of fibrotic disease.
Fibrosis is a common outcome in chronic diseases due to a reparative process to injury. The
formation or development of excess fibrous connective scar tissue (largely type I collagen)
eradicates the architecture of the underlying tissue and may result in organ dysfunction. As
described in Chapter 4, the thickness of fibrotic caps in atherosclerotic plaques has been shown
to be an indicator of lesion rupture and thrombosis. In mouse models of myocardial infarction,
MR imaging of the contrast agent delineated the infarct zone where necrotic myocytes are
replaced by a fibrotic myocardial scar32,33
Finally, matrix proteins can be targeted to convert the matrix from a barrier into a
reservoir. Researchers have targeted collagen IIlX 134 of dense, avascular intra-articular cartilage
tissue to resist the rapid clearance of NPs from cartilage. Future applications using targeted
polymeric NPs may include therapeutic delivery for the treatment of degenerative joint disease
and osteoarthritis. In contrast with local avascular delivery to the knee joints, our study targets
vascular basement membranes by systemic delivery. Conceptually however, in both cases the
matrix no longer serves as a barrier but instead provides a drug reservoir. Through this drug
depot, we hope to deliver anti-proliferative medicines that distribute into the inner layers of the
injured vessel wall.
Our binding studies to sites of injured vasculature altogether show the successful
targeting and retention of nanoburrs to injured carotid arteries in vivo and abdominal aortas ex
vivo. In Chapter 7, we explore whether the localization of anti-proliferative therapies through
collagen IV-targeted NPs corresponds to improved treatment outcomes.
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Chapter 7. Targeted Nanoparticles for Anti-Restenotic
Drug Delivery to Injured Vasculature.
Abstract
Percutaneous angioplasty, a procedure to revascularize lesions, provides a short-term solution to
coronary artery disease (CAD). The balloon device induces extensive local injury, endothelial
denudation and exposure of the underlying basal lamina. Collagen IV, the primary component of
the basement membrane, becomes abundantly visible to circulation. This study aims to determine
if the localization of anti-proliferative therapies through collagen IV-targeted NPs corresponds to
reduced neointima formation in balloon-injured rat carotid arteries. Using -55 nm biodegradable
lipid-polymeric hybrid NPs and phage-displayed peptides with affinity for collagen IV, we
loaded the NPs with paclitaxel for targeted delivery. In vivo efficacy studies where targeted-NPs
were given by systemic delivery on Day I and 6 of surgery resulted in lower neointimal/media
(N/M) scores at two weeks compared to FDA-approved Taxol@ and injury-only sham groups (1
mg/kg paclitaxel dose: N/Msham=1.249 ± 0.046 versus N/MTaxo=0.837 ± 0.087, N/MNP=0.749 +
0.136 and N/MPep-NP=0.662 ± 0.169, all P < 0.01 versus injury-only group, mean + SEM, n=5).
At low paclitaxel doses of 0.3 mg/kg, targeted-NP groups showed better lumen patency
compared to non-targeted NP groups (N/MNP=l -063 + 0.097 versus N/MPep-NP=0.744 + 0-13, P <
0.08, mean ± SEM, n=5). Our findings suggest that the collagen IV-targeted NPs may potentially
be used as a systemically delivered treatment in CAD.
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Introduction
Cardiovascular disease constitutes the leading cause of illness and death worldwide of
which atherosclerosis is a dominant contributor'. In the United States, approximately 500,000
deaths occur annually due to atherosclerotic cardiovascular disease. The arterial wall thickening
and lumen narrowing associated with the growing atherosclerotic plaque gradually results in
insufficient blood supply to organs such as the heart and brain. In severe circumstances, it may
abruptly rupture causing a blood clot in the vessel and subsequent thrombosis, heart attack or
stroke. In clinical cardiology, percutaneous coronary interventions (PCI) are widely employed
for the revascularization of stenotic coronary arteries as a complementary alternative to medical
therapy and coronary artery bypass graft surgery (CABG). During PCI, intraluminal balloon
inflation may result in various outcomes such as acute elastic recoil of the damaged wall within
one hour of angioplasty, followed by slower unfavorable vascular remodeling and neointimal
SMC formation within one to six months, eventually leading up to restenosis, the cell-mediated
narrowing of the vessels, in 30-50% of patients . Bare metal stents (BMS) were originally
developed to improve vessel patency and reduce abrupt closure, but they likely stimulate SMC
proliferation leading to a 15-25% risk of in-stent stenosis4 (Figure 1).
As a result, drug eluting stents (DES) such as the Cypher sirolimus-eluting (Cordis
Corporation), Taxus paclitaxel-eluting (Boston Scientific) and Xience V everolimus-eluting
(Abbott Laboratories) stents were developed to deliver therapeutic agents directly into the site of
vascular injury4'5. DES combine a drug delivery system via polymer-coated matrices and a
mechanical scaffold to maintain vascular patency in atherosclerotic lesions. Cypher stents elute
sirolimus which induces G1 cell cycle inhibition, while Taxus stents release paclitaxel (Ptxl)
which causes M-phase arrest. Since their introduction, DES have become the treatment of choice
and currently more than six million people worldwide have a DES fitted4 5 . DES are generally
superior to BMS with regards to Major Adverse Cardiac Events (MACE), generally defined as
death, myocardial infarction, or the need for a repeat revascularization procedure. Although the
use of DES significantly reduces the need for subsequent revascularization, it is associated with
an increased incidence of very late stent thrombosis (VLST) beyond the one year mark6 . The
non-biodegradable polymers used as drug-eluting matrices may also result in delayed arterial
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healing7'8, as evidenced by persistent fibrin deposits, incomplete endothelialization and
hypersensitivity reactions (such as eosinophilic infiltrates)' 10 . This delayed healing is the
primary substrate underlying all cases of late DES thrombosis at autopsy8 . Hence, DES
implantation is associated with a dual-antiplatelet regimen of aspirin and clopidogrel to prevent
thrombus formation"" . Furthermore, small-vessel (< 2.5 mm) arteries, large-vessel (> 3.5 mm)
arteries, very long lesions (> 33 mm) and bifurcation lesions are not amenable to stenting.
Together with premature antiplatelet therapy discontinuation, renal failure, diabetes and low
ejection fraction, all these 'off-label' uses were identified as predictors of VLST2-1 4 . Despite the
risks involved and the current unavailability of long-term safety results, sirolimus-eluting DES
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remained superior to BMS at five-years after implantation
It has become increasingly attractive to find complementary options to DES-based drug
delivery from a nanotechnology standpoint'6 ,17. Sub-100 nm targeted NPs are virtually free from
fixed constraints, deliver drugs in a controlled manner, and are biodegradable and biocompatible.
In this study, the peptide-targeted NP system from Chapter 618 is delivered as a systemic,
intravenous infusion after angioplasty. We hypothesized that the improved localization of anti-
proliferative therapies to angioplastied vasculature may contribute to improved treatment
outcomes such as reduced SMC proliferation and improved vessel patency. We compare our
formulations against injury-only sham controls and FDA-approved Taxol, a Cremophor-EL
(polyethoxylated castor oil) micelle formulation of Ptxl. In vivo efficacy studies where targeted-
NPs were given as i.v. doses on Day I and 6 of surgery resulted in lower neointimal/media
(N/M) scores at two weeks compared to Taxol and injury-only groups.
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Methods
Materials.
All peptides were custom synthesized by Genscript (Piscataway, NJ) with C-terminal amidation
and purified by RP-HPLC to >95% purity by mass spectral analysis. Peptides were synthesized
with a linker sequence (GGGC) at the C-terminus for thiomaleimide coupling. Soybean lecithin
consisting of 90-95% soybean phosphatidylcholine was obtained from MP Biomedicals (Solon,
OH). DSPE-PEG2000 and DSPE-PEG2000-maleimide were obtained from Avanti (Alabaster,
AL). PLGA with 50:50 monomer ratio, ester-terminated and 0.72-0.92 dl/g inherent viscosity
was purchased from Durect Corporation (Pelham, AL). Paclitaxel (Ptxl) and all other materials
were purchased from Sigma-Aldrich unless otherwise noted.
Synthesis and Characterization of Targeted NPs.
DSPE-PEG-peptide triblocks were synthesized in 4% EtOH at a peptide/DSPE-PEG 1.25/1
molar ratio for 4 h with gentle rocking. The peptides were previously reduced for 30 min using
Bond-breaker TCEP solution, Neutral pH (Thermo Scientific) in pH 7.2 PBS buffer with 5 mM
EDTA at a 1/1 disulfide bond/TCEP molar ratio. Free peptides were removed by dialysis using
3,500 Da MWCO Spectrapor membranes (Spectrum Laboratories, Houston, TX) for 24 h with
two water changes. A 3 mL DSPE-PEG/lecithin mixture in 4% EtOH containing 1.5 mg DSPE-
PEG-peptide/DSPE-PEG (1/9 molar ratio) and 0.75 mg lecithin was heated for 3 min above the
lipid phase transition temperature to 68 'C under gentle stirring. 9 mg of PLGA mixed with 0.45
mg of paclitaxel in 3 mL acetone (3 mg/mL polymer, 5 wt% Ptxl initial load) was added
dropwise at 3 mL/min. The solution was vortexed vigorously for 3 min followed by self-
assembly under gentle stirring for 2 h at RT. The NPs were washed three times using a 30 kDa
MWCO Amicon Ultra-4 centrifugal filter (Millipore). NPs were resuspended in saline and
sterile-filtered using 25 mm Acrodisc syringe filters with 0.8 pm Supor membranes (Pall
Corporation, Port Washington, NY) before HPLC drug quantification and i.v. injection into
animals. For scale-up, multiple vials of NPs were made with concentrations and volumes kept
constant to maintain small NP diameters.
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Preparation of Taxol Formulations.
Taxol formulations were prepared according to the manufacturer's instructions. Briefly, Ptxl was
dissolved under gentle stirring to 6 mg/mL at a 1/1 ratio in Cremophor-EL and anhydrous
ethanol, 200 proof. This formulation was then diluted 1:10 in saline for a final dosing solution
containing 0.6 mg/mL of Ptxl. The solution was sterile-filtered using 25 mm Acrodisc syringe
filters with 0.8 pm Supor membranes (Pall Corporation, Port Washington, NY). The drug
loading in all Taxol and NP batches were quantified by RP-HPLC against a standard curve of
known Ptxl concentration before i.v. administration to animals. All discussions of drug dosing in
units of mg/kg relate to the active drug composition.
Animals.
Sprague-Dawley rats weighing approximately 400-500 g were obtained from Charles River
Laboratories and kept on standard rodent chow and water ad libitum peri-operatively. Male rats
are preferred for surgery because of their larger sizes. All animal procedures were conducted by
a certified contract research organization using protocols consistent with local, state, and federal
regulations as applicable and approved by the Institutional Animal Care and Use Committee.
Rat Carotid Model and In Vivo Proliferation Studies.
Rat carotid injury was performed as described by Tulis, D.A.19. In this study, animals were given
aspirin (20 mg/kg) by oral gavage on Day -1 of surgery. On Day I of surgery, animals were
given heparin (250 IU/kg) by i.v. injection immediately before surgery. Animals were
anesthetized intramuscularly with ketamine (60 mg/kg)/kylzaine (10 mg/kg) and given
buprenorphine as an analgesic. The arteriotomy site for insertion of the balloon catheter is on the
external carotid artery branch between the bifurcation of the common carotid artery and the site
of distal ligation and retraction. The left common carotid artery was denuded of endothelium by
intraluminal passage of a Fogarty arterial embolectomy 2F balloon catheter (Model 120602F;
Edwards Lifesciences) introduced through the external carotid artery in a rotating fashion.
Lidocaine hydrochloride was gently swabbed onto the exposed carotids. Following permanent
ligation of the external carotid artery, the skin incision was closed with sutures and swabbed with
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bactericide gel around the sutures to reduce the likelihood of infection. Animals were given more
analgesic and kept warm on 37 *C heating pads for ~1 h after surgery. During this recovery
period, samples (n=5 per dosing group) were i.v. injected into the tail-vein and animals were re-
dosed on Day 6 after surgery. The surgical procedure and sample dosing did not cause mortality
or any apparent morbidity. Animals were sacrificed on Day 14 by CO2 inhalation. Both the left
and right carotids and vital organs were harvested during necropsy.
Morphometric Analysis.
Tissues were fixed in 4% paraformaldehyde/4% sucrose/saline overnight at 4 'C. Tissues were
paraffin-embedded and cryosectioned to give nine representative cross-sections across the artery
length and H&E stained (AML Laboratories, Rosedale, MD). Images were obtained with a Zeiss
microscope using the bright field setting at 5x objective. Cross-sections were analyzed using
ImageJ (http://rsb.info.nih.gov/ij/) computerized morphometric analysis software from the NIH,
by an investigator blinded to the experimental group. The degree of neointimal thickening was
expressed as the ratio between the neointimal area to the medial area (N/M). The cross-section
with the greatest luminal narrowing results in the highest N/M ratio and this value is assigned to
the artery.
Immunohistochemistry.
Paraffin-embedded cryosectioned slides were deparaffinized and incubated with 1 % H20 2 in
methanol for 10 min to block endogenous peroxidase, followed by 10% horse serum in PBS for
20 min to block non-specific antibody binding. Primary antibodies for rat a-SMC (DAKO,
Carpinteria, CA) were applied for 1 hour at 37 'C. Sections were washed with PBS and
incubated with biotinylated secondary antibodies (horse anti-mouse IgG, Vector Laboratory,
Burlingame, CA) and avidin-biotin-peroxidase complexes (ABC Elite kit, Vector Laboratory) for
30 min each. Color development was achieved by a 5 mm exposure to 3,3'-diaminobenzidine
tetrahydrochloride (DAB peroxidase substrate). Slides were lightly counterstained with Gill No.
3 hematoxylin. Positive staining was evaluated using a Zeiss microscope under a bright field
setting at 5x objective.
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Statistics.
All error bars represent mean ± SEM. Comparisons of histological findings between control and
treatment groups were made using one-way ANOVA with Tukey post hoc tests. Differences
were termed statistically significant at P <0.05.
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Results
Rat Carotid Injury Model.
The rat carotid injury model was first designed by Clowes, A.W. et al. in 198321 to
investigate the mechanism of stenosis from cellular proliferation after arterial injury (Figure 2).
In these studies, acute thrombosis is prevented by anti-platelet or anti-thrombotic therapies such
as aspirin and/or a small i.v. bolus of heparin.
This injury model involves isolating a carotid arterial segment and creating an
arteriotomy incision in the external carotid branch through which the balloon catheter is inserted
and advanced into the common carotid artery (Figure 2A). Repeated inflation and withdrawal of
the catheter induces endothelial cell loss and intimal injury. Subsequently, the catheter is
removed and the suture is closed at the arteriotomy site before blood flow is resumed (Figure
2B). Figure 2C gives a close-up of the surgery and shows the arteriotomy site at the left external
carotid artery. Figure 2D gives a simplified diagram of the surgical procedure and rat carotid
artery vascular anatomy along with sites of placement of arterial clamps, sutures and ligations.
Histological and morphometric analyses with this model can be employed for long-term
quantification of neointima development and vessel wall restructuring. Representative images of
carotid artery cross-sections taken from the same animal show the result of arterial balloon-
injury when compared to non-injured arteries. In the left column of Figure 3, left carotids that
received the balloon-injury showed extensive neointimal formation and lumen occlusion at two
weeks in both H&E and VvG stained sections. In the right column however, non-injured right
carotids remained healthy and intact, with no neointimal formation and lumen occlusion
observed at two weeks.
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Characterization of NP Treatment Groups.
NPs were made in -I g batches (based on PLGA weight). The NPs were found to be 55.1
i 0.4 nm (polydispersity=0.075, n=3) in one representative batch after sterile filtration, and this
value was found to vary batch-to-batch by only ± 5 nm. NP batches that were functionalized with
peptides did not show any significant size increase beyond 5 nm.
To determine the final drug loading based on a 5 wt% initial drug/polymer input, a batch
of NPs were lyophilized to get the final polymer weight (80% of final weight, other 20% is lipids
and PEG). Samples were resuspended in 1/1 acetonitrile/water for measurements of drug content.
The final drug load was 1.04 wt% (n=3), giving a 21.35% overall encapsulation efficiency of
Ptxl. The initial drug input was kept low to prevent a drug release burst observed with higher
drug loadings. Although we used Ptxl-PLA drug conjugates in Chapter 6, here we used free
Ptxl to compare our NPs against Taxol micellar formulations. Any modification of the drug
through amine side-chain modification and ring-opening polymerization would change the active
drug composition and render direct comparisons with Taxol difficult.
Morphometric Analyses of Treatment Groups.
On Day 1 of surgery, the mean weights of animals were approximately 400-500 g.
During the study, the mean body weight of the animals in all treatment groups increased and was
similar when the study was concluded. Treatment groups (n=5) were Taxol, hybrid NPs and
peptide-functionalized NPs, versus sham injury-only groups. Samples were i.v. injected as a
bolus with Ptxl doses set at 0.3 mg/kg and 1 mg/kg. Here, all discussions of drug delivery relate
to the active drug composition and not the material composition.
Repeat dosing may be important in the treatment of vascular disease, since
atherosclerosis is a chronic disease that needs long-term care. Furthermore, systemic dosing is
non-invasive and does not require additional surgical procedures. Therefore, all our treatment
groups were given as doses on Day I and Day 6, midway to the conclusion of the study.
The studies were terminated at 14 days after angioplasty. Animals were sacrificed and
both carotids were harvested for inspection. Using the ImageJ morphometric analysis software
(NIH), cross-sections of arteries were analyzed by an investigator blinded to the type of
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experimental group. The degree of neointimal thickening was expressed as the ratio between the
neointimal area to the medial area (N/M). The cross-section with the greatest luminal narrowing
results in the highest N/M ratio and this value is assigned to the artery (Figure 4A). Using an
injury-only group carotid artery cross-section as an example (Figure 4B), three rings were made
to surround the (i) tunica media (at the external elastic lamina, EEL), (ii) tunica intima (at the
internal elastic lamina, IEL) and (iii) lumen. Next, the areas denoted by these three rings were
noted. The medial area (M) is calculated from the area bordered by the EEL and the IEL, i.e. area
(i) subtract area (ii). The neointimal area (N) is calculated from the area bordered by the IEL and
the lumen, i.e. area (ii) subtract area (iii). From there, N/M ratios can be derived and this gives a
unitless ratio (Figure 4C).
N/M measurements taken from the site of greatest luminal narrowing per artery showed
that sham injury-only saline groups had N/M scores of N/MSham=l 249 + 0.046 versus I mg/kg
treatment groups of N/MTaxoi=0.837 ± 0.087, N/MNP=0-749 + 0.136 and N/MPep-NP=0.662 ±
0.169 (all P < 0.01 vs. injury-only group, mean ± SEM, n=5). When doses were lowered three-
fold to 0.3 mg/kg, average N/M ratios per treatment group of N/MTaxo=0.937 ± 0.126 (P<0.05
mean ± SEM, n=5), N/MNP=1.063 ± 0.097 (P>0.05 mean ± SEM, n=5) and N/MPep-NP=0.744 +
0.129 (P < 0.01 mean + SEM, n=5) were obtained. This suggests that even at low therapeutic
doses, the peptide-functionalized hybrid NPs were still able to localize and treat injured
vasculature. In Figure 6, representative H&E cross-sections are taken from each treatment
group. In Figure 7, representative a-smooth muscle cell actin (ax-SMA) immunostained cross-
sections were taken from each treatment group. Both Figure 6 and Figure 7 suggest qualitative
differences in neointimal proliferation when compared to saline groups, and also a dose-response
when higher or lower doses of Ptxl were given.
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Figure 1. Schematic of events after angioplasty and stenting.
Revascularization of a stenotic atherosclerotic lesion results in acute
damaged wall within one hour of angioplasty, followed by a slower
elastic recoil of the
unfavorable negative
remodeling within one to six months. These two unfavorable outcomes can be prevented by bare
metal stenting (BMS). In stented and non-stented arteries, neointimal proliferation is observed
after one to six months, eventually leading to restenosis in 30-50% of patients. This risk is
reduced to 15-25% of patients with BMS.
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Figure 2. A rat carotid model of vascular injury.
(A) Photograph of carotid surgery. The balloon catheter is inserted into the external carotid
artery branch between the bifurcation of the common carotid artery and the site of distal ligation
and retraction. (B) Photograph of skin incision and post-procedure sutures. (C) Close-up of
carotid surgery. (D) Simplified diagram of the rat carotid artery vascular anatomy along with
sites of placement of arterial clamps, sutures and ligations. IC, internal carotid; EC, external
carotid; LCC, left common carotid. This figure (Figure 3) was reproduced with kind permission
from Springer Science + Business Media, License: 2364821090061. Tulis, D.A.. Rat Carotid
Artery Balloon Injury Model. Methods in Molecular Medicine, Vascular Biology Protocols.
(2007) 139, 1-30. Springer Science + Business Media @ 2007.
157
Injury only
L carotid
H&E
VVG
No injury
Figure 3. Representative carotid arteries with and without injury.
Injury only left carotids versus uninjured right carotids. Representative H&E and VvG stained
sections. Images were obtained with a Zeiss microscope using the 5x objective. L, lumen; N,
neointima; M, media; A, adventitia.
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Figure 4. Determination of N/M ratios of carotid samples.
(A) Nine arterial cross-sections were analyzed across the length of the artery (denoted by
arrows). The section with the highest N/M ratio value gives the site of greatest luminal
narrowing and that numerical value is assigned to each artery. (B) Representative H&E-stained
artery cross-section. (C) N/M ratio measurement. Using the ImageJ software (NIH) region-of-
interest (ROI) function, the N/M ratio is derived from the area of the neointima (yellow) over the
area of the media (green). L, lumen; N, neointima; M, media; A, adventitia.
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Figure 5. N/M ratio measurements of intimal proliferation.
N/M ratios taken from the site of greatest luminal narrowing per artery. Doses indicate active
Ptxl drug composition and are independent of the formulation method. Animals were dosed on
Day 1 and Day 6 of surgery and the study was concluded on Day 14. All results are taken as
mean ± SEM, n=5. *, P < 0.05; **, P < 0.01 by one-way ANOVA with Tukey post hoc test.
Below, representative H&E pictures from different treatment groups. L, lumen; N, neointima; M,
media; A, adventitia; IEL, internal elastic lamina; EEL, external elastic lamina.
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Figure 6. Representative H&E carotid cross-sections from different treatment groups.
Representative H&E pictures from different treatment groups show qualitatively different levels
of neointima and lumen occlusion versus sham injury-only groups and intact right carotids.
These pictures also suggest a dose-response relationship within treatment groups.
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Figure 7. Representative a-SMA immunostained carotid cross-sections from different
treatment groups.
Representative a-SMA immunostained cross-sections with mild hematoxylin staining from
different treatment groups show qualitatively different levels of smooth muscle cell proliferation
in the neointima (brown stain) versus sham injury-only groups and intact right carotids. These
pictures also suggest a dose-response relationship within treatment groups.
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Discussion
Recent clinical trials have tested new DES devices to overcome the problems posed by
* 22
non-biodegradable drug-eluting matrices . Biodegradable polymer matrices on stent surfaces
(Supralimus, Nevo, Infinnium and BioMatrix stents), stents without polymers (Artax stents) and
even completely biodegradable stents (Igaki-Tamai stents 23,24) have been tested. Novel stents
(Geneous stents) have been designed to capture endothelial progenitor cells and program them to
mature into endothelial cells, preventing the adhesion of platelets, fibrin and inflammatory cells
that lead to in-stent thrombosis. In parallel, there has also been a number of contradictory large-
scale clinical reports underscoring the long-standing and unresolved debate on the efficacy and
safety of approved DES6 ,25 ,26 . These safety reports are impeded by a lack of long-term safety data
beyond current five-year studies.
Amidst improvements in DES design and progressively longer-term safety reports, NP-
based drug delivery may be useful for patients who (i) cannot receive a DES due to a pre-
existing condition, (ii) cannot take the antiplatelet medicine due to a planned surgery or allergies,
(iii) have lesions in pre-stented arteries, and (iv) have lesions which are non-amenable to
stenting 3. A number of locally27,28 and systemically29-32 delivered NPs have been described in
the literature for the treatment of restenosis. Systemic-acting therapies such as bisphosphonates
lead to an overall reduction in inflammatory cells that infiltrate and worsen lesions 29. Anti-
proliferative drugs such as Ptxl, however, need to be localized for action and systemically
delivered infusions have been unable to achieve therapeutic doses at the injury site. Hence, anti-
proliferative Ptxl treatments in clinical trials have been administered to patients as local
intraarterial infusions. Coroxane, a 130-nm albumin-bound paclitaxel carrier by Abraxis
Biosciences (equivalent to Abraxane) is currently in Phase II trials for coronary restenosis. In
these trials, Coroxane is delivered as a local intraarterial infusion following balloon angioplasty
with BMS placement 33,34 . However, vascular disease remains a chronic, life-long condition that
requires long-term maintenance. Hence, systemic delivery of anti-proliferative drugs remains an
attractive goal.
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In this efficacy study, Taxol was used as an active control group because there is an
urgent requirement for alternatives to Cremophor-EL (CreEL). The amount of CreEL required
for Ptxl is significantly higher than for other drugs containing CrEL34 . CreEL has been shown to
cause neuropathy, serious hypersensitivity reactions35,36 and to activate both alternative and
37,38
classical pathways of the complement system3 . To prevent these hypersensitivity reactions,
Taxol administration requires steroid pretreatment with antihistamines and corticostereoids.
Despite pretreatment, 3% of patients will still have life-threatening reactions 9 . Targeted hybrid
NPs do not contain CrEL and therefore do not require pre-medication and long infusion times.
The short-term binding studies to injured vasculature in Chapter 6 did not take into
account an increase in matrix production over time. In this experimental angioplasty model of
intimal proliferation, studies have shown that along with cell proliferative and migration
responses, there is also a pronounced accumulation of extracellular matrix as the neointima
grows. The response-to-injury involves the proliferation of medial SMC (first wave) followed by
2
migration (second wave) and neointimal formation (third wave) . In a process termed
modulation, the SMC in the neointima undergo a phenotypic change from 'contractile' to
'synthetic' and synthesize matrix molecules such as collagen 2. In one study, Sprague-Dawley
rats showed a 50% increase in collagen deposition one week after surgery based on total arterial
hydroxyproline content 40. Hence, the increased collagen levels corresponding to neointimal
formation may form a positive loop where more vascular injury equals more target binding sites.
Since the animals were also dosed on Day 6 post-procedure, the increased collagen expression
may account for one aspect of the efficacy seen here.
In Chapter 6, we used Ptxl-PLA drug conjugates that exhibit slow elution rates in
vitro'8 . In this chapter however, we used unmodified Ptxl drugs to make direct comparisons of
potency against Taxol. The peptide-targeted NP groups gave lower N/M values of N/Mep.
NP=0. 74 4 ± 0.129 compared to N/MTaxoI=0.937 ± 0.126 (P < 0.3, mean ± SEM, n=5) for 0.3
mg/kg treatment groups, but the N/M ratios observed in this study may be further improved
(Figure 5). Beyond this study, the experimental set-up can be modified by: (i) extending the
study to 28 days for more pronounced differences to be observed, if any, since shorter-term
studies may overestimate efficacy, (ii) incorporating Ptxl-PLA conjugates for slow-release
capacity, (iii) reducing the i.v. dose to accentuate N/M ratio differences at very low doses and (ii)
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dosing only once instead of twice, since higher and/or more frequent doses compensate for a lack
of targeting.
In conclusion, anti-proliferative therapies given as a systemic infusion on Day 1 and 6 of
injury reduced neointimal hyperplasia and arterial stenosis more effectively in the targeted-NP
group compared to non-targeted NP, Taxol and saline-only groups. Our findings indicate that
collagen IV-targeted NPs may be clinically relevant in the treatment of injured vasculature
following percutaneous angioplasty.
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Chapter 8.
Closing Remarks.
Despite the significant advances of this decade in cardiovascular treatment,
cardiovascular diseases continue to be the leading cause of morbidity and mortality in
developing nations, and remains the greatest health problem in the United States.
Cardiovascular-related deaths claim 500,000 lives annually and estimated treatment costs exceed
$360 billion per year in the US alone'.
Currently, one of the treatments for atherosclerosis relies on the use of oral statin therapy,
which at best reduces cardiovascular events by 25% to 30%2. Patients with atherosclerotic
disease often survive their first cardiac event through optimal medical therapy, coronary bypass
graft surgery and acute revascularization with stent placement. Despite the high usage of
commercially-available DES in the cardiac field, there are a number of limitations and only
select coronary lesions are amenable to DES placement. This results in the use of BMS or plain
balloon angioplasty, both of which lack the benefit of anti-restenotic therapy. In other patients,
transient ischemic attacks and stroke constitute the initial presentation of disease, resulting in
highly limited diagnostic and therapeutic options.
Nanomedicine offers options to each of these individual challenges3 . For predictive
purposes, targeted NPs against plaque architecture may be used to sequentially detect and
quantify plaque development in high-risk, asymptomatic patients, by monitoring underlying
lesion activity and vulnerability to rupture. NPs can locally deliver anti-angiogenic therapy,
which may acutely retard plaque progression, allowing aggressive statin therapy to become
effective. Novel multimodal NPs may be used as theranostics to combine both diagnostic and
therapeutic entities for the personalized treatment of atherosclerosis4 . In cases proceeding to the
catheterization laboratory for revascularization, NPs incorporating anti-restenotic drugs can be
delivered to lesions independently of stent placement5 . Moreover, delivery of anti-proliferative
agents to the vascular wall when neointimal proliferation is most aggressive, followed by
complete degradation and clearance, is most likely to improve healing of the endothelium. Prior
studies have provided strong support for the importance of endothelialization in post-procedural
clinical outcomes6. Polymer-based NPs, liposomes and micelles in the treatment of coronary
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restenosis have been tested in vitro and in vivo with favorable results5, while clinical trials are
underway for NP-based treatments of in-stent stenosis7.
The targeted drug delivery NP platform developed in this thesis work may be applicable
for restenotic therapy independent of stent design and type of injury. The variety of anti-
proliferative treatments delivered can be expanded to include drugs such as sirolimus and its
analogs, or even to co-deliver more than one type of treatment. The targeted NPs may be used to
treat longer lesions, multiple lesions, branch points and smaller arteries currently non-amenable
.8to stenting . Maintenance of stented arteries may also be possible when used in conjunction with
stenting by giving NP doses at later time points (months and years), given the knowledge that
atherosclerosis is a chronic, lifelong condition that may not be completely resolved by
revascularization. Therefore, efficacy studies using stented animal models may be carried out to
investigate if the targeted NPs are able to reduce in-stent stenosis. Finally, the targeted NPs may
also be tested in non-stenotic models of atherosclerosis using apolipoprotein E-knockout mice
for the delivery of anti-inflammatory treatments.
By expanding the utility of NP-based treatments to the application of cardiovascular
disease, one would hope that the explosion in technology previously associated with oncologic
treatments will be repeated9 . Based on this ever-expanding platform of technologies, we look
forward to achieving our most desired experimental result, that of improved patient outcomes.
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